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ABSTRACT 
 
 
Studies on Gene Expression Profiling in JB6 Cells Susceptible and Resistant to Tumor 
Promoter Induced Neoplastic Transformation and Regulation of Gene Expression at the 
AP-1 DNA Binding Site. (August 2004) 
Shaija Samuel, B.S., Madras University; 
M.S., Madras University 
Chair of Advisory Committee: Dr. Lori R. Bernstein 
 
 Gene expression underlies all important biological processes in a cell and mis-
regulated gene expression plays a causal or contributory role in several diseases 
including cancers.  Towards identifying molecular determinants that confer 
susceptibility and resistance to tumor promoter induced neoplastic transformation, we 
analyzed the gene expression profile differences among tumor promoter TPA treated and 
untreated mouse epidermal JB6 cells by means of cDNA microarray analyses.  The 
expression patterns for several genes were validated by real time PCR analyses.  
Seventy-four genes belonging to six functional categories were found to be differentially 
expressed.  Data from this study implicate pathways which mediate cell adhesion, 
migration and interferon signalling, tumor suppressors, apoptotic proteins and 
transcription factors and includes twenty-six genes whose involvement has not been 
previously implicated in cancer.   
In a second study we used a DNA affinity chromatography based assay to purify 
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two proteins that bound specifically to the AP-1 DNA binding site.  Analyses of the 
purified proteins by mass spectrometric sequencing determined the identities of these 
proteins as nucleolin and Y-box binding protein 1 (YB-1).  We tested the hypothesis that 
these proteins regulate transactivation at the AP-1 site.  Overexpression of nucleolin and 
YB-1, both alone or in combination, repressed AP-1 dependent gene transactivation.  To 
understand the mechanism of transrepression, we analyzed whether nucleolin and/or 
YB-1 affected the levels and/or disrupted the intracellular localization of the AP-1 
protein subunits. Western blot analyses of all the AP-1 subunits revealed that the levels 
of AP-1 were unaffected.  Cell fractionation confirmed that the AP-1 levels were not 
altered in the nuclear or cytoplasmic compartments.  We further tested the hypothesis 
that nucleolin and YB-1 repressed AP-1 transactivation by competing with AP-1 
proteins for the AP-1 site.  The results from this experiment were inconclusive and the 
precise mechanism of repression is currently under investigation.  
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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 The human body is composed of trillions of cells, each programmed to grow, 
differentiate, divide, function, and die on a defined time scale in an orderly manner. 
Cancer develops when a cell undergoes mutations in its DNA and loses one or more of 
these biological restraints.  According to the World Health Organization (WHO) 
statistics, more than 10 million people are diagnosed with cancer every year (WHO, 
2004).  With 6 million deaths every year, or 12% of total deaths, cancer has become one 
of the most devastating diseases worldwide (WHO, 2004).  The last thirty years have 
seen an amazing growth in our understanding of cancer, resulting in significant 
breakthroughs in the prevention, detection and treatment of cancer. However, further 
research into the key events that mediate the process of malignant transformation is 
essential to elucidate the molecular basis of this multi-step process in order to improve 
cancer prevention and cancer treatment strategies.  
Gene Expression and Cancer 
 Cancer encompasses a group of diseases characterized by uncontrolled and 
abnormal division of cells.  Experimental and clinical studies carried out during the past 
century have established that many cancers develop through a multistage process  
______________________ 
This dissertation follows the style of Oncogene. 
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(Weinstein, 2000).  Genetic alterations in oncogenes and/or tumor suppressor genes 
confer growth advantages to a cell resulting in formation of a benign tumor.  Subsequent 
acquisition of genetic and epigenetic changes leads to progression of the cells to an 
invasive and metastatic phenotype.   Hanahan and Weinberg have highlighted six 
essential alterations in cell physiology that underlie most cancers.  These include: (1) 
Self-sufficiency in growth signals; (2) Insensitivity to growth inhibitory signals; (3) 
Evasion of programmed cell death; (4) Limitless replicative potential; (5) Sustained 
angiogenesis and; (6) Tissue invasion and metastasis (Hanahan and Weinberg, 2000).  
All of these biological endpoints are governed by the expression of specific sets of 
genes. As such, gene expression and its regulation play an important role in both 
physiology and pathology of cells. 
 Each cell in a eukaryotic organism contains the complete genomic template for 
the organism.  Morphological and functional specificities of cells constituting a 
particular tissue or organ are determined by tightly controlled expression of a specific 
subset of genes within those cells.  Cellular responses to various extracellular and 
intracellular cues are mediated through signaling pathways that ultimately result in 
regulated expression of specific genes.  Regulation of gene expression is therefore one of 
the most important biological processes in the cell.  Any disorders in the process of gene 
expression and subsequent alterations in functions within the cells can result in 
deviations from programmed cellular responses.  A possible outcome is a tumor cell. 
Understanding mechanisms of gene regulation will not only help us to understand 
fundamental biological events such as proliferation, differentiation and apoptosis, but 
  
3
also the causes of various diseases that result from deregulated gene expression, 
including cancers.  
Regulation of Gene Expression 
 Regulation of eukaryotic gene expression can occur at several levels, including 
chromatin condensation, DNA methylation, transcriptional initiation, alternative splicing 
of RNA, mRNA stability, translational controls, several forms of post-translational 
modification, intracellular trafficking, and protein degradation (Lewin, 2000; Alberts et 
al., 2002).  In the nucleus, genomic DNA is compacted via associations with nuclear 
proteins to form higher order structures which may restrict the accessibility of genes. 
Another level of control may be exerted by regulation of mRNA degradation rate 
(reviewed in Mitchell and Tollervey, 2000 and Guhaniyogi and Brewer, 2001). 
Increased stability of specific mRNA species leads to increases in the steady state levels 
of those mRNA transcripts in the cell.  One of the most common and key forms of 
control is regulation at the level of transcription (Carey and Smale, 2000; Lemon and 
Tjian, 2000). Transcriptional regulation is a complex process, involving recruitment and 
interactions of several proteins with each other and with the DNA. The process is 
mediated both common proteins, called general transcription factors that act on all 
genes, and specific factors called regulatory transcription factors, that act on particular 
DNA sequences within the promoter of genes, under particular physiological conditions.  
 Initiation of transcription occurs when components of the basal transcription 
machinery, including RNA polymerase II (RNA PolII) and general transcription factors 
are recruited to the transcription initiation site (Orphanides and Reinberg, 2002, 
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Woychik and Hampsey, 2002). Most eukaryotic promoters for protein-coding genes 
share three common features: the transcription start site, the TATA box, and sequences 
bound by transcriptional regulators (see Lee and Young, 2000 for review).  The core 
promoter element consists of the start site and the TATA box, and is sufficient for 
transcription initiation by the basal transcription machinery. The sequences that are 
bound by transcriptional regulators include Upstream Activating Sequences (UASs), 
enhancers, Upstream Repressing Sequences (URSs) and silencers (Lee and Young, 
2000).  The core promoter which is located approximately -40 base pairs (bp) upstream 
of the transcription start site often contains a TATA box consensus sequence.  The 
general transcription factor (GTF) TFIID is believed to directly bind to the TATA box 
through its TATA box binding protein (TBP) subunit, followed by binding of the other 
GTFs including, TFIIB, TFIIF, TFIIE and TFIIH and RNA PolII (see Figure 1; Wray et 
al., 2003; Lemon and Tjian, 2000).  The UAS and URS are located upstream of the 
promoter and are bound by activators and repressors respectively.  Additional regulatory 
elements include enhancers and silencers that function in orientation- and position-
independent fashion.  The UAS elements are binding sites for sequence specific 
transcription factors and/or co-regulatory proteins that control the rate of gene 
expression in a tissue specific manner in response to specific stimuli.  Regulatory 
transcription factors bind to the cis element in the promoter region and interact with the 
transcriptional machinery either directly, or by recruiting co-regulators (Narlikar et al., 
2002).  Regulatory transcription factors function to communicate with the core promoter 
machinery to enhance or decrease the rate of transcriptional initiation.   
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Figure 1  Schematic organization of a typical eukaryotic promoter. Transcriptional 
initiation at the promoter requires several different proteins that interact with each other 
in specific ways. These include the RNA polymerase II holoenzyme complex; TATA-
binding protein (TBP); TAFs (TBP-associated factors) and regulatory transcription 
factors and transcription cofactors (Adapted from Wray et al., 2003). 
modules
Looping factors 
TATA box
TAFs RNA polII 
TATA binding protein 
Transcription factors 
chromatin
chromatin
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Regulatory transcription factors are generally modular consisting of a DNA binding 
domain (DBD) and a transactivating domain (TAD; Mitchell and Tjian, 1989). The 
DNA binding domain dictates the enhancer sequence that the transcription factor can 
bind to and the transactivation domain determines its transactivation potential. 
Transcription factors can also interact with other proteins including transcription factors 
of the same or other families, co-regulators, and the general transcription factors 
(Narlikar et al., 2002).  Co-regulatory proteins add another level to control of gene 
expression by either enhancing (e.g. co-activators) or repressing (e.g. co-repressors) 
gene transcription mainly through chromatin remodeling. The co-regulators may have 
either histone deacetylase activity (HDAC) associated with repression of transcription or 
histone acetylase activity (HAT) associated with pro-transcriptional role (McKinsey et 
al, 2001). 
Research Outline and Objectives 
 Novel insights into the key events that mediate the process of malignant 
transformation can be obtained by studying gene expression and its regulation.  Research 
presented in this dissertation addresses these two aspects of gene expression in the 
context of carcinogenesis.  Given that the gene expression profile of a cell determines its 
phenotype, function and response to environmental stimuli, measuring the levels gene 
expression can provide insights into functions, regulatory mechanisms and biochemical 
pathways that underlie the cells phenotype.  With this in mind, in the first part of this 
study we compared the global gene expression profiles of two cell lines which are either 
susceptible or resistant to tumor promoter induced neoplastic transformation, using 
  
7
cDNA microarray analyses.  As a complementary approach to understanding gene 
expression, we studied regulation of gene expression at a specific promoter element 
implicated in carcinogenesis, i.e. the AP-1 DNA binding site.  The research is presented 
in the form of two studies in Chapters II and III.  The following section briefly outlines 
the hypothesis and specific aims of each of the studies. 
 In Chapter II, TPA induced differential gene expression in tumor promotion 
sensitive and resistant JB6 cells were compared using cDNA microarray analyses.   The 
following hypothesis provided the basis upon which the research presented in this part of 
the study was based.  We hypothesize that both intrinsic and TPA induced differential 
gene expression between the tumor promotion sensitive and resistant JB6 cells are 
determinants of susceptibility and resistance to tumor promoter induced neoplastic 
transformation.  This hypothesis was tested by pursuing the following specific aims: 
 1. Identify genes differentially expressed in untreated and TPA treated JB6 
   P+ and P- cells 
 2. Identify groups of genes sharing biological functions and expression 
   patterns 
 3. Use expression patterns to define TPA modulated phenotypes of P+ and  
  P- cells 
 4. Define biological pathways underlying susceptibility and resistance of  
  JB6 cells. 
 In Chapter III, two novel transactivational repressors at the AP-1 DNA binding 
site were identified.  The following hypothesis provided the basis upon which the 
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research presented in this part of the study was based. We hypothesize that gene 
expression at the AP-1 DNA binding site is regulated by proteins that bind specifically 
to the AP-1 site.   This hypothesis was tested by pursuing the following specific aims: 
 1. Identify specific AP-1 DNA binding proteins. 
 2. Characterize the role of these proteins in AP-1 dependent gene  
  expression. 
3. Understand the mechanism of transcriptional regulation mediated by 
these proteins at the AP-1 site. 
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CHAPTER II 
GENE EXPRESSION PROFILING IN JB6 CELLS SUSCEPTIBLE AND 
RESISTANT TO TUMOR PROMOTER INDUCED NEOPLASTIC 
TRANSFORMATION 
Synopsis  
 Towards understanding the molecular mechanisms responsible for tumor promoter 
induced transformation, and identifying the molecular determinants that confer cancer 
susceptibility and resistance, we analyzed comparative gene expression profiles of tumor 
promoter TPA treated and untreated promotion susceptible (P+) and resistant (P-) mouse 
epidermal JB6 cells by means of cDNA microarray analyses.  Seventy-four of the 9,500 
gene elements in the array, belonging to six different functional categories, were 
differentially expressed as follows. (I) ECM and basement membrane proteins (20 genes).  
While P+ expressed higher levels of fibrillar and basement membrane collagens and of 
proteases, and lower levels of protease inhibitors, P- cells preferentially expressed several 
genes encoding cell-cell, cell-ECM and cell-basement membrane adhesion molecules, and 
protease inhibitors.  (II) Cytoskeletal proteins (13 genes).  These include nine isoforms of 
actin and actin-associated proteins that are more highly expressed in P- cells. (III) Enzymes 
and signal transduction proteins (12 genes).  Among these are several tumor suppressors  
_________________ 
Sections and figures in this chapter are reprinted with permission from Adhesion, migration, 
transcriptional, interferon-inducible, and other signaling molecules newly implicated in 
cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses. Samuel S 
and Bernstein LR., Molecular Carcinogenesis, 39(1):34-60.  Copyright (2004) Wiley-Liss, 
Inc. 
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and apoptotic mediators including Ras GTPase activating protein (Ras-GAP), deleted in 
oral cancer-1 (Doc1) and connexin 43 (Cx43), all preferentially expressed in P- cells. (IV) 
Interferon inducible proteins (3 sequences).  These include interferon inducible protein 
(IFI16), a transcriptional regulator expressed preferentially in P- cells.  (V) Transcription 
factors and DNA binding proteins (4 genes).  These include retinoic acid regulated proteins 
Nur77 and cellular retinoic acid-binding protein II (CRABPII), and paired related 
homeobox gene 2 (Prx2), all preferentially expressed in P- cells and RIN ZF preferentially 
expressed in P+ cells.  (VI) Sequences of unknown function. Real time-PCR validated the 
expression patterns for 91% of genes analyzed.  Phalloidin staining revealed that P- cells 
have more cell-cell contacts both in the presence and absence of TPA compared to P+ cells 
and wound healing assays revealed that TPA treated P- cells have impaired ability to 
migrate into wounds compared to P+ cells.  Phalloidin staining also revealed that TPA 
treated P+ cells have more lamellipodia and filopodia than P- cells.  Taken together these 
results support the hypothesis that gene expression patterns favoring an adhesive and tumor 
suppressive phenotype are implemented in P- cells, and those favoring motility and tumor 
promotion are implemented in P+ cells.  Twenty five genes and one expressed sequence tag 
(est) are implicated for the first time in neoplastic transformation.  Further investigations 
into the functions of the genes identified in this study should improve our understanding of 
the events that mediate neoplastic transformation. 
Introduction 
 Cancer research over the past thirty years has revealed that carcinogenesis is a 
complex process, requiring cells to overcome numerous barriers that ensure their proper 
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functioning in the context of their locations in the human body.  The diversity of cell types 
and the accumulation of a combination of multiple genetic and epigenetic events contribute 
to the wide heterogeneity of human cancers.  However, despite the morphological and 
molecular heterogeneity between different types of cancers, there exist a few common 
features.  The structures and/or expression of some functional classes of genes are 
invariably altered when a normal cell becomes transformed.  These include receptors, 
enzymes, and/or genes involved in cell cycle, adhesion, motility, apoptosis and 
angiogenesis.  Interactions between a cell and its environment play a major role in cell 
growth, proliferation, differentiation and death.  The cellular microenvironment can 
influence gene expression, and adverse changes in the cellular microenvironment could 
trigger transformation processes. 
The Extracellular Matrix 
 The extracellular matrix (ECM) is an important component of the extracellular 
environment and is typically composed of secreted proteins and polysaccharides 
collectively referred to as ECM proteins.  These include the collagens, fibronectins, 
laminins, and proteoglycans that assemble into fibrils or other complex macromolecular 
arrays (Cooper, 2000).  Cells attach either directly to components of the collagen-rich 
interstitial matrix or to the basement membrane, a more distinct sheath of the ECM that 
surrounds many kinds of tissues.  The ECM can regulate cellular behavior by at least three 
mechanisms, including composition of the ECM, synergistic interactions between growth 
factors and matrix molecules and through cell surface receptors that mediate adhesion to 
ECM components (Adams and Watt, 1993). Contrary to general notions, the composition of 
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ECM is diverse and changing. ECM molecules not only interact with growth factors and 
serve as a store of growth factors by limiting their diffusion but can themselves serve as 
growth factors.  ECM molecules act as important ligands for transmembrane receptors and 
therefore provide important outside-in signals (Bosman and Stamenkovic, 2003).  They also 
play an important role in cell adhesion through receptor mediated interactions.  
Role of Cell Adhesion 
 The cell adhesion receptors are usually transmembrane glycoproteins that mediate 
binding interactions at the extracellular (EC) surface with either other cell adhesion 
receptors on neighboring cells or with proteins of the ECM.  They include members of the 
integrin, cadherin, immunoglobulin, selectin, and proteoglycan superfamilies (Cooper, 
2000).  At the intracellular surface of the plasma membrane, cell adhesion receptors 
associate with cytoplasmic plaque or peripheral membrane proteins and with cytoskeletal 
proteins (Critchley, 2000).  Cooperation between adhesive systems and the actin 
cytoskeleton results in the formation of adhesive contacts between cells or between cells 
and the ECM.  A common type of adhesive contact that cells make with the ECM is the 
focal adhesion contact (Yamada and Geiger, 1997; Sastry and Burridge, 2000).  Normal 
cells require cell-cell and cell-ECM-mediated adhesion to survive; if detached, they undergo 
programmed cell death (apoptosis) in a process known as anoikis.  By contrast, transformed 
cells exhibit two prime features of tumorigenicity, serum-independence and anchorage-
independent growth.  This ability to escape anoikis is a cardinal feature which allows 
transformed cells to detach from the primary site and metastasize.  Cancer cells commonly 
show decreased intercellular adhesiveness when compared to their normal counterparts.   
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 The acquisition of motile properties also correlates with a loss of their ability to 
recognize and adhere to their neighbors.  Cell migration entails the coordination of a cycle 
of cytoskeletal-mediated extension of filopodia and lamellipodia, the formation of adhesive 
contacts at the leading edge of the cell, the breaking of adhesive contacts, and cytoskeletal-
dependent retraction at the trailing edge of the migrating cell (Lauffenburger and Horwitz, 
1996;  Mitchison and Cramer, 1996).  The cytoskeleton of a cell is composed of three types 
of cytoplasmic protein polymers including microtubules, intermediate filaments and actin 
filaments (Cooper, 2000).  Actin filaments made up of actin monomers, are arranged as 
networks beneath plasma membrane called cell cortex, as tight bundles in filopodia, as 
criss-crossing networks in lamellipodia, as antiparallel structures in contractile rings and, as 
densely packed bundles in stress fibers (Welch and Mullins, 2002).  Actin filaments not 
only play a critical role cell-cell adhesion, but are also involved in several dynamic cellular 
processes such as changes in cell shape, cell spreading, motility, cytokinesis and polarity 
(Pollard et al., 2000).  Cells with decreased cell-cell contacts and interactions are more 
refractive to growth inhibitory signals. 
Matrix Metalloproteinases and Their Inhibitors 
 Invading cancer cells overcome physical barriers such as the interstitial stroma and 
basement membrane by regulating the expression of adhesion molecules, actin cytoskeletal 
rearrangements and by increased expression or activity of degradative enzymes such as 
matrix metalloproteinases (MMPs) and cysteine proteases (cathepsins).  Several studies 
have demonstrated that MMPs are upregulated in invasion and metastasis in a variety of 
cancers.  MMPs are a family of zinc-dependent endopeptidases that can degrade ECM 
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components as well as cleave cell surface molecules to mediate tumor progression, invasion 
and metastasis (Kähäri and Saarialho-Kere, 1997).  The MMP superfamily consists of 
collagenase, stromelysins, gelatinases, transmembrane MMPs and other MMPs (Coussens 
and Werb, 1996; Shapiro, 1998; Matrisian, 1999, Westermarck and Kahari, 1999).  
Increased expression of MMPs has been observed in lung carcinomas (Bolon et al., 1995), 
squamous cell carcinomas of the head and neck (Johansson et al., 1997), bronchial tumor 
(Galateau-Salle et al., 2000), and colorectal tumors (Murray et al., 1996).  Furthermore, 
mouse models deficient in specific MMPs exhibit decreases in growth, angiogenesis and 
invasion in response to various carcinogens (McCawley and Matrisian, 2000).  Studies are 
now elucidating specific mechanisms by which the expression and activity of individual 
MMPs contribute dynamically to tumor invasion and metastasis (Leeman et al., 2003).  
Evidence is also emerging for new significant biological roles for MMPs in tumor 
development and progression, including roles in apoptosis, cell proliferation, and cell 
differentiation (McCawley and Matrisian, 2000).  
 Studies in both human and animal models of colorectal cancer have 
demonstrated an important role for MMPs in the early stages of cancer development. 
MMP-7 (matrilysin) mRNA and activity have been shown to be present in colorectal 
adenomas (Yamamoto et al., 1994).  In contrast to its absence in most normal tissues, 
matrilysin has been detected in a high percentage of pre-invasive lesions, and is 
expressed by the epithelial-derived tumor cells.  Manipulating the level of this enzyme 
in vitro results in cell lines with enhanced tumorigenic potential, correspondingly 
ablating the gene in vivo leads to a significant reduction in tumor number in two 
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different animal models of intestinal tumorigenesis (Fingleton et al., 1999).  
Additionally, regulation of matrilysin gene expression appears to be under the control of 
genetic pathways which are activated very early in the tumor development sequence.  
The precise mechanism by which matrilysin activity contributes to early stages of tumor 
formation is not yet very clear.  
Maintaining Homeostasis 
 Cells have several inherent strategic defense mechanisms to maintain 
homeostasis.  One such mechanism is by secretion of tissue inhibitors of 
metalloproteinases (TIMPs), which bind to the highly conserved zinc binding site of 
active MMPs and specifically inhibit the activity of MMPs.  The TIMP gene family 
consists of four structurally related members, TIMP-1, -2, -3, and -4. TIMPs-1, -2, and -4 
are secreted in soluble form whereas TIMP-3 is associated with ECM (Gomez et al., 
1997).  Increased expression of TIMPs by either host or tumor cells results in reduced 
invasion and metastatic capacity of transformed cells (Kruger et al., 1998; Ahonen, et 
al., 1998).   
 Another protective mechanism is apoptosis or programmed cell death.  Apoptosis 
is a genetically regulated, morphologically distinct form of cell death that can be 
initiated by many different physiological and pathological stimuli. Such intracellular 
programs are initiated in many instances during the normal life cycle and development 
of a multicellular organism in order to maintain homeostasis and to eliminate unwanted 
cells.  Dysregulation of apoptosis has emerged as an important mechanism in 
carcinogenesis (Kukhta et al., 2003). 
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Multi-stage Origin of Cancers 
 Several types of human cancers are now believed to have a multi-stage origin (see 
Hanahan and Weinberg, 2000 for review) with each step conferring increased neoplastic 
characteristic to the cell.  Multi-stage carcinogenesis generally involves both genetic and 
epigenetic events in the cell.  While the genetic events, including structural alteration of 
critical gene(s) are mostly irreversible and occur rapidly, the epigenetic events are partially 
reversible, and occur more slowly over the course of several years. The genetic events are 
mediated by exposure to a sub-threshold dose of carcinogen and are not rate-limiting steps 
in tumor development. The epigenetic events, however, generally require repeated 
applications of a noncarcinogenic tumor promoting agent and are known to be the rate-
limiting steps (see Digiovanni, 1992 for review) in tumor development. The molecular basis 
of such genetic and epigenetic events in tumor development has been the subject of 
extensive investigations.  
 Colorectal cancer is one of the best studied examples of the multi-stage nature of 
tumorigenesis in humans.  It has been demonstrated that the development of colorectal 
carcinoma involves at least seven sequential alterations, including mutation of the 
adenomatous polyposis coli (APC) tumor-suppressor gene, mutation of Ki-ras and loss 
of function of p53 gene (Kinzler and Vogelstein, 1996).  Studies into the role and 
function of APC in colon carcinoma and melanoma development have led to the 
identification of another novel pathway for the tumor onset (Compagni and Christofori, 
2000).  While direct studies of human cancers such as these have greatly increased our 
understanding of tumor development, the difficulty in tumor tissue procurement and 
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diversity in genetic background of the subjects make it difficult to study tumorigenesis 
in humans.  Additionally, the procurement and analyses of human cancer samples are 
further complicated by ethical and legal constraints.  By contrast, animal systems such as 
the mouse offer several distinct advantages and have proved to be a valuable model 
systems for the study of multistep tumorigenesis (Wu and Pandolfi, 2001), although 
mice are often not predictive of effectiveness of cancer treatment modalities. 
Mouse Skin Carcinogenesis and the JB6 Model 
 Mouse skin carcinogenesis constitutes one of the best studied models of 
multistage tumorigenesis. Skin tumors can be induced in mice by the sequential 
application of a carcinogen, followed by a non-carcinogenic promoter.  Chemically 
induced mouse skin tumorigenesis proceeds through three stages of development: 
initiation, promotion and progression (Yuspa, 1998).  In initiation, topical application of 
a single subcarcinogenic dose of a carcinogen, such as 7, 12-dimethyl-benzanthracene 
(DMBA) leads to initiation of tumor development resulting from irreversible DNA 
damage. The promotion is achieved by repeated application of skin promoters, most 
commonly the phorbol esters, such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA). 
Tumor promoters induce biochemical changes that promote the selective clonal 
expansion of initiated cells and leads to the formation of multiple squamous papillomas. 
The progression stage is generally a spontaneous process characterized by a high level of 
genetic instability (reviewed in Digiovanni, 1992).  
 Studies on the mouse skin carcinogenesis models have provided numerous leads 
into the potential tumorigenic roles of genes that have later been supported by other in-
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vivo studies.  Agonistic roles for cyclin D1 in the Ha-Ras pathway in tumorigenesis, p53 
in the tumor-progression phase, c-fos gene in malignant conversion and epidermal 
growth factor (EGF) in SOS-dependent skin tumor development, as well as antagonistic 
role for promyelocytic leukemia (PML) tumor-suppressor gene the initiation phase of 
skin tumorigenesis and a dual role for TGF-β in tumorigenesis, have all been identified 
using mouse skin carcinogenesis models (see Wu and Pandolfi, 2001 for review).  
Recent progress in understanding the mechanism by which TPA induces tumor promotion 
comes from both in vivo studies using mouse skin model (Drinkwater et al., 1989; 
Digiovanni, 1989; Gould et al., 1989 and Malkinson, 1989), as well as from in vitro studies 
using the mouse epidermal JB6 system (Colburn et al., 1979; Colburn et al., 1980; Gindhart 
et al., 1985; Smith et al., 1986; Nakamura et al., 1988 and Bernstein and Colburn, 1989).   
 The JB6 model consists of distinct clonal genetic variants that were originally 
derived from untreated primary BALB/c mouse epidermal cells, that spontaneously gave 
rise to immortalized cells, that later stably acquired susceptibility (P+) or resistance (P-) to 
TPA induced anchorage independent colony formation and tumorigenicity in nude mice 
(Colburn et al., 1979;  see Figure 2).   The P+ cells undergo neoplastic transformation in 
response to TPA treatment while the P- cells do not.  But, because these cells exhibit 
similar mitogenic responses to TPA (Colburn et al., 1981), they provide a means to 
specifically identify transformation-relevant differences in gene expression by excluding 
those related to cell proliferation. The key role of transcription factor AP-1 in the 
promotion of neoplastic transformation was first identified in the JB6 model (Bernstein 
and Colburn, 1989) and was later found to be applicable to mouse and human 
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keratinocyte progression models (Dong et al., 1997; Li, et al., 1998), and in mouse skin 
in vivo (Young et al., 1999).  JB6 cells have also been used to identify several other key 
genes, expression events, and signaling pathways of major significance in cancer 
(described in detail in a later section). 
Tumor Promoter TPA and Signal Transduction 
 TPA is one of the most potent known tumor promoters (Slaga et al., 1980).  The 
effects of tumor promoters are pleiotropic, ranging from changes in cellular morphology, to 
alterations in cell cycle and apoptosis (Cmarik et al., 1999).  Although tumor promoters 
such as phorbol esters and growth factors do not cause genetic changes in the DNA, they 
exert their influence by causing transient changes in gene expression through signal 
transduction pathways (Gindhart et al., 1985; Bernstein et al., 1991; Angel and DiGiovanni, 
1999; Cmarik et al., 1999).  A subset of these induced gene expression changes is thought to 
be relevant to tumorigenesis.  Intracellular TPA signal transduction is initiated by its 
binding to protein kinase C (PKC; Ron and Kazanietz, 1999).   
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Figure 2   Derivation of JB6 Cl307b promotion susceptible (P+) and promotion resistant  
(P-) cells. 
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PKC is a family of serine/threonine kinases which are involved in intracellular signaling 
(Nishizuka, 1995).  PKC serves as an intracellular receptor for TPA and its kinase activity is 
activated by binding to TPA (Ashendel, 1985; Castagna et al., 1982). Short term treatment 
of cells with TPA results in the translocation of PKC from the cytoplasm to the membrane 
where it interacts with phospholipid and becomes activated (Huang, 1989).  Long term TPA 
treatment causes down regulation of PKC via the proteolysis of its hinge region (Fournier 
and Murray, 1987).  Both activation and down regulation of the different PKC isoforms 
could play a role in tumor promotion process (Droms and Malkinson, 1991). The PKC 
family consists of at least 12 different isoforms that are classified into three groups; the 
conventional (cPKCs) that are activated by calcium and diacylglycerol (DAG), the novel 
(nPKCs) that are calcium-independent, but DAG-dependent and the atypical isoform 
(aPKCs) that are both calcium- and DAG-independent. These isoforms differ in terms of 
their cell type and subcellular distribution and the targets of their action. Only cPKCs and 
the nPKCs, but not aPKCs, can be activated by TPA (Mellor and Parker, 1998).  Several 
events and molecules in the signaling cascade downstream of PKC have been identified. 
Activation of PKC results in rapid activation of extracellular signal-regulated kinases 
(ERKs, Hoshi et al., 1989, and Schonwasser et al., 1998).  Functional ERK2 MAP kinase is 
required for TPA promotion of transformation, and for activity of activator protein-1 (AP-1) 
in P+ cells (Watts, 1998).  However, induction of AP-1 by TPA occurs in PKC-depleted 
mouse suggesting the existence of additional TPA receptors (Kennard et al., 1995). 
 TPA treatment results in the activation of several genes including genes 
belonging to the AP-1 family that function downstream of the mitogen activated protein 
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kinase (MAPK) signaling cascade. The AP-1 family consists of members from the jun and 
fos oncogene families.  AP-1 transcription factors exist as heterodimeric complexes 
containing one product each from the jun and fos families or homodimers containing two 
members of the jun family.  AP-1 transcription factors transcriptionally activate genes that 
contain the AP-1 binding site or TPA-responsive element (TRE) in their promoter.  Another 
transcription factor also downstream of MAPK that has been shown to play a role in TPA 
tumor promotion is NF-kB (Li et al., 1998).  Inhibition of AP-1 and NF-kB activity in JB6 
cells blocks the transformation response (Li et al., 1997).  While a number of AP-1 and NF-
kB regulated genes are known, only a few have been implicated in TPA induced 
transformation (Cmarik et al., 1999) and it is likely that genes downstream of other 
transcriptional regulators may also be involved. 
Molecular Responses of JB6 Cells to TPA 
 The molecular responses contributing to differential TPA-induced transformation 
capacity of the JB6 P+ and P- variants have been studied extensively.  Bernstein and 
Colburn demonstrated that P+ cells but not P- cells display tumor promoter TPA inducible 
AP-1 transactivation (Bernstein and Colburn, 1989). TPA also induced c-jun expression 
preferentially in P+ cells (Ben-Ari et al., 1992).  Functional AP-1 activity is required for 
neoplastic transformation by TPA since expression of dominant negative c-jun in P+ cells 
inhibits TPA induced AP-1 transactivation and neoplastic transformation (Dong et al., 
1994).  Transgenic mice with transactivation mutant c-jun further demonstrated that AP-1 is 
required for tumor promotion (Young et al., 1999).  Differential display of untreated P+, P- 
and transformed (Tx) cell mRNAs identified seven differentially expressed sequences 
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including the tissue inhibitor of the metalloproteinases (TIMP-3) gene, whose transcription 
undergoes progressive decline as a function of progression toward a neoplastic endpoint 
(Sun et al., 1994).  Another study using differential display comparison of JB6 P+ and P- 
led to the identification of a gene product that blocks susceptibility to TPA tumor 
promotion. The cDNA, identical to the murine Pdcd4 gene, was found to be preferentially 
expressed in P- cells (Cmarik et al., 1999).  Differential display comparison of P+ and P- 
cells treated with TPA also led to the cloning of the mouse pleckstrin gene which is induced 
in P- cells (Cmarik et al., 2000).  Taken together, these differential display and other studies 
with JB6 cells suggest that the differential expression of a number of genes in P+ and P- 
cells, both constitutively and in response to TPA, may contribute to the transformation 
susceptibility and resistance of the JB6 variants.  
cDNA Microarrays – A Tool for Gene Expression Analyses  
 The advent of microarray technology makes it possible to assess and compare 
global gene expression changes by simultaneously monitoring the relative expression 
levels of a large number of genes in a quantitative manner. It therefore allows for rapid 
and precise identification of critical genes that could potentially serve as diagnostic and 
prognostic markers in pathological states. Additionally, discovery of patterns of gene 
expression are informative about regulatory pathways involved. The challenge in a 
microarray experiment is ‘making sense’ from the overwhelming amount of data 
obtained and to understand, on a global level, the biology behind the differential 
expression of hundreds of genes.        
 Complementary DNA (cDNA) microarrays compare expression of genes in two 
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samples, by measuring the concentration of the cDNAs corresponding to the mRNA 
transcripts in two samples.  A cDNA microarray consists of a glass or nylon slide 
containing a set of spots, each of which corresponds to a cDNA sequence from the 
genome, referred to as a probe.  cDNAs are generated from the two samples by reverse 
transcription of the isolated messenger RNAs (mRNAs), fluorescently-labeled with two 
different dyes, and co-hybridized to the microarray chip.  The fluorescently-labeled 
cDNAs from each sample competitively hybridize to the corresponding probe.  The 
concentration of cDNA in each sample is then measured on the basis of the fluorescence 
level for the spot of the corresponding probe.     
  cDNA microarray technology has significantly contributed to the identification 
and characterization of global gene expression profiles in several types of cancers as 
substantiated by the existing literature in this field.  A survey of recent literature on the 
use of cDNA microarray in gene expression profiling reveals its adaptability and 
applicability in a wide range of cancer types.  Briefly, cDNA microarray based gene 
expression profiling have been performed to study of human medulloblastomas (Packer, 
2003), T-cell leukemia/lymphoma (Tsukasaki et al., 2004), prostate cancer cells (Chesire 
et al., 2004), cervical cancer (Ahn et al., 2004) and papillary thyroid carcinoma (Yano et 
al., 2004), and many others.          
 A central challenge in the application of the available gene expression data to 
molecular diagnosis and treatment of cancer, is to define a set of molecular features that, 
taken together, distinguish a given cancer, or type of cancer, from all normal cells and 
tissues.  Microarray analyses of a broad variety of adenocarcinomas have led to the 
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identification of 61 genes whose expression levels predict the site of origin of the 
primary tumor (Dennis et al., 2002).  In gastric cancer of the intestinal subtype, 124 
genes were commonly up or down regulated, and profiles of 12 of these were associated 
with lymph node metastasis (Hasegawa et al., 2002).  In breast cancer a gene expression 
signature based on 70 genes was highly predictive of recurrence and survival in both 
node-negative and node-positive patients (van de Vijver et al., 2002).  Gene expression 
profiling of esophageal adenocarcinomas has led to identification of characteristics that 
can be used to distinguish between Barrett's esophagus and esophageal adenocarcinoma 
(Xu et al., 2002; Barret et al., 2002).  Molecular classification of cancers based on gene 
expression data have also been used in distinguishing myeloid from lymphoid cancer and 
subclasses within these two diseases (Golub et al., 1999; Armstrong et al., 2002; Schoch 
et al., 2002; Debernardi et al., 2003).  These and several other such studies underscore 
the efficacy of cDNA microarray analyses in identification of global gene expression 
changes that contribute to a given cellular phenotype.     
 One of the biggest contributions of microarray technology in cancer biology, 
however, will be its application as a diagnostic tool for cancer patient profiling for 
prediction of progression of the disease.  Several new clinical trials using DNA 
microarray chips are currently underway including those in breast cancer at the 
Netherlands Cancer Institute, Massachusetts General Hospital, M. D. Anderson Cancer 
Center and Baylor College of Medicine and, in multiple myeloma at the Dana-Farber 
Cancer Institute (Branca, 2003).  The first patient profiling tests to diagnose the chance 
of developing metastases based on gene expression profiling were launched by a Dutch 
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company ‘Agendia’, in early march of this year (Garber, 2004).  Larry Norton, an 
oncologist from the Memorial Sloan-Kettering Cancer Center, is said to have aptly 
described DNA array technology as, "This is the Wright Brothers' airplane. ... It's just 
the beginning of the era of molecular characterization of cancer" (Quoted from Branca, 
2003).                   
Research Outline         
 In this study, we used cDNA microarray analysis to identify constitutive and 
TPA induced global differences in the gene expression profile between the P+ and P- 
cells that contribute to their susceptibility and resistance to TPA induced neoplastic 
transformation.  Validation of the array data was accomplished through real-time PCR 
analysis of candidate genes. We then classified all the genes according to their biological 
functions as described in the biomedical literature in an attempt to link the expression 
pattern of gene classes to the phenotype of the two cells. Candidate cancer susceptibility 
and resistance relevant genes were grouped into six functional classes.  Valuable clues 
emerged as to the processes that might underlie the coordinate expression of these genes 
contributing to the migratory phenotype of the TPA treated P+ cells and the adhesive 
phenotype of the TPA treated P- cells.  A number of genes within the functional groups 
showed coordinated up- or down-regulation, which suggests the existence of distinct 
molecular pathways that are possibly deregulated during the process of neoplastic 
transformation.                    
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Preliminary Note         
 In this gene expression study the endpoint being measured is mRNA. The term 
‘gene’ has been used to refer to the identity of a gene or its expression product that is 
represented by a cDNA clone on the array. Identities of clones on the array were those 
provided by the company, Incyte Genomics. The identities of some of the clone which 
lacked known identities were later determined by us by aligning the clone sequence to 
the NCBI nucleotide database.  For still many unknown genes and sequences, their 
identity is subject to change as the public database becomes updated.  Furthermore, the 
current gene names are also subject to changes as the databases are continually updated. 
 The genes that are newly implicated in neoplastic transformation this study have been 
identified by doing extensive literature searches using the names of the genes. It is 
possible that one or more of these genes have been identified previously in microarray 
studies and exist in other array databases. 
Materials and Methods 
Cell Culture and Derivation of P+ Cl307b Cell   
 The Cl307b, tumor promotion resistant (P-) cell line was purchased from ATCC 
(Manassas, VA). Cells were grown and passaged as described (Bernstein and Walker, 
1999). The cells were routinely monitored for their tumor-promotion resistant phenotypes 
by analyzing the number of TPA induced colonies in soft agar assays. After 91 passages, the 
Cl307b P- cells spontaneously gave rise to cells that displayed a P+ phenotype in soft agar 
assay.  The change in phenotype was confirmed through soft agar assays performed in 
duplicate and repeated three times.  Frozen Cl307b P- cells (passage 85) which are close in 
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passage number to the now Cl307b P+ cells were revived and their phenotype was 
confirmed by soft agar assay. The two Cl307b P+ and P- cell lines were thus within six 
passages of one another and formed a matched pair of cell lines of highly similar genetic 
background. 
Soft Agar Transformation Assay 
  This assay was carried out according to established protocol (Colburn et al., 1981).  
Briefly,  bottom and top agar layers were prepared with agar mixture containing fetal bovine 
serum (FBS), dulbeccos phosphate buffered saline (DPBS), basal medium eagle’s (BME) 
and Bacto agar (1.25%; Difco, Detroit, MI).  The bottom layer consisted of 7 ml of 0.5% 
agar medium with DMSO or 10 ng/ml of TPA prepared in 60 mm petridishes.  Cells at 104 
cells per dish were suspended in the 1.5 ml of 0.33% top agar medium containing DMSO or 
TPA and layered on the prepared layer of bottom agar.  The dishes were incubated at 37◦C 
and the colonies were counted after 14 days. 
Treatment of Cells and RNA Isolation  
 Cl307b P- and P+ cells were grown in T150 flasks to 80% of plateau density and 
treated with 10ng/ml TPA or with DMSO solvent control for 8hrs in fresh EMEM with 4% 
FBS as described (Bernstein and Walker, 1999).  Total RNA was extracted from the treated 
cells by phenol guanidine isothiocyanate method using TRIZOL reagent (GibcoBRL Life 
technologies, Gaithersburg, MD).  High quality RNA is essential to the success of a 
microarray experiment.  The quality of the RNA samples was assessed by electrophoresis 
through denaturing agarose gels and staining with ethidium bromide.  Intact bands 
corresponding to 18S and 28S ribosomal RNA constituents were visualized under UV light 
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in an Alpha Multi-imager light cabinet (Alpha Innotech Corporation, San Leandro, CA).  
Poly (A) + RNA was purified from total RNA using an Oligotex mRNA isolation kit 
(Qiagen Inc, Valencia, CA) and quantitated using the Ribogreen RNA quantitation kit 
(Molecular Probes, Eugene, Oregon) according to manufacturer’s instructions.  
Microarray Set-Up   
 800ng/sample of poly (A)+ RNA from TPA treated and untreated P+ and P- cells 
were dispatched at 50ng/µl concentration in TE buffer to Incyte Genomics (Palo Alto, CA). 
 cDNAs were generated using reverse transcription.  The experimental set-up consisted of 
three sets of comparative hybridizations: (I) P- TPA vs. P+ TPA; (II) P- TPA vs. P- DMSO 
and (III) P+ TPA vs. P+ DMSO.  Each pair of cDNA was respectively labeled with Cy3 
(green) and Cy5 (red) flourophores, then co-hybridized for competitive binding to the 
mouse GEMTM 2 cDNA microarray (Incyte Genomics, Palo alto, CA).  The spots on the 
arrays corresponding to each of the hybridization sets were scanned independently for the 
two fluorescent colors and the ratios of the two fluorescence intensities provided a 
quantitative measurement of the relative gene expression level in the two samples.  To 
offset differences in the fading properties of the Cy3 and Cy5 dyes, the poly (A)+ RNA 
quality in terms of rRNA contamination and minor quantity differences between the 
samples, the fluorescent intensity corresponding to Cy5 (P2; Probe 2) was expressed as the 
balanced P2 signal which is a product of the P2 signal times balanced coefficient derived 
from the average Cy3 and Cy5 fluorescence intensities for each array.  The relative gene 
expression level is thus expressed as balanced differential, which can be written as P1 signal 
(Cy3) / P2 balanced signal (Cy5). 
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Primer Design and Reverse Transcription  
 Specific primers for real time PCR analyses were designed corresponding to 
accession numbers obtained for genes from the microarray results using the Primer Express 
software (Perkin-Elmer Applied Biosystems, Foster City, CA).  BLASTn searches were 
performed against the nonredundant set of genbank database sequences to confirm the 
likelihood of specific amplification of the chosen mRNA species without concomitant 
amplification of other gene products.  Primers were custom synthesized by Macromolecular 
Resources (Colorado State University, Fort Collins, CO) and Proligo USA Corp (La Jolla, 
CA). Primer sequences are shown in Table 1.  Amplification of the mRNA of interest was 
further verified by agarose gel electrophoresis of the PCR product.  100ng of poly (A)+ 
RNA/sample was reverse transcribed in a final volume of 100 µl containing 1X reverse 
transcriptase buffer (500mM each dNTP, 3mM MgCl2, 75mM KCl and 50mM Tris-HCl, 
pH 8.3), 25units of RNase inhibitor (Promega, Madison, WI), 10mM DTT, 10units/µl of 
Superscript II RNAse H- reverse transcriptase (Life Technologies Inc., Gaithersburg, MD) 
and 5µM oligo d(T) primer.  Samples were incubated at 42◦C for 50 min and reverse 
transcriptase was inactivated by heating at 90◦C for 5 min and cooling at 4◦C for 5 min.  The 
samples were then stored at -20◦C. 
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Table 1   Sequences of primers used in real time PCR analysis. 
 
 
         
             GENE                                              5'   -   FORWARD   -  3'                                      5'   -    REVERSE   -  3' 
_____________________________________________________________________________________________________________ 
             
HMG I-C                               TTACCGCCCATCTCCAGAGT                            TGTTGGTGCCCGTTTGC 
ZYXIN                                                      AGATGACAACGGCGGTTT                               GCTCTAGCGGAGTGGCACTT 
PROCOLLAGEN  TYPE V                     AAATGTCTTATGATAACAACCCCTACA         TTCTGTTAGCCTTTCTTGGTAGCA 
PROCOLLAGEN  TYPE I               CCTCCACCCCAATCTGGTT                       TGGGTTGTTCGTCTGTTTCCA 
NUR77                                                      TCCTGGCAGACCTTCAACAGT                  CTGCAGTGGCCTTTCCAGAT 
TENASCIN C                                        CTATCGCAACTGGAAGGCCTAT                  TTGCTCAGGTTATCCAGTCCAA 
PG-M/ VERSICAN                            AACTGCTTTCCTGATTGGCATT                  CAGAGATCAGGTCCTGGTAGGTAAA 
GAPDH                                         TGTGTCCGTCGTGGATCTGA                  CCTGCTTCACCACCTTCTTGA 
LYSYL OXIDASE                            TTTTAATGAGTGAGCCACAATTTGA     GAGGCAAATATAGGCTCATCATCA 
SLPI             CCTCGGGACTGGTCATCAGA                  GAGCACCGTGAAAGGTAAAAGG 
CATHEPSIN H      TCCCATTCCTCAGGTATAAGCC                  CAGTTCCTCCCTTGGTCTGC 
CATHEPSIN L       AGCCAAAGACCGGGACAAC                  CCCATCAATTCACGACAGGAT 
TIMP 1         TCATGGAAAGCCTCTGTGGAT                  CGGCCCGTGATGAGAAACT 
MATRIX  GLA      GCTCCCTCTGGCCATCCT                               TCCATGCTTTCGTGAGATTCG 
DECORIN      TGGAAAGGCTTTACCTGTCTAAGAA     GACACGAAGTTCCTGGAGAGTTC 
WDR1         ACATTGCCTGGACGGAAGAC                  GCTCCAAACTTCTCCCTTCCTT 
CALPONIN 2       CTTTCCCACGACTCTCAGACTTC                  ACATCTGGCTTGCCTCAGTTC 
P203/P205 (AI036073)     TGTGTGGAGACCACAGTTTCGT                  TTGTGCTTGACAGGACAGTTGA 
IFI – 16                   TGGGTTGCAGCTGAAGTCTGT                  TTGAGTGGCTTTCCTTCACCTT 
PROCOLLAGEN TYPE IV    AGCTGGGAAGTTGCCTGTGT                  GTTAGCCTCCTTCATCCTGCAT 
CONNEXIN 43      GGCCTGATGACCTGGAGATTT                  ACGTTCTGCAAGCACCCTTT 
SLIT2         TCATTTGTGGACGAGGTTGAGA                  CGCGCTTAGGAGGCACAT 
CRABP II      TGGAGAGCTGATCCTGACAATG                  AGGCACTCACTCTCGGACGTA 
RAS GAP      TCAGTTCAGCATAAGTGGCCTACA     CAGGATAGCAGGGCAGATAGG 
PRX2/S8      GGCCAAAGAGTTCAGCCTACA                  AGCTGGACCCAATGCACAGT 
_____________________________________________________________________________________________________________ 
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Real-time PCR Analysis  
 All Real-time PCR reactions were performed using an ABI Prism 7700 Sequence 
Detection System (Perkin-Elmer Applied Biosystems, Foster city, CA).  PCR was 
performed using SYBR Green PCR Core Reagent Kit (Perkins-Elmer Applied Biosystems, 
Foster City, CA) according to manufacturer’s instructions. Each reaction (50µl) contained 
25 µl of 2X Master SYBR Green I mix (containing Taq DNA polymerase, dNTP, MgCl2 
and SYBR Green I dye), 0.3 µmol/L primers and 2.5 µl of cDNA from the reverse 
transcription reaction detailed above. The thermal cycling conditions comprised an initial 
denaturing step at 95◦C for 10min and amplification program of 50 cycles at 95◦C for 15s 
and 65◦C for 1 min. The end point used in the real-time PCR quantitation, threshold cycle 
(Ct), is defined as the PCR cycle number at which the fluorescence signal generated passes a 
fixed threshold over baseline.  Experiments were performed in duplicates or triplicates for 
each gene analyzed. 
Wound Healing Assay   
 P+  Cl307b and P- Cl307b cells were plated into 6 well tissue culture dishes 
(Nunc, Inc. Napersville, IL) at 1.5 x 104 cells per well in 4% fetal bovine serum (FBS) in 
Eagle’s minimal essential medium (EMEM) on day 1 of the experiment.  Media was 
then changed to 4% FBS in EMEM with 10ng/ml TPA or DMSO solvent control.  
Within 15 minutes of media change, cultures were wounded by scratching the monolayer 
of cells with a P1000 eppendorf pipet tip, and media was again changed to fresh EMEM 
with or without TPA.  Cells were allowed to migrate into the wound for up to 48 hours.  
Wounds were fixed in 2% (w/v) paraformaldehyde in PBS, stained with 1% crystal 
 33
violet and photographed within the course the recovery period with an Olympus SC 32 
type 12 camera in an Olympus CK2 microscope at 4X magnification. 
Phalloidin Staining   
 P+ and P- Cl307b cells at 90% confluence growing in 60mm Nunc tissue culture 
dishes (Nunc Inc., Napersville, IL) were treated with TPA (10ng/ml) or DMSO solvent 
control for 8 hours duration then stained with phalloidin as described (Stephens and 
Banting, 2000) and photographed with a Nikon FX-35A camera in a Nikon Labophot 
fluorescent microscope (Nikon, Tokyo, Japan) at 10X, 20X and 40X magnifications.    
Results 
 To identify candidate genes that mediate transformation susceptibility and resistance 
and early events in TPA tumor promoter-induced transformation, we analyzed the 
comparative gene expression profiles of tumor promoter TPA treated and untreated P+ and 
P- JB6 cells by comparative cDNA microarray analyses.  To minimize the likelihood of 
gene expression differences attributable to non-specific genetic differences, the cell lines 
used in this comparative gene expression profiling were a closely matched pair.  The P+ 
cells arose spontaneously from the P- cell line and were within six passages of the 
transition.  Transformation assays for anchorage independent growth demonstrated that the 
P+ cells formed significantly more number of colonies in response to TPA treatment than 
the P- cells. The mean number of colonies per 10,000 cells was 739 for P+ cells and 82 for 
P- cells.  The average colony size for the P+ cells was also significantly larger compared to 
that for P- cells as shown in (Shown in Figure 3). 
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Figure 3   TPA treated P+ cells form significantly larger and greater number of 
anchorage independent colonies than P- cells.  Cl307b P- and P+ JB6 cells at 104 cells 
per dish were suspended in the 1.5 ml of 0.33% top agar medium containing DMSO 
(solvent control) or TPA (10 ng/ml) and layered on the prepared layer of bottom agar.  The 
dishes were incubated at 37◦C and the colonies were counted after 14 days and 
photographed with an Olympus microscope at 20X magnification.  
 
 
 
 
P- 
P+ 
TPA DMSO 
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Figure 4   Comparative cDNA microarray strategy. The experimental setup consisted of 
three comparative arrays: (I) TPA treated P- cells and TPA treated P+ cells;  (II) TPA and 
DMSO treated P- cells and (III) TPA and DMSO treated P+ cells.  
 
P- D    P+ D 
 
 
 
 
 
P- T    P+ T 
(II) (III) 
   (I) 
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To specifically identify both endogenous and TPA induced differences in the gene 
expression profiles between the two cell lines, three comparative microarray hybridizations 
were performed.  To identify genes whose expression levels are modulated by TPA in the 
resistant (P-) cells, Cy3 and Cy5 fluorescent labeled probes prepared from P- cDNA treated 
with TPA or DMSO were co-hybridized for competitive binding to the GEMTM 2 cDNA 
microarray.  This constituted the first “leg” of the experimental setup (Figure 4).  The 
second leg, designed to identify genes whose expression levels are modulated in response to 
TPA in the susceptible (P+) cells, consisted of Cy3 and Cy5 labeled cDNA probes prepared 
from P+ cells treated with TPA or DMSO.  The third leg was designed to identify those 
TPA modulated genes whose expression levels are differential between the P- and the P+ 
cells and consisted of co-hybridization of Cy3 and Cy5 labeled probes generated from TPA 
treated P- and P+ cDNAs.        
 In the initial analyses, balanced differential expression data corresponding to every 
element (i.e., genes and ests) on the array was evaluated.  The raw fluorescence 
hybridization data illustrating differential expression of several prototypical genes are 
shown in Figure 5.   Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serves as a 
control showing little or no significant differential expression in any of the three legs of the 
experiment.  The detectable levels of differential expression in the Incyte array are 
differential expression ratios greater than or equal to 1.7.  Therefore 1.7-fold differential 
expression was chosen as the minimum differential and genes exhibiting fold changes of 
less than 1.7-fold were excluded from further analyses.    
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Figure 5  Microarray scan data for select prototypical genes showing Cy3 and Cy5 
fluorescence intensities. The spots on the arrays for each leg of the experiment (I, II and III) 
were scanned independently for the red and green fluorescent colors and the ratios of the 
two fluorescent intensities provided a quantitative measurement of the relative gene 
expression level in the two samples. Yellow spots represent a range of combinations of the 
red and green contributions.
T D T DP- P+
(II) P- (III) P+(I) TPA
GAPDH 
MATRIX GAMMA 
CARBOXYGLUTAMATE 
TIMP 1 
PROCOLLAGEN  
5.4 16-3.1
4.9 4.51.2
-4.8 -4-2.1
1.31.2 1
TYPE 1 ALPHA 1 
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Figure 6  TPA up regulates more genes in P- cells.  Scatterplots showing the modulation of gene expression in P- and P+ cells 
following TPA treatment. cDNA was generated from P+ and P- cells treated with TPA or DMSO and labeled with Cy3 and Cy5 
fluorescent dyes for microarray hybridization. Samples were hybridized to the Mouse GEMTM 2 array (Incyte Genomics, Palo Alto, 
CA) as described in Materials and Methods. Data were analyzed using the SPSS software (SPSS Inc. Chicago, IL) and plotted as 
balanced differential revealing up- and down- regulated expression of genetic elements on the array. The x and y-axes represent 
Cy3 and Cy5 fluorescence intensity values in log scale. Each small blue square in the plot represents one gene element on the array. 
Data points above diagonal black lines were for upregulated genes; below diagonal black lines were for downregulated genes. All 
spots between the red diagonal lines exhibit 1.7-fold or lower differential expression ratios; those between the red and green 
diagonal lines have between 1.7-fold to 2-fold; those between the green and dark blue diagonal lines have between 2-fold and 5-
fold ratios; those outside the dark blue lines exceed 5-fold ratios. (I, II and III) Ratios of the distribution of fluorescence intensities 
between cDNAs prepared from (I) TPA treated P- cells and TPA treated P+ cells; (II) TPA and DMSO treated P- cells; (III) TPA 
and DMSO treated P+ cells.   
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TPA Induces More Genes in P- than P+ cells by Comparative cDNA Microarray   
 The relative fluorescence intensities of Cy3 and Cy5 for the 9500 elements are 
represented as scatterplots in Figure 6 showing the global gene expression profile in the 
three microarray hybridizations.  As shown in the Figure 6, majority of the 9500 represented 
elements are not differentially expressed as a function of TPA treatment or phenotype 
(compare I and II, and III).  However, the spread of the data points in the last two 
scatterplots demonstrate that there are more TPA modulated genes in the P- cells than the 
P+ cells.  These data are further illustrated by Figure 7 which shows histograms comparing 
the distribution of fold change in differential expression ratios for all the elements in the 
arrays. TPA treatment resulted in the modulation of expression of 204 genes in P- cells and 
168 genes in the P+ cells.  As shown in Figure 7B, 123 genetic elements are upregulated in 
P- cells while only 82 are upregulated in the P+ cells. The number of genetic elements down 
regulated by TPA is almost equal in the P- and P+ cells (81 and 86 respectively).  Seventy-
four of the 9500 genes (0.78%) were differentially expressed between the two lines 
following TPA treatment, 52 genes were induced by TPA in P- cells and 22 genes were 
induced the P+ cells.  
 The differential expression ratios of all the genes and expressed sequence tags (ests) 
that show more than 1.7-fold TPA modulated differential expression in P- and P+ cells 
(First leg of the hybridizations) are summarized in Table 2.  Both constitutive and TPA-
induced differential expressions are considered to be significant, since either differential can 
have impact upon promotion susceptibility or resistance.  Since comparison of expression 
levels in TPA treated P+ vs. TPA treated P- cells will yield a composite of the constitutive  
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Figure 7   Distribution of fold change in gene expression: TPA modulates more genes in P- 
cells than P+ cells.   A. Distribution of TPA induced fold change in legs II and III of the 
array. Each category includes all genes that have at least (and up to the next higher value) 
the fold change indicated on the x-axis. ‘NC’, no change.  B. Number of genes up-
regulated and down-regulated by TPA in P+ and P- cells.  C.  Distribution of fold change in 
leg I of the array.  
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Table 2   Genes up- or down-regulated in P+ and P- cells in comparative cDNA microarray. 
 _____________________________________________________________________________________________ 
GENES/ESTs                                  Accession      Leg 1a      Leg 2 a      Leg 3 a 
               Number     P-T/P+T   P-T/P-D  P+D/P+T 
P- > P+ 
 PG-M/Versican     AA755868 3.4 -1  1.3 
 Fractalkine/neurotactin     W16003 3.4 3.3  -1.9 
 Recombining binding protein suppressor of hairless AI390138 3.1 3.5  -1.7 
 Complement factor H-related protein   AA570965 2.8 -1.4  1.3 
 Interferon inducible p203/p205    AI036073 2.4 1.3  1.2 
 Neuritin      AA237727 2.4 2.2  -1.5 
 Similar to microsomal dipeptidase precursor  AA444538 2.4 2.3  -1.3 
 Decorin      AA755007 2.3 -1.2   -1.3 
 SLIT 2       AA691931 2.3 -1.7  -1.2 
 LOC328494 gene     AA856323 2.3 2.5  -1.6 
 Interferon inducible family    AA472976 2.2 1.4  1.1 
 Interferon inducible IFI-16    AA238257 2.2 1.5  -1.1 
 Secretory leucocyte protease inhibitor (SLPI)  AI020539 2.2 1.9  -1 
 WDR1       AA624634 2.2 1.8   1 
 Nur77/N10      AA209882 2.1 2.5  -1.2 
 Zyxin       AA617310 2.1 -1.4  2.7 
 HSP 25       W34262 2.1 1.8  -1.1 
 VLDL receptor      AA020307 2.1 1.4  2.5 
 Calponin 2      W34124 2 -1.4  1.9 
 Skeletal muscle alpha actin    AA770902 2 1.5  1.7 
 Vascular smooth muscle alpha actin    AA624460 2 1.4  2.3 
 Semaphorin 3a/D/collapsin 1    AI894009 2 -1.1  1.3 
 UDP-glucoronosyltransferase 1    AA822117 2 1.1  -1 
 Ras GAP      AA432613 2 3.4  -3 
 Phosphoserine phosphatase    AA066981 2 1.3  1.8 
 Tenascin C      W12942 1.9 4.3  -1.8 
 Smooth muscle enteric gamma actin   AA756136 1.9 1.5  1.8 
Transgelin 2 / SM22 beta    AI643202 1.9 2.2   1 
 Connexin 43      AA738914 1.9 1.3  -1.4 
 Procollagen, type VI, alpha 1    W16221 1.9 -1.4   2 
 Nidogen / entactin     AA606605 1.9 1.7  -1.7 
 Cellular retinoic acid binding protein II (CRABPII) AA051397 1.9 -1.1  1.2 
 Regulatory protein, T lymphocyte 1   AI614435 1.9 -1.8   2 
 Cardiac alpha actin     AI325745 1.8 1.5  1.6 
 Deleted in oral cancer 1 ( Doc1)   AA638778 1.8 1.6  -1.3 
 Voltage dependent calcium channel, alpha2/delta AA734015 1.8 1.1  -1.3 
 Variable group of 2-cell-stage gene family  AA415841 1.8 1.2  1.2 
 Monocyte to macrophage differentiation-associated geneAA072083 1.8 1.3  -1.3 
 cGMP-dependent protein kinase type II   AA771678 1.7 4.5  -3.8 
 Destrin      AI390104 1.7 1.5  1.3 
 Immediate early response 3 / IEX 1   AA833402 1.7 2.3  -1.5 
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Table 2 continued 
_________________________________________________________________________ 
GENES/ESTs                                     Accession      Leg 1a     Leg 2 a     Leg 3 a 
                   Number  P-T/P+T  P-T/P-D  P+D/P+T 
 
Selenoprotein P      AA066225 1.7 -1.7   1.1 
 Ninjurin 1      AI036381 1.7 1.3   1.2 
 Thymic epithelial cell surface antigen   AA619756 1.7 1.4   1.1 
 Bone morphogenetic protein 5 (BMP5)   AA242542 1.7 2.4   -1.7 
 Kinesin family member 21A    AI390275 1.7 1.3   -1.1 
 Prx2/ S8      W97877 1.7 -1.2   1.3 
 Neprilysin/CD10/NEP     AA450725 1.7 -2.6   1.5 
 RIKEN clone 1600012F09 gene   AA789636 1.7 1.5   -1 
 Est       AA413015 1.7 1.1   1.2 
 Tissue inhibitor of metalloproteinase 1 (TIMP1) AA184223 1.2 4.9   -4.5 
 Cathepsin L      AA619763 1 3.9   -3.7 
P+ > P-       
 Matrixgamma carboxyglutamate (matrix GLA)  W88093 -3.1 5.4   -16 
 Cathepsin H      W17422 -2.9 1   -1.7 
 RIKEN clone 5730559C18    AA689893 -2.8 0.45   -2.1 
 CDP-diacylglycerol synthase    AA067625 -2.8 4   -11 
 Troponin T2, cardiac     AA671284 -2.2 1.2   -2.3 
 Procollagen  TypeI, alpha 2    AA798297 -2.2 -4   3.3 
 RIKEN clone 4932442K08    W62706 -2.2 -1.6   -1.3 
 Procollagen Type I, alpha 1    AI425767 -2.1 -4.8   4 
 Lysyl Oxidase      W83882 -2.1 1.1   2.7 
 Calcyclin (S100A6)     W09198 -2.1 -1.2   -1.3 
 RIKEN cDNA 2810418N01 gene   AA543968 -1.9 -1.4   -1.4 
 Clone B930019K04     AA760161 -1.8 1.9   -2.3 
 Clone RP23-10B20     AA575501 -1.8 -1.1   -1 
 RIN ZF zinc finger DNA binding protein  AA619834 -1.7 1    1 
 Procollagen, type IV, alpha 1    AA760135 -1.7 2   -2.3 
 60S ribosomal protein L38    AA718476 -1.7 -1.3   -1.5 
 Calreticulin      AA562976 -1.7 -1.4   -1.3 
 Homolog of 60S RIBOSOMAL PROTEIN L39   AA600661 -1.7 -1.4   -1.5 
 RIKEN cDNA 9130005N14 gene   AA718842 -1.7 -1.5   -1 
 RIKEN clone 5330401006    W80245 -1.7 -1.9   -1.1 
 LOC 209096 gene     AA220093 -1.7 -1.3   -1.3 
 Procollagen TypeV, alpha 1    AA792297 -1.1 -1.9   2.4 
 High mobility group protein I-C   AA097062 -1.2 2.7   -5.5 
_____________________________________________________________________________________________ 
 
a   The balanced differential expression data from the three microarray sets were analyzed (Columns 3-5). The 
table shows the ratios of mRNA expression for genes in the three legs of the array experiment.  Column 1, gene 
names; column 2, accession numbers; column 3, leg I of the array (P- TPA/P+ TPA); column 4, leg II of the 
array (P-TPA/P-DMSO); column 5, leg III of the array (P+TPA/P+ DMSO). 
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and induced contributions to the final level, we focused on these genes for further analysis.  
A total of 74 genes and ests are differentially expressed in TPA treated P- vs. P+ cells (Leg 
I).  Two genes showing high differential expression ratio in the P- TPA / P- DMSO 
hybridization have also been included in this list.  
Real-time PCR Validates Differential Expression Ratios of 25 Candidate Tumor Promotion-
Relevant Genes  
 Real-time PCR was carried out to validate the changes in gene expression observed 
by microarray using an independent method.  Real-time PCR analysis was repeated at least 
twice for each gene analyzed.  The first real-time PCR was performed using RNA samples 
identical to those used in the microarray experiment.  The duplicate and triplicate real-time 
PCR experiments were performed with new samples of RNA prepared from the same P- 
and P+ cells.  The values obtained from the different experiments were averaged and the 
mean values were then compared to the values obtained from the cDNA microarray 
analyses.  Even though there was a slight variability in the magnitude of the response 
between the two methods for several genes, the patterns of response were essentially in 
concordance.  The real-time PCR results for 91% (68 of the 75 profiles; see Figure 8) of the 
25 genes analyzed correlated well with the various legs of the cDNA microarray data.  
Genes exhibiting discordance include; tissue inhibitor of metalloproteinase (TIMP1) and 
cathepsin H that showed significant differential expression by real time PCR but not in the 
array, and secretory leukocyte protease inhibitor (SLPI) that showed significant induction in 
the array but not in real time PCR.  
While the three legs of the microarray experiment did not directly provide  
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Figure 8  Real-time PCR analyses validate relative mRNA expression data obtained from cDNA microarray.  Roman numbers on top panel 
represent one leg of the experiment. I, P- TPA vs. P+ TPA; II, P- TPA vs. P- DMSO; III, P+ TPA vs. P+ DMSO; IV, P- DMSO vs. P+ DMSO.  
A, Blue border, Class I genes (ECM and basement membrane proteins); B, Black, Class II (Cytoskeletal proteins); C, Pink, Class III (Enzymes 
and signal transduction proteins); D, Grey, Class IV (Interferon inducible proteins); E, Green, Class V (Transcription factors and DNA binding 
protein). Standard deviation for duplicates are indicated with asterisks; standard error of mean for triplicate have error bar and no asterisks. 
Black bar graphs, real time PCR; Grey bar graphs, microarray data. Black horizontal reference line in each graph indicates no change in 
expression Values below black line, down regulation. Values above black line, Up regulation.  
 I      II     III  IV             I      II     III  IV             I      II     III  IV             I     II      III  IV            I      II     III  IV A 
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Figure 8 continued 
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Table 3    Functional categorization of genes differentially expressed in TPA treated P- and 
P+ cells into six classes.  
 
         Moleculea                                                                                        P+ vs. P-b 
_____________________________________________________________________________
          
CLASS I: Extracellular Matrix/ Basement membrane  
structural and regulatory proteins 
 
ECM collagen related 
     Procollagen I, α1        P+ > P- 
     Procollagen I, α2        P+ > P- 
     Procollagen V, α2        P+ > P- 
     Lysyl oxidase        P+ > P- 
     Procollagen VI, α1        P- > P+ 
Basement membrane structural protein 
      Nidogen/entactin        P- > P+ 
      Procollagen IV, α1        P+ > P- 
Proteases and inhibitors 
   Proteases 
     Cathepsin H         P+ > P- 
     Neprilysin/CD10/NEP       P+ > P- 
  Inhibitors 
     TIMP1         P- > P+ 
     SLPI         P- > P+ 
Adhesion and migration factors 
   ECM proteoglycans 
     Decorin         P- > P+ 
     PG-M/versican        P- > P+ 
     Tenascin C         P- > P+ 
  Axon guidance specific adhesion  factors 
     SLIT2         P- > P+ 
     Semaphorin D        P- > P+ 
     Fractalkine         P- > P+ 
     Neuritin         P- > P+ 
     Ninjurin         P- > P+ 
Calcium regulatory ECM protein 
     Matrix GLA         P+ > P- 
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Table 3 continued 
 
          Molecule                                                                                        P+ vs. P- 
_____________________________________________________________________________ 
 
CLASS II: Cytoskeletal proteins 
Calcium regulated cytoskeletal proteins 
     Calponin 2         P- > P+ 
     Calcyclin         P- > P+ 
     Troponin T2         P+ > P- 
Actin and other cytoskeletal proteins 
     Smooth muscle enteric actin       P- > P+ 
     Vascular smooth muscle cell actin      P- > P+ 
     Cardiac actin        P- > P+ 
     Skeletal muscle actin       P- > P+ 
     Transgelin         P- > P+ 
     HSP25         P- > P+ 
     Zyxin         P- > P+ 
     WDRI         P- > P+ 
     Destrin         P+ > P- 
     Macrophilin         P+ > P- 
 
 
CLASS III: Enzymes and signal transduction proteins  
Enzymes and associated proteins 
     Ras GTPase activating protein      P- > P+ 
     Bone morphogenetic protein       P- > P+ 
     Phosphoserine phosphatase       P- > P+ 
     UDP gluconosyl transferase-1      P- > P+ 
     cGMP dependent protein kinase type II     P- > P+ 
     CDP diacylglycerol synthase       P+ > P- 
Receptors 
     VLDL receptor        P- > P+ 
     Calcium regulatory proteins       P- > P+ 
     Voltage dependent calcium channel alpha2/delta    P- > P+ 
     Calreticulin         P+ > P- 
Cell cycle and apoptotic mediators 
     Deleted in oral cancer-1       P- > P+ 
     IEX-1         P- > P+ 
Intercellular junctional protein 
     Connexin 43 GAP junction protein       P- > P+ 
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Table 3 continued 
 
 Molecule                                                                                P+ vs. P- 
_____________________________________________________________________________ 
 
CLASS IV: Interferon inducible genes 
     IFI 203/205         P- > P+ 
     IFI 16         P- > P+ 
 
CLASS V: Transcriptional regulators 
     RIN ZF zinc finger DNA binding protein                  P+ > P- 
     Nur77/N10         P- > P+ 
     Retinoic acid binding protein II (CRABPII)     P- > P+ 
     Prx2/S8         P+ > P- 
 
CLASS VI: Genes of unknown function 
Ribosomal proteins and homolog 
     60S ribosomal protein L38       P+ > P- 
     Homolog to ribosomal protein L39       P+ > P- 
Other genes 
     Kinesin family member 21A       P- > P+ 
     Complement factor H related protein      P- > P+ 
     Recombining binding protein suppressor of hairless    P- > P+ 
     Variable group of two cell stage family      P- > P+ 
     Selenoprotein P, plasma 1       P- > P+ 
     Thymic epithelial cell surface antigen      P- > P+ 
     Regulatory protein T lymphocyte (Rpt-1)      P- > P+ 
     Monocyte to macrophage differentiation associated gene    P- > P+ 
     Similar to microsomal dipeptidase      P- > P+ 
     RIKEN cDNA 1600012F09 gene      P- > P+ 
     LOC328494 gene        P- > P+ 
     RIKEN cDNA 9130005N14       P+ > P- 
     RIKEN cDNA 5730559C18       P+ > P- 
     RIKEN cDNA 4932442K08       P+ > P- 
     RIKEN cDNA 2810418N01       P+ > P- 
     Clone B930019K04        P+ > P- 
     RIKEN clone 5330401006       P+ > P- 
     LOC209096         P+ > P- 
    Clone RP23-10B20        P+ > P- 
Ests of unknown genes 
     EST AA413015        P- > P+ 
_____________________________________________________________________________________ 
 
a Column 1, Names of genes; b Column 2, Relative expression in TPA treated P- and P+ 
cells: genes for which P-/P+ ≥ 1.7say P- > P+; genes for which P+/P- ≥ 1.7 say P+ > P-. 
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differential expression ratios of TPA untreated P+ versus P- cells, the real-time PCR 
analysis directly provided values corresponding to the endogenous differential expression 
ratios of P- DMSO vs. P+ DMSO and these were used for verification of the ratios derived 
from the three legs of the cDNA microarray analysis. The endogenous expression ratios 
derived from the three legs of the microarray hybridization analysis are in agreement with 
those obtained from the real-time PCR analyses. 
Candidate Genes Relevant to TPA Induced Transformation Susceptibility and Resistance 
Belong to Six Functional Categories 
 The genes showing significant differential expression are categorized into six 
different functional groups according to their biological functions as shown in Table 3, and 
are; Class I, Extracellular matrix (ECM) /basement membrane structural and regulatory 
proteins (20 genes); Class II, Cytoskeletal proteins (13 genes); Class III, Enzymes and 
signal transduction proteins (12 genes); Class IV, Interferon inducible genes (IFI;  2 genes); 
Class V, transcription factors/DNA binding proteins (4 genes); Class VI, Genes of unknown 
function (21 genes and 1 EST). 
Increased Cytoskeletal Actins and Cell-Cell Interaction in P- Cells 
 Nine isoforms of actin and actin-binding proteins are preferentially expressed in 
P- cells.  Actins and actin binding proteins are key cytoskeletal components involved in 
formation of cell cortex and stress fibers. The formation of stress fibers favor a adhesive 
phenotype.  These data along with the expression pattern of several other groups of 
genes (including higher expression of several adhesion-related genes in the ECM 
category and, protease inhibitors) in the P- cells support the notion that P- cells have a  
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Figure 9  TPA treated P- cells contain more cortical actin staining, and cell-cell interaction 
compared to P+ cells.   P+ and P- cells  plated at equal densities were treated with TPA or 
DMSO solvent control for 8 h, stained as described in ‘Materials and methods’ and 
photographed. Left column, DMSO treated cells; right column, TPA-treated cells; Top row; P- 
cells, 20X magnification; second row, P+ cells, 20X magnification; Third row, P- cells, 40X 
magnification; Fourth row, P+ cells, 40X magnification.             , Lamellipodia;               , 
Filopodia 
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more adhesive phenotype.  Cytoskeletal arrangement and cell-cell interactions in P+ and 
P- cells were therefore studied by phalloidin staining.  Phalloidin staining in Figure 9 
shows that P- cells exhibit significantly more cortical actin compared to P+ cells.  
Additionally, P- cells also exhibit more cell-cell adhesion, both in the presence and 
absence of TPA, compared to P+ cells.  TPA-treated P+ cells exhibit limited cell-cell 
adhesion and contained significantly more lamellipodia and filopodia than P- cells.  
While almost 100% of TPA untreated P- and P+ cells contain stress fibers, most of the 
cells of both phenotypes lack stress fibers following 8 hours of TPA treatment.   
Increased Wound Healing in TPA Treated P+ Cells 
 Phalloidin data illustrated increased lamellipodia and filopodia in TPA treated P+ 
cells.  Because lamellipodia and filopodia implement cell migration and because of the 
expression pattern of several other groups of genes that mediate migration (including 
higher expression of proteases and the cytoskeletal proteins, Calcyclin and Troponin T2) 
in the P+ cells, we hypothesized that TPA treated P+ have a more migratory phenotype 
than P- cells.   To test this hypothesis, P+ and P- migration rates were compared in 
wound healing assays (Figure 10).  P- and P+ cells exhibited similar rates of wound 
closure in the absence of TPA, with partial closure by 12 hours, and with the majority of 
the wound closed by 48 hours in both cell types.   However, the P- and P+ cells 
displayed markedly different migratory responses following TPA treatment.  While TPA 
significantly inhibited wound closure in P- cells, TPA enhanced healing in P+ cells such 
that wounds had closed completely after 48 hours.  These data demonstrate that TPA-
treated P+ cells migrate significantly faster than P- cells.  
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Figure 10  Increased cell migration and wound healing in TPA treated P+ cells 
compared to P- cells.  P+ and P- cell cultures were wounded, treated with TPA for times 
ranging from 0 to 48 h, stained as described in ‘Materials and methods’ and 
photographed at 4X magnification. Left column, P- cells; right column, P+ cells; top 
row, 0h, DMSO; second row, 12h, DMSO; third row, 48h, DMSO; fourth row, 12h, 
TPA; Fifth row, 48h, TPA. 
P- P+ 
12h D 
0h D 
48h T 
12h T 
48h D 
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Table 4   Twenty-six genes and ESTs that have not been previously implicated in 
carcinogenesis are differentially expressed in TPA treated promotion-susceptible and 
resistant cells.  
________________________________________________________________________ 
Adhesion (Neuronal guidance) 
   Neuritin (P- > P+)a   
 
Transcription factors               
   Prx2/S8 homeobox transcription factor (P- > P+)    
   RIN-ZF putative transcription factor (P+ > P-) 
 
Ribosomal Protein 
   Homolog to ribosomal protein L39 (P+ > P-) 
 
Interferon inducible proteins (IFI family) 
   IFI 16 (P- > P+) 
   IFI p203/p205 (P- > P+) 
 
Cytoskeletal function/actin binding 
   WDR1 (P- > P+) 
   Transgelin 2/SM22β (P- > P+) 
 
Signal Transduction 
   Cytidyl diphosphate (CDP)-diacylglycerol synthase (CDS) (P+ > P-) 
 
Uncharacterized 
   Kinesin Family member 21A (P- > P+ ) 
   Thymic epithelial cell surface antigen (P- > P+) 
   Recombining protein suppressor of hairless (P- > P+) 
   Variable group of two cell-stage family (P- > P+) 
   Monocyte to macrophage differentiation associated protein (P- > P+)   
   RIKEN clone 9130005N14 gene (P+ > P-) 
   Similar to putative to microsomal dipeptidase precursor (P- > P+) 
   RIKEN cDNA 1600012F09 gene (P- > P+) 
   LOC328494 gene (P- > P+)  
   CloneRP23-10B20 (P- > P+) 
   RIKEN clone 5730559C18   (P+ > P-) 
   RIKEN clone 4932442K08   (P+ > P-) 
   RIKEN clone 2810418N01 gene (P+ > P-) 
   RIKEN clone 5330401006 (P+ > P-) 
   Clone B930019K04 (P+ > P-) 
   LOC209096 gene (P+ > P-) 
 EST AA413015 (P- > P+) 
__________________________________________________________________________________ 
a The genes with known functions have been categorized into their respective classes. 
Relative expression in TPA treated P+ or P- cells are designated with ‘>’ or ‘<’ signs in 
parenthesis. 
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Nine Known and Sixteen Unknown Genes are Newly Implicated in TPA Induced 
Transformation 
 Among these differentially expressed genes are 26 sequences implicated in cancer 
for the first time in this study (shown in Table 4). These include 25 genes and an EST.  Of 
the 25 genes, 13 sequences have no known function.  Genes with known functions include 
transcription factor Prx2/S8, interferon inducible genes IFI16 and IFI-p203/p205, CDS and 
adhesion molecule neuritin. 
Discussion 
 The study described in this chapter has led to the identification of several 
functional categories of genes that are potential candidates in susceptibility and 
resistance to tumor promoter induced neoplastic transformation.  Furthermore, the study 
has implicated several genes for the first time in the process of neoplastic 
transformation.  Collectively, our results provide indications of a more adhesive, pro-
apoptotic, pro-tumor suppressive effect, consistent with a protective response in the P- 
cells against TPA induced neoplastic transformation and more motile, anti-tumor 
suppressive effect in P+ cells consistent with susceptibility to TPA induced neoplastic 
transformation.   The following model (Figure 11) illustrates an overview of the major 
categories of differentially expressed genes in the P- and P+ JB6 cells that contribute to 
their susceptibility and resistance.  
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Figure 11  Model illustrating an overview of the major categories of differentially 
expressed genes in the P- and P+ JB6 cells that contribute to their susceptibility and 
resistance.   , increase in gene expression. 
TPA 
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Tumor supressors 
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In this study, we used gene expression profiling by high density cDNA microarray and real-
time PCR analyses to obtain exact information about the identities of candidate genes that 
provide potentially important insights into the events and pathways in tumor promoter 
induced neoplastic transformation. Since differences in gene expression profiles could 
potentially arise from differences in genomic background of the P+ and P- cells due to a 
large difference in passage numbers of the two cell lines, we chose a matched pair of P+ and 
P- cell line that had very similar genetic backgrounds.   The P+ cell line used in this study 
had spontaneously arisen from a P- line and the two cell lines were within six passages of 
the P- to P+ transition.  The 8 hour timepoint of TPA treatment selected for this study was 
early relative to manifestation of transformation effect which takes four days and therefore it 
is more likely that the gene expression changes observed are causative of transformation 
rather than resulting from the transformation event.  
 Comparison of the global gene expression profile of the P- and P+ cell lines reveals 
that majority of the genes are not differentially expressed in the two lines either 
constitutively or as a function of TPA treatment. These results are consistent with previous 
reports by Cmarik et al. using differential display according to which only a small 
percentage of genes are differentially expressed between the two JB6 cell lines (Cmarik et 
al., 2000). A comparison of the TPA modulated genes in P- and P+ cells reveals that there 
are more TPA modulated genes in the P- cells when compared to the P+ cells.  This result is 
also in agreement with the differential display data of Cmarik et al. (Cmarik et al., 2000). 
 It is interesting to note that the TPA modulated pattern of gene expression observed 
in the P+ and P- cells does not correlate with the activities in P+ and P- cells of AP-1 and 
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NF-kB, two major transcription factors implicated in tumor promotion.  Both AP-1 and NF-
kB activation occurs in P+ cells but not in P- cells and have been shown to be necessary for 
susceptibility of P+ cells to TPA induced transformation (Bernstein and Colburn, 1989; 
Dong et al., 1994; Li et al., 1997).  If these two transcription factors were the sole 
transcriptional regulators responsible for tumor promoter induced transformation, we would 
expect to find more TPA modulated genes in P+ cells than in P- cells.  On the contrary, 
differential display studies by Cmarik et al. (Cmarik et al., 1999) and the current study 
demonstrate that significantly more genes are modulated by TPA in P- cells, suggesting the 
existence of additional pathway/s possibly controlled by other transcription factor/s that are 
important for regulating signal transduction in P- cells.  Little work has been done to date to 
identify transcriptional activators in P- gene expression that may control resistance to 
transformation.  Identification of these transcription factors may provide key insights into 
this process and advance our understanding of resistance to tumor promoter induced 
transformation.  This study has identified several transcription factors, described later in this 
section, which are more highly expressed in P- cells.  These constitute good candidates for 
further studies.  
 Differences in both basal (TPA untreated) and TPA induced mRNA expression 
levels between P+ and P- cells can provide significant clues to understanding tumor 
promotion susceptibility and resistance.  Of the three legs of the cDNA microarray 
experimental design that we performed, comparison of expression level of TPA treated P- 
vs. TPA treated P+ cells (i.e., the first leg of the array) yields a composite of the basal and 
induced contributions to the final expression levels and therefore provides the most insight 
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into transformation relevant differences in P+ and P- gene expression.  We therefore 
focused on the genes that showed higher differential expression in the first leg of the array. 
 Candidate genes identified in this study can be broadly classified into six categories 
based on their physiological functions.  The first class is comprised of 20 members 
broadly classified as ‘Extracellular matrix/ basement membrane structural and regulatory 
proteins.  This group is further categorized into 5 subgroups based on the specificity of 
the function of the members.  This includes: ECM collagen related, basement membrane 
structural proteins, proteases and inhibitors, adhesion and migration factors and calcium 
regulatory ECM proteins.   This group includes several isoforms of procollagen that are 
more highly expressed in P+ cells, including α1 and α2 subunits of collagen I and 
collagen V.  Expression of all three genes was down regulated by TPA in both cell types. 
 The TPA dependent decrease in levels of the two procollagen species is in agreement 
with a previous report by Dion et al (Dion et al., 1982).  Additionally, lysyl oxidase is 
also preferentially expressed in P+ cells.  Lysyl oxidase is crucial collagen cross-linking, 
and disruption of the crosslinking process can result in severe structural collagen 
changes (Hong et al., 2004). 
 Among the other genes in this group, differential expression of those encoding the 
cysteine proteases cathepsin H and transmembrane ectoprotease neprilysin is noteworthy.  
Both the proteases are expressed at higher levels in P+ cells both constitutively and 
following TPA treatment.  This expression pattern seems consistent with the expected 
pattern in final stages of tumor progression i.e., during invasion and metastasis, as proteases 
have been previously shown to be involved in tumor progression either by direct 
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degradation of extracellular matrix or by activation of other proteases, such as urokinase-
type plasminogen activator (reviewed in Kos and Lah, 1998; Sloane, 1990; Lah and Kos, 
1998).  Cathepsins may be involved either directly in the degradation of components of 
ECM, such as laminin, fibronectin, and collagen, or through the modulation of protease-
sensitive regulatory networks, involving other proteases as well as non-proteases, such 
as annexin II, found at the cellular surface of cancer cells (Turk et al., 2004).  In general, 
the roles of these proteases in tumor invasion and metastasis are well characterized.  Recent 
studies on the expression of cathepsin H in basal cell carcinomas (BCC) revealed that 
cathepsin H activities, immunoreactivities and mRNA were higher in  BCC cells than in 
normal skin cells (Frohlich et al., 2004).  Joyce et al., reported upregulation of several 
cathepsins during tumor progression and indicated cathepsins as being effectors of 
invasive growth and angiogenesis during multistage tumorigenesis (Joyce et al., 2004). 
The expression of these two proteases in our system, which is a model for the early stages 
of tumorigenesis, is intriguing.    
 Based on our observation of higher protease expression in P+ cells, we hypothesize 
that these proteases may play a role susceptibility to tumor promoter induced transformation 
possibly by increased destruction of collagen and proteoglycan components of the 
extracellular matrix, which could trigger the release of sequestered growth factors such as 
epidermal growth factor (EGF) and transforming growth factor beta (TGFβ) that enhance 
the growth rate of the cells, and have also been demonstrated to have transformation 
promoting activity in P+ cells (Taipale and Kaeski-Oja., 1997; Wilder and Rizzino, 1991).   
This hypothesis is consistent with increasing evidence demonstrating that proteases are 
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involved in earlier events of tumorigenesis.  Increased expression of cathepsin B, another 
member of the cysteine protease family, has been reported in certain premalignant lesions 
(Koblinski and Sloane, 2000) and it is postulated to increase cell growth and, thereby 
tumorigenesis, by activating growth factors or liberating them from the ECM where they are 
sequestered.  In studies by Colandrea et al., TPA induced tumor promotion in mouse skin 
was found be enhanced by transgenic overexpression of interstitial collagenases (Colandrea 
et al., 2000).  Stromelysin-1 (MMP-3) has been shown to function as a tumor promoter in 
mouse mammary tumorigenesis (Sternlicht et al, 1999 and 2000; also see Sternlicht and 
Werb, 2001 for review).  Although degradation of ECM has largely been attributed to 
MMPs, the importance of other classes of proteases including cathepsins in ECM 
degradation is now becoming clearer.  The failure of broad-spectrum MMP inhibitors in 
clinical trials has opened the door for other proteases to be considered as relevant drug 
targets in anticancer therapies (Turk et al., 2004). 
 In reciprocal relation to the proteases, the two protease inhibitors TIMP 1 and SLPI, 
show higher levels of constitutive and TPA modulated expression in P- cells.  TIMP 1 is a 
key metalloproteinase inhibitor that can inhibit active forms of all MMPs studied to date, 
with the exception of MMP-19 (Baker et al., 2002).  TIMPs play an important role in 
tumor invasion and metastasis (Belloc et al., 1995 and Azuma et al., 1993) by functioning as 
negative regulators.  In tissue culture, TIMP-1 can be induced in keratinocytes (Petersen et 
al., 1989) and fibroblasts in response to treatment with tumor promoting agents (Murphy 
and Werb, 1985).  TIMP1 has been shown to block TPA-induced neoplastic transformation 
in culture (Shoji et al., 1997).  The biological significance of higher expression of TIMP 1 
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in P- cells is unclear in light of conflicting reports on the role of TIMP 1 in tumorigenesis 
with an antitumor activity reported by some investigators (Gomez et al., 1997) and cell 
growth stimulation activity reported by others.   While there are no definite explanations for 
these opposite functions of TIMP 1, it is possible that TIMP 1 functions both as an inhibitor 
of MMP and as a growth- promoting factors in different contexts.   P- cells may express 
higher level of TIMP 1 in an effort to control MMP activity and preserve the ECM integrity. 
  In the context of the antitumor activity attributed to TIMP1, it is interesting to note 
the reciprocal pattern of expression of the proteases and protease inhibitors in P- and P+ 
cells with proteases being expressed at higher levels in P+ cells and the inhibitors being 
expressed at higher levels in P- cells.  Such a tilt in the balance between levels of proteases 
and protease inhibitors may be a significant factor in determining the susceptibility or 
resistance of cells early on in the process of neoplastic transformation.  SLPI is a potent 
serine protease inhibitor and is a member of the rapidly evolving seminal transcribed 
(REST) gene family (Lai et al., 2004).  It inhibits elastase, cathepsin, trypsin and 
chymotrypsin (Zitnik et al., 1997).  SLPI also downregulates MMP biosynthesis thus 
indirectly downmodulating collagen hydrolysis (Zhang et al., 1997).  
 Cell-cell and cell-matrix attachments are mediated through interactions between 
extracellular matrix (ECM) components, integrins, focal adhesion-linked molecules, and the 
actin cytoskeleton.  Decreased cell-cell and cell-matrix adhesiveness is associated with loss 
of contact inhibition of proliferation that allows cells to escape from contact mediated 
growth control signals (Bast et al., 2000).  This results in uncontrolled proliferation and the 
dramatic morphological changes that occur at the cell surface and in the cytoskeleton of 
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transformed cells and is crucial for both early and late stages of tumorigenesis (Wijnhoven 
et al., 2000).  Based on this, we hypothesize that decreased constitutive and TPA modulated 
expression of cell adhesion molecules in the P+ cells contribute to their tumor promotion 
susceptibility and increased anchorage independent growth in soft agar assays.  Consistent 
with our hypothesis,   multiple genes that mediate cell adhesion show higher expression 
levels in P- cells than P+ cells, this includes the three ECM proteoglycans (PGs): decorin, 
tenascin C and PG-M/versican.  
 Decorin is essential for collagen fibril formation and promotes the stability of the 
fibers (Stander, 1999).  Decorin suppresses neoplastic transformation by blocking multiple 
pathways that stimulate proliferation (Stander et al., 1999), including the EGF and TGFβ 
pathways.  Decorin binds to TGFβ thereby inhibiting its activity and also downregulates 
EGF receptors on the cell surface (Santra et al., 2000; Csordas et al., 2000).  Decorin is also 
a suppressor of malignant phenotype by inhibiting the migration on ECM (Merle et al., 
1999; Kinsella et al., 2000).  Moreover, decorin expression is down-regulated in 
hepatocellular carcinomas (Miyasaka et al., 2001) and in about 70% of ovarian 
carcinomas and ovarian cancer cells (Shridhar et al., 2001) as compared to their normal 
counterparts.  Reed et al., demonstrated that transient transgene expression decorin causes 
a significant growth inhibition of colon carcinoma and squamous carcinoma tumor 
xenografts (Reed et al., 2002).  Tenascin C can reorganize the actin cytoskeleton and 
modulate focal contacts (Jones and Jones, 2000).  Tenascin C has been shown to modulate 
cell adhesion both positively and negatively (Sheetz-Jones and Jones, 2000).  PG-
M/versican modulates cell-matrix adhesion and promotes cell-cell adhesion (Yang et al., 
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1999).  
 In addition to these ECM proteoglycans, several axon guidance molecules that 
mediate both cell-ECM and cell-cell adhesion are higher in the P- cells.  These include 
fractalkine, ninjurin 1, Semaphorin D (SemaD) and SLIT2.  Fractalkine and ninjurin are 
membrane bound cell-cell adhesion molecules (Lucas, 2001).  Soluble forms of fractalkine 
and ninjurin have been identified that promote migration.  SemaD and SLIT2 are secreted 
ECM adhesion molecules.  SLIT functions in cooperation with sema D and both proteins 
are inhibitors of cell migration (Goshima et al., 2002).  Higher expression of these multiple 
cell adhesion molecules in the P- cells may contribute to their resistance to neoplastic 
transformation and decreased anchorage independent growth in soft agar assays.  
 The second group comprises of 13 ‘cytoskeletal proteins’.  In the first subgroup, 
‘Calcium regulated cytoskeletal proteins,’ Calcyclin and Troponin T2 are higher in P+ 
cells.  Both proteins have been shown to promote the actomyosin bridge cycle, which is 
exhibited during cell migration, in the presence of increased intracellular Ca2+ (El-
mezgueldi, 1996; Fujii et al., 1994; Taylor, 1986). Additionally, calcyclin expression is 
correlated with metastatic migratory behavior (see Stradal and Gimona, 1999 and 
references therein).  A third member in this subgroup, Calponin 2, known to inhibit the 
cross-bridge cycle is expressed at higher levels in the P- cells.  In the context of the 
expression pattern of these genes, it is conceivable that the P+ cells more actively 
implement the contractile cross-bridge cycle than P- cells, thereby promoting a more 
motile phenotype that we observe in P+ cells.  The migratory phenotype of P+ cells is 
supported by the presence of significantly more lamellipodia and filopodia as revealed 
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by phalloidin staining of the cells.  Lamellipodia and filopodia are known to implement 
cell migration and as could be expected, the P+ cells also demonstrated markedly higher 
TPA induced migratory response in wound healing assays. Induction of cellular motility 
by phorbol ester induced PKC activation has been described previously (Montesano and 
Orci, 1985; Murphy et al., 1995; Hirakata et al., 1993).   
 In the second subgroup of ‘actin and other cytoskeletal proteins’, nine members 
have higher TPA induced levels in the P- cells.  In the context of the anchorage 
dependent growth property of the P- cells, we hypothesized that P- cells have more 
stress fibers than P+ cells.  The increased expression of the genes in this subgroup 
supports this hypothesis as many of them have been previously demonstrated to have 
important roles in the formation of stress fibers.  Among these are four isoforms of actin; 
cardiac α actin, skeletal muscle α actin, vascular smooth muscle α actin and smooth 
muscle enteric γ actin and actin-associated proteins; SM22β, heat shock protein 25, 
WDR1 and destrin.  Formation of stress fiber favors an adhesive phenotype (Alberts et 
al., 2002) and is associated with inhibition of anchorage independent growth (Masuda et 
al., 1996).  Dynamic function of actin cytoskeleton is controlled by rates of 
polymerization, depolymerization, and assembly of F-actin filaments and stress fibers.  
These are in turn dependent upon levels of actin expression, and upon the expression and 
binding of various actin binding proteins that regulate actin function.  The higher 
expression of multiple actin isoforms and actin-associated proteins in conjunction with 
higher expression of several cell-adhesion molecules in P- cells may thus promote a 
more adhesive phenotype.  This notion is further supported by phalloidin staining data 
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which demonstrates that P- cells have significantly had more cortical actin and also more 
cell-cell contacts than P+ cells.  
 Phalloidin staining also revealed that both P+ and P- cells had abundant stress 
fibers in the absence of TPA.  Four hours of TPA treatment resulted in a drastic 
reduction in the number of P+ and P-cells with stress fibers.  After eight hours of TPA 
treatment majority of cells still lacked stress fibers, however a significantly higher 
percentage of TPA-treated P- cells had reconstituted them compared to P+ cells.   
Scoring of phalloidin stained cells for the presence stress fibers was performed by Dr. 
Lori R. Bernstein.  Dr. Bernstein observed that whereas 35% of P- cells contained stress 
fibers after 8 hours of TPA treatment (58/163 cells scored for presence or absence of 
stress fibers), only 11% of P+ cells contained them (15/139 cells scored).  These data 
indicate that TPA induces stress fiber decomposition by 4 hours, and that by 8 hours P- 
but not P+ cells have partially reconstituted their stress fibers. Takahashi et al. 
previously reported that TPA induced irreversible decomposition of actin stress fibers in 
P+ cells, whereas in P- cells the effects of TPA treatment were reversible within a 10 
day period, being first detectable within 5 days (Takahashi et al., 1986).   
 It is interesting that several genes that mediate motility and metastasis are 
expressed at a higher level in the P+ cells.  While the prevailing theory regarding 
metastasis supports the notion that only a tiny portion of a primary tumor contains cells 
with metastatic potential, Weinberg et al. argue that some of the initial mutations that 
transform a normal cell into a cancerous one can also cause metastasis (Couzin, 2003).  
In support of Weinberg’s theory, recent work by  Golub et al. demonstrates a 17-gene 
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signature in primary tumors predictive of metastasis indicating that a ‘tumor's destiny is 
carved out early on’ (Couzin, 2003).  In this context it is intriguing that we observe 
expression of several markers of motility and metastasis in our model of early stage 
tumorigenesis, before neoplastic transformation has even occurred. 
 In the third group of ‘Enzymes and signal transduction proteins’ group, all five 
constituent members of first subgroup of enzymes and associated proteins are higher in 
P- cells compared to the P+ cells. This includes p120/Ras-GTPase activating protein 
(Ras GAP), BMP-5, phosphoserine phosphatase, UDP glucoronosyl transferase-1 and 
cGMP dependent protein kinase type II.  TPA treatment results in activation of Ras via 
PKC-dependent (Hirai et al, 1994) and independent mechanisms.  Ras induces cell 
proliferation and neoplastic transformation (Hay and Zuk, 1995). Physiological function 
of Ras includes the disassembly of actin stress fibers (Uberall et al., 1999; Maruta et al., 
1999).  We hypothesize that the P- cells by virtue of increased Ras GAP (which 
negatively regulates ras by enhancing its intrinsic GTPase activity) expression inhibit 
Ras activity and thereby prevent the disassembly of actin stress fibers.  This mechanism 
further favors the role of actin stress fibers in the promotion resistance of P- cells. 
 TPA treated P- cells also preferentially express higher levels of nine genes that 
encode tumor suppressors and/or apoptotic mediators.  Notable among these are the 
genes, deleted in oral cancer-1 (Doc 1), connexin 43 (Cx43), Ras-GAP, immediate early 
response factor X-1 (IEX-1), Nur77, IFI16, decorin and SLIT2.  Doc 1 is a tumor 
suppressor gene for oral cancer (Daigo et al., 1997) and suppresses anchorage 
independent growth in soft agar when overexpressed in oral keratinocytes (Todd et al., 
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1995).  Connexin 43 is a major gap junctional protein that mediates intercellular 
communication and passage of solutes and second messengers.  Gap junctional proteins 
play crucial roles in relaying contact inhibitory signals to the cells.  Cx43 has been 
shown to inhibit anchorage independent growth and tumorigenesis (Hirschi et al., 1996; 
Su et al., 2000; King et al., 2002).  Decreased constitutive and TPA-induced levels of 
Cx43 in P+ cells may allow them to override contact inhibition and anchorage-
dependence, and become tumorigenic.  Both IEX-1 and Nur77 are proapoptotic in 
stressed cells and IFI16, decorin and SLIT2 have all been shown to inhibit growth of 
tumor cells (Dallol et al., 2003a and 2003b).  The preferential expressions of all these 
molecules in P- cells indicate that multiple pathways implementing growth arrest are 
effective in these cells possibly contributing to their transformation resistance.  
 In the fourth group of interferon inducible genes, the increased constitutive and TPA 
induced expression of IFI16 and IAP 203/205 homolog in P- cells is noteworthy.  The 
interferon (IFN) family of cytokines is known for its growth-inhibitory activity, which 
plays an important role in IFN-mediated antitumor activity.  These functions are 
performed by proteins encoded by interferon inducible genes that are induced by IFN 
(see Johnstone and Trapani, 1999 for review).  IFIs belongs to the ‘gene 200 cluster’ (HIN-
200 family / IfI 200 genes) which consists of several genes located in the q21-q23 domain 
of murine chromosome 1 (Johnstone and Trapani, 1999).  HIN-200 proteins are primarily 
nuclear proteins involved in the transcriptional regulation of genes important for cell 
cycle control, differentiation, and apoptosis (Asefa et al., 2004).  Members in this family 
include IFIs 202, p203, p204, p205, D3, MNDA, AIM2, IFI-16, and I-8U.  These 
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proteins have in common one or two contiguous conserved 200 amino acid domains (A 
and B) that bear a LXCXE motif known to be a potential binding site for the Rb-family 
proteins (reviewed in Johnstone and Trapani, 1999).   
 Recent reports have shown that IFI16 is expressed in epithelial cells in addition 
to lymphoid cells (Gariglio et al., 2002; Wei et al., 2003).  Ding et al., recently reported 
the identification of IFIX, a new member of the IFI family and demonstrated that IFIX is 
expressed in normal breast tissues and nontransformed breast epithelial cell lines (Ding 
et al., 2004).  These observations suggest that IFIs may play a role in maintaining the 
normal growth of epithelial cells and the downregulation of IFIs expression may 
contribute to the uncontrolled cell growth and lead to tumorigenesis.  Interestingly, both 
IFI16 and IAP 203/205 homolog show similar pattern of regulation in our system and they 
have not been previously observed in or associated with promotion resistance or cancer.   
 The antitumor activity of several HIN-200 proteins has been demonstrated.  p202 
suppresses tumor growth, reduces tumorigenicity, induces apoptosis, and suppresses 
metastasis and tumor angiogenesis of human cancer cells (Wen et al., 2000, 2001; Ding 
et al., 2002).  Overexpression of IAP 202 decreases growth rate of normal and cancer cells 
(Lembo et al.1995, Yan et al., 1999).  Furthermore, cells overexpressing p202 show reduced 
anchorage independent growth in soft agar (Yan et al., 1999).  Overexpression of IAP 204 
has been shown inhibit cell proliferation (Lembo et al., 1998) and, it was later demonstrated 
that this inhibition is mediated via the pRb regulatory system (Hertel et al., 2000).  In the 
context of known anti-proliferation functions of various members of this family, it is 
conceivable that the increased expression of these genes in the P- cells may contribute to 
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their transformation resistant phenotype.  
 In the fifth group of transcription factors and DNA binding protein group, three of 
the four members, including Nur77/N10, cellular retinoic acid binding protein II 
(CRABPII) and Prx2/S8 homeobox transcription factor are more highly expressed in TPA 
treated P- cells, while RIN/ZF zinc finger DNA binding protein are more highly expressed 
in P+ cells. Nur77 and CRABPII are regulators of the retinoic acid (RA) pathways.  RAs 
inhibit cell proliferation, papilloma formation in mouse skin, and neoplastic transformation 
in JB6 cells and are potent anticancer agents in several human cancerous and precancerous 
conditions (Budhu and Noi, 2002; Verma and Boutwell, 1977; Li et al., 1996 and Altucci 
and Gronemeyer, 2001).  Nur77 encodes an orphan member of the steroid/thyroid/retinoid 
nuclear receptor superfamily (Lin et al., 2004) and modulates gene expression linked to 
cell proliferation and apoptosis (Winoto and Littman, 2002; Zhang, 2002).  TPA 
selectively induced Nur77 expression in P- cells and the induced level was 6-fold higher in 
P- cells than in P+ cells.  These results are consistent with previous studies using northern 
blot analysis of Nur77 mRNA in P+ and P- cells by Cmarik et al (Cmarik et al., 1994).  
Nur77 also transactivates transcription in a RA-independent manner.  Similarly, CRABPII 
can also interact with the RAR-RXR-RARE complex independently or coupled to bound 
ligand thereby inducing transcription.  The enhanced expression of Nur77 and CRABPII 
in P- cells may thus mediate tumor promotion resistance via transcriptional activation of 
genes that confer resistance. 
 Like the Nur77 and CRABPII transcription factors, the Prx2/S8 homeobox 
transcription factor is expressed higher in P- cells.  Prx2/S8 is mesenchymal specific 
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factor that modulates ECM synthesis in vessel wall nonmuscular cells and fibroblasts 
(Kongsuwan et al., 1988).  Prx2 binds to a consensus homeobox DNA sequence and 
contains trans-activating homeo- and Prx domain and a transrepressing OAR domain (de 
Jong and Meijlink, 1993; Noris and Kern, 2001).  Prx2 may also function to activate the 
expression of genes that mediate resistance to TPA induced transformation.  A fourth 
gene in this group, RIN ZF, is more highly expressed in P+ cells.  RIN ZF was originally 
identified as a zinc finger transcription factor that binds to an SP-1 response element and 
RIN ZF coexpression with SP1 inhibits activating effects of SP1 mediated through SP-1 
response element (Tillotson, 1999).  These findings suggest that RIN ZF may regulate 
gene expression by interfering with SP-1 transactivation.  However, no other literature is 
available about RIN ZF and it represents a novel protein that may potentially control the 
expression of genes involved in tumor promotion susceptibility.  Functional 
characterization of this protein would be a novel contribution to the understanding of the 
process of neoplastic transformation. 
Limitations of Present Study 
• While our study uncovered many genes that are differentially modulated by TPA 
in the P- and P+ cells, our study was limited to an 8 hour TPA treatment period. 
We cannot rule out the possibility that the time point selected may not have been 
optimum and that some of the relevant changes in expression have been missed. 
• Differences in mRNA levels detected may not always be reflected at protein 
level. Confirmation of expression at protein level may thus be necessary before 
embarking on detailed analysis of any differentially expressed genes identified 
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through this study.  
• It is also possible that activities of these differentially expressed gene products 
may be modulated post-translationally for which it may be necessary to employ 
proteomics based approaches of analyses.  
• Microarray systems are limited to detection of what is on the array, e.g., the 
source of the cDNA clones. Genes with low mRNA abundance may not be 
equally represented on the array. Conversely, genes that show very little change 
in expression in the array may have a significant effect physiologically. 
Furthermore, the combined effect of subtle changes in many genes may have a 
significant net physiological effect. 
Suggestions for Future Work 
 Based on existing literature, the differentially expressed genes identified in this 
study can be classified into four groups: 
1. Known genes, well characterized, known role in neoplastic transformation 
2. Known genes, well characterized, implicated for the first time  in neoplastic 
 transformation 
3. Known genes, not well characterized 
4. Unknown gene 
 This microarray analysis identified many known genes, of which some had 
previously been implicated in the process of neoplastic transformation. For many of the 
other genes identified in this study however, this represents the first report implicating their 
potential role in carcinogenesis. This includes genes such as neuritin, transgelin 2 IFI16 and 
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IFI 203/205.  These genes serve as very interesting candidates for further investigations. In 
addition to known genes, several genes with unknown functions have been identified.  This 
includes genes such as RIN ZF, kinesin family member 21A and thymic epithelial cell 
surface antigen.  The characterization and assignment of function to genes in the third and 
forth groups is most challenging and likely to contribute to novel and important leads into 
the process of neoplastic transformation.  Further analysis of these genes to establish their 
specific role in the transformation event may provide information about other unknown 
pathways involved.  
 It is noteworthy that three transcription factors are highly expressed in the P- 
cells. Whether one or more of these transcription factors regulate groups of genes 
showing coordinated pattern of expression in these cells, remains to be determined.  
Members belonging to several transcription factor subfamilies have been shown to be 
key regulators in cancers. RIN ZF zinc finger DNA binding protein is a putative 
transcription factor found to be differentially expressed in our system and shows higher 
expression in P+ cells. RIN ZF, a largely uncharacterized gene represents a novel protein 
that may control the expression of genes involved in tumor promotion susceptibility.  
Functional characterization of this protein would be a novel contribution not only to 
understanding of the process of neoplastic transformation but also to the transcription 
factor field in general.  Further studies, following verification of differential expression 
pattern in P- and P+ cells by realtime PCR and westerns may involve construction of 
sense and antisense expression vectors.  Overexpression of the RIN ZF sense construct 
in P- and/or inhibition of RIN ZF in P+ cells through antisense constructs or siRNA 
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followed by transformation assays may reveal whether this protein is necessary and/or 
sufficient for transformation.   
 In an identical approach, the role for IFI16 in transformation may also be 
assessed.  The expression of IFI16 and two other interferon inducible proteins was 
higher and also TPA inducible in P- cells but not in P+ cells.  IFI16 has been previously 
shown to be a negative regulator of cell proliferation and also to possess transactivation 
functions.  In this context, it will be interesting to study the tumor suppressor role of 
IFI16 in mediating transformation resistance in P- cells.  Furthermore, another clone 
homologous to IAP 203/205 is selectively upregulated in P- cells and is also an 
interesting candidate for future investigations to better understand the role of interferon 
pathway in carcinogenesis.  
 Identification of novel genes is of significance not just in the context of 
neoplastic transformation but also in understanding their roles in other biological 
processes in the cell.  One est identified in our study shows a 2-fold TPA induced 
expression in P+ cells compared to the P- cells. Interestingly, the expression is 
upregulated by TPA in P+ cells and downregulated by TPA in P- cells.  This est 
represents yet another novel protein that may control the expression of genes involved in 
tumor promotion susceptibility.  The unknown identity of this candidate represents some 
challenges in characterization, however follow-up experiments can proceed even in the 
absence of accurate identities since sequence from the arrays provide the necessary 
information.  The complete clone may be picked out from a mouse library by 5’ RACE 
using primers based on the sequence from the array.  Sequence information of the clone 
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can then be obtained and compared to those in databases for identities to known gene 
families.  Functional roles can be determined by generating fusion proteins and using 
them for identification of interacting partners. Functional characterization may also 
involve overexpression and antisense studies described earlier in this section. 
 Assuming that cascades of gene expression events operate as a function of time 
to produce the hallmark TPA responses observed in these cells, further studies of time-
course analysis of expression patterns of selected candidate genes in response to TPA 
are needed to better understand this process in its entirety. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
75
 
CHAPTER III 
 
REGULATION OF GENE EXPRESSION AT THE AP-1 DNA BINDING SITE: 
IDENTIFICATION OF TWO TRANSACTIVATIONAL REPRESSORS 
 
 
Synopsis 
 
 The AP-1 DNA binding site, present in the promoters of a number of genes, is a 
critical regulatory element that contributes to the transcriptional regulation of gene 
expression.  Transcriptional regulation at the AP-1 site controls several important 
physiological and pathological processes, including neoplastic transformation.  We 
isolated several AP-1 DNA binding proteins by a combination of DNA affinity 
chromatography followed by mass spectrometric analysis to identify novel proteins that 
bind the AP-1 site, with the hypothesis that these proteins may regulate transcriptional 
activation at the AP-1 site.  Here we report that the proteins nucleolin and Y box binding 
protein 1 bind specifically to AP-1 DNA binding sequence.  Reporter gene assays 
demonstrated that nucleolin and YB-1 repress AP-1 dependent gene expression in 
response to TPA treatment and c-fos overexpression.  Analysis of intracellular levels and 
intra-compartmental localization of the AP-1 proteins in cells overexpressing nucleolin 
and/or YB-1 revealed that repressive effect of nucleolin and YB-1 is not due to reduced 
availability of AP-1 proteins.  The precise mechanism of nucleolin and YB-1 mediated 
AP-1 transrepression is currently under investigation.  Specific binding of nucleolin and 
YB-1 at the AP-1 site may be a key component in the integration of different signaling 
  
76
pathways enabling cells to best respond to a given stimuli. 
Introduction          
 This section of the dissertation describes the characterization of nucleolin and 
YB-1 as two AP-1 DNA binding transrepressors.  The nucleolin project was originally 
started by Dr. Lori Bernstein and Dr. Vinay Kumar in an effort to isolate and 
characterize MAPK-related proteins that bound to the AP-1 DNA binding site.  They 
observed a 97 kDa protein which bound specifically to the AP-1 site in NAPSTER 
(Kumar and Bernstein, 2001).  The identification the p97 protein as nucleolin was done 
by Dr. Jean-Claude Twizere in the Bernstein laboratory.  During the course of p97 
isolation by Dr. Twizere using the NAPSTER assay, I observed two additional 
coomassie stainable bands at 47 and 49 kDa that also bound specifically to the AP-1 
DNA.  I initiated the identification and characterization of p47 and p49 proteins.  
Following the separation of his protein of interest, the large scale NAPSTER assay 
samples generated by Dr. Twizere were further processed by me for the purification of 
these two proteins. The 49 KDa protein was identified as YB-1 and the 47 KDa protein 
is believed to be a degradation product of YB-1 protein.  Because of the theoretical and 
experimental overlaps between the nucleolin and YB-1 projects, some data generated by 
Dr. Twizere are presented herewith with his kind permission and are cited wherever 
used.  The major focus of this section is however on isolation and characterization of 
YB-1 protein as an AP-1 DNA binding transrepressor. 
Overview 
 Eukaryotic gene promoters are composed of multiple cis-acting sequence elements.  
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Gene expression is regulated through combinatorial interactions among a wide variety of 
transcription factors that recognize these cis-acting promoter elements through both protein-
DNA and protein-protein interactions.  Activator protein-1 (AP-1) family is one such key 
family of transcription factors.  Although the AP-1 factors were identified 17 years ago 
(Angel et al., 1987; Lee et al., 1987), transcriptional responses at the AP-1 DNA binding 
site and the biological and physiological relevance of these responses are still being 
elucidated.  We set out to identify proteins that regulate AP-1 dependent gene expression by 
binding to the AP-1 site, with the aim to better understand the molecular mechanisms 
underlying regulation of AP-1 dependent gene expression.                   
The AP-1 Transcription Factors       
 The AP-1 transcription factors belong to the bZIP family of proteins and have been 
demonstrated to regulate many biological functions including cell differentiation, 
proliferation, apoptosis and oncogenic transformation (Angel and Karin, 1991; Jochum et 
al., 2001; Mechta-Grigoriou et al., 2001).  A variety of external stimuli, such as growth 
factors, tumor promoters, hormones, and analogs of the cAMP second messenger, have been 
shown to induce the levels and binding of AP-1 proteins (Angel and Karin, 1991; Shaulian 
and Karin, 2001; Mechta-Grigoriou et al., 2001). AP-1 complexes are comprised homo- 
(Jun-Jun) or hetero- (Jun-Fos) dimers of proteins from the Fos (c-Fos, Fos B, Fra-1 and Fra-
2) and Jun families (Jun B, c-Jun and Jun D; Angel et al., 1987, 1988; Bohmann et al., 1987; 
Lee et al., 1987; Chiu et al., 1988; Sassone-Corsi et al, 1988) that share the same structural 
domains          
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Figure 12   Schematic illustration of the structural domains of c-Jun and c-Fos proteins. 
Detailed description provided in the text.  Adapted from the web address 
http://www.blc.arizona.edu/marty/411/Modules/homeo.html 
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for dimerization and DNA binding: a basic region and a leucine zipper region (Figure 
12).  The leucine zipper enables the formation of homo- and heterodimeric AP-1 
complexes which are essential for DNA binding, and enhances their nuclear 
translocation (Chida et al., 1999; Figure 13). The basic region contains the actual DNA 
binding surface.  AP-1 complexes regulate transcription by binding to the DNA 
sequence, 5’ - TGA(C/G)TCA – 3’ known as an AP-1/TRE element or AP-1 site (Lee et 
al., 1987; Angel et al., 1987; Angel and Karin,1991). The TRE element was first 
identified in the collagenase promoter as an element necessary for gene induction by 
phorbol ester 12-O tetradecanoylphorbol-14 acetate (TPA) (Lee et al., 1987; Angel et 
al., 1987; Angel et al., 1988). AP-1 sites in promoters of several genes have been 
characterized including collagenase (Frisch and Morisaki, 1990), metallothionein IIA 
(Angel et al., 1986), stromelysin (Kerr et al., 1990), transforming growth factor β (Kim 
et al., 1989) and interleukin 2 (Muegge et al., 1989).    
 AP-1 complexes have been reported to regulate transcription in response to 
several other stimuli including stress, UV irradiation, growth factors and genotoxic 
agents (Angel and Karin, 1991; Angel et al., 1988; Derijard et al., 1994; Devary, et al., 
1991; Hibi et al., 1993; Shaulian and Karin, 2001).  AP-1 mediated transcription at the 
AP-1 site is dependent on a variety of factors including the composition of AP-1 dimer 
(De Cesare et al., 1995; Chinenov and Kerppola, 2001), phosphorylation (Angel and 
Karin, 1991; Gruda et al., 1994), binding (Angel et al., 1987; Auwerx et al., 1990) 
potential of AP-1 complexes, AP-1 binding site context (Ryseck and Bravo, 1991; Vogt,  
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Figure 13  Schematic illustration of formation of AP-1 dimers and binding to the TRE 
sequence. NH2, Amino terminal; COOH, Carboxy terminal.  Adapted from the web 
address http://www.blc.arizona.edu/marty/411/Modules/homeo.html 
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2001), other proteins that interact with AP-1 proteins (Vogt, 2001; Chinenov and 
Kerppola, 2001; De Cesare et al., 1995) and/or other proteins that bind at the AP-1 site 
(Farrell, et al., 1989; Masquilier and Sassone-Corsi, 1992). 
Nucleolin 
 Nucleolin (NCL) is a conserved and abundant protein present predominantly in 
the nucleolus but also present diffusely throughout the nucleus especially in proliferating 
cells (Zhou et al., 1997, Schwab et al, 1998).  Its major function is the regulation of 
ribosomal RNA transcription and processing and ribosome biogenesis (Serin et al., 
1997; Ginisty et al., 1998). However, NCL is believed to be multifunctional protein 
(reviewed in Srivastava and Pollard, 1999).  NCL is also involved in several other 
cellular processes such as transcription (Ying et al., 2000), attachment of genomic DNA 
to nuclear matrix and chromatin decondensation (Erard et al., 1990), cell proliferation 
and growth, and in embryogenesis and nucleogenesis (Ginisty et al., 1999; Srivastava 
and Pollard, 2000). Interestingly, NCL is a substrate for several kinases including protein 
kinase C (Zhou et al., 1997).  Both, transcriptional activator and repressor roles have 
been demonstrated for NCL.  NCL has been shown to be an activator of the E6 and E7 
oncogene transcription in HPV-18 (Grinstein et al., 2002) and to transactivate expression 
of the c-myc P1 and the Epstein-Barr virus F promoters (Brys and Maizels, 1994; 
Bulfone-Paus et al., 1995).  NCL has also been implicated as a repressor of transcription 
of the alpha-1 acid glycoprotein promoter via the B motif (Yang et al., 1994).  NCL has 
also been shown to represses transcription by inhibiting the transcriptional machinery 
and/or via interactions with promoter sequences in rDNA (Roger et al., 2002).  NCL 
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binds to several nucleotide sequences in RNA, single-stranded DNA and double 
stranded DNA. 
YB-1            
 The YB-1 protein represents a multi-gene family called the Y-box binding 
proteins defined by their ability to bind to the DNA sequence CTGATTGG 
(C/T)(C/T)AA; called inverted CCAAT box or Y-box (see Wolffe et al., 1992 for 
review).  YB-1 family members have been identified in a number of eukaryotic and 
prokaryotic organisms and found to be conserved in sequence throughout evolution from 
bacteria to vertebrates (Li et al., 1992).  YB-1 is translocated from the cytoplasm into the 
nucleus in response to various cellular inducers (Holm et al., 2002; Higashi et al., 2003; 
and Sun et al., 2000).  The YB-1 protein contains three domains: a variable N-terminal 
domain, a central cold shock domain (CSD) and a hydrophilic C-terminal tail domain 
(Figure 14).  The N-terminal domain contributes to variability between the various YB-1 
family members. The CSD serves in nucleic acid recognition and binding, and is highly 
conserved across species. The C-terminal domain is hydrophilic and consists of alternate 
segments of basic and acidic residues (Fukada and Tonks, 2003).  This domain is 
involved in protein-protein interactions and interestingly has also been shown to play an 
important role in DNA binding (Chen et al., 1995; Nambiar et al., 1998). 
 Y-box binding proteins can also bind to many other DNA sequences that do not 
contain an inverted CCAAT box (Mertens et al., 1997; Li et al., 1997), as well as to 
single stranded DNA and RNA (Wolffe et al, 1992; Hasegawa et al., 1991) contributing 
to the pleiotropic cellular functions (Ohga et al., 1996) that Y-box binding proteins have  
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Figure 14  Schematic illustration of the YB-1 protein domains. Detailed description 
provided in the text. 
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been demonstrated to possess.  YB-1 proteins have been implicated in direct 
transcriptional activation and repression of gene expression and the transcriptional 
regulation mechanism by YB-1 has been studied using several different genes 
(Matsumoto and Wolffe, 1998; Ogha et al., 1998; Higashi et al., 2003, Lasham et al., 
2000). 
 The presence of NCL and YB-1, together, has been observed in several 
multiprotein complexes.   Roles for NCL and YB-1 in mRNA stabilization have been 
demonstrated for renin and IL-2 transcripts.  NCL and YB-1 bind to the 3’ untranslated 
region of the renin mRNA (Skalweit et al., 2003; Persson et al., 2003), and to a Jnk 
Response Element (JRE) within the interleukin-2 (IL-2) mRNA sequence (Chen et al., 
2000).  NCL and YB-1 are present in a multicomponent complex composed of at least 
60 protein subunits along with multiple ribosomal components (Yanagida at al., 2001).  
NCL and YB-1 have also been found together in a fragile X mental retardation protein-
associated ribonucleoprotein particle composed of 40 proteins (FMRP-associated mRNP 
particle; Ceman et al., 2000).  In a more recent study, NCL and YB-1 were identified in 
a multiprotein complex by pull-down experiments using YB-1 fusion protein and a role 
in DNA repair was implied (Gaudreault et al., 2004).  Although direct interaction 
between NCL and YB-1 has not been demonstrated, their presence in the same 
multiprotein complex suggests a possible cooperative function in cellular processes. 
 In the present study we used the NAPSTER assay to identify p97 and p49, two 
new AP-1 DNA binding proteins.  We then determined that p97 and p49 were NCL and 
YB-1 respectively.  We performed reporter gene assays in order to elucidate the trans-
  
85
regulatory effect of NCL and YB-1 on gene regulation at the AP-1 site. The present 
study has shown for the first time that NCL and YB-1 repress transactivation at the AP-1 
site.  NCL and YB-1 do not affect the expression or intracellular localization of any of 
the AP-1 subunits.  Our data are consistent with the hypothesis that the NCL and YB-1 
mediate repression by directly binding to the AP-1 site.  The regulation of AP-1 
dependent gene expression may possibly be subject to cooperative control by NCL, YB-
1 and AP-1 family of proteins.   
Materials and Methods 
Cell Culture  
 Human colon HT29 adenocarcinoma cells and human cervical carcinoma HeLa 
cells were obtained from American Type Culture Collection (ATCC; Manassas, VA). 
HT29 cells were cultured as described earlier (Kumar and Bernstein, 2001).  HeLa cells 
were grown in minimal essential media (MEM; Gibco-InVitrogen) supplemented with 
10% fetal bovine serum (FBS). 
Antibodies 
 The αNCL, αHemaglutinin (HA), αOct-1 and all the αAP-1 antibodies were from 
Santa Cruz Biotechnologies (Santa Cruz, CA); αYB-1 was a rabbit polyclonal antibody 
to a 15 amino acid “C1” peptide corresponding to residues 299-313 in the C-terminal of 
human YB-1 protein.  Initial experiments using αYB-1 were performed with whole 
rabbit αYB-1 antisera kindly provided by Dr. K. Kohno (University of Occupational and 
Environmental Health School of Medicine, Kitakyushu, Japan).  Subsequent 
experiments were performed with immunoaffinity purified αYB-1 antibody custom 
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prepared against the C1 peptide antigen by Bethyl Laboratories (Woodlands, TX).     
αFlag M2 was a mouse monoclonal antibody from Sigma (St. Louis, MO). 
αGlyceraldehyde phosphate dehydrogenase (GAPDH) was a mouse monoclonal from 
Research Diagnostics Inc. (RDI, Flanders, NJ).  Peroxidase conjugated αrabbit and 
αmouse secondary antibodies were from Calbiochem (San Diego, CA). 
Plasmid Constructs         
  The Flag epitope tagged YB-1 expression construct, pcDNA3-Flag-YB1, 
harboring a full-length human YB-1 gene was kindly supplied by Dr. K. Kohno 
(University of Occupational and Environmental Health Kitakyushu, Japan).  
Hemagglutinin (HA) tagged NCL expression construct, pNtag4, harboring full length 
NCL gene was a gift of Dr. N. Maizels (University of Washington).  The constitutive 
pSVBgal plasmid harboring a full-length beta galactosidase gene (expressing beta 
galactosidase) was obtained from Promega (Madison, WI).  pGL3AdML-Luc used as a 
template for generation of GALV AP-1 reporter constructs were a kind gift of Dr. Gary 
Kunkel (Texas A&M University).  pcDNAc-Fos and pcDNAJunD expression constructs 
harboring full length human c-Fos and  JunD genes and 4X GCN AP-1 luciferase 
reporter construct were a gift of N. Colburn (NCI-FCRDC, Frederick, MD).   
Wild Type and Mutant GALV AP-1 Luciferase Reporter Constructs 
   These luciferase reporter constructs were generated by Dr. Twizere in the 
Bernstein lab. Oligonucleotides (“oligos”) harboring three tandem copies of the wild 
type or mutant AP-1 DNA binding site from the gibbon ape leukemia virus long terminal  
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Figure 15  Schematic diagram of wild type and mutant AP-1 luciferase reporter 
constructs.  Wild type and mutant constructs contain three tandem GALV-LTR AP-1 
sequences (shown in brown), each containing minimal AP-1 DNA binding sites (shown 
in red), ligated upstream of the adenovirus major late basal promoter (AdML basal 
promoter).  Promoter sequences are upstream of the firefly luciferase reporter gene 
(“Luc,” grey rectangle).  Upper diagram:  wild type 3XGALV-AP1-luc construct; lower 
diagram, mutant GALV-mut-AP1-luc construct harboring three tandem mutant AP-1 
sites.  Mutations are shown with asterisks below mutated sequences.  Base sequences of 
wild type and mutant AP-1 DNAs are shown in red boxes.   
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repeat (GALV-LTR; Kumar and Bernstein, 2001) flanked by 5’-XhoI and 3’-BamH1 
restriction sites were custom synthesized (Integrated DNA Technologies, Inc.; IDT; 
Coralville, IN). The sequences of the oligos (sense strand) are; Wild type: 5’-
agccagagaaatagatgagtcaacagc-3’; Mutant: 5’ agccagagaaatagaggagtctacagc-3’ 
(mutations in bold).  The oligos were subcloned into the plasmid vector pGL3AdML-
Luc at XhoI and BamH1 restrictions sites by replacing the 5X UASG sequences with the 
3XGALVAP-1 sequences to generate wild type 3XAP-1-GALV-luc and mutant 3XAP-
1mutGALV-luc luciferase reporter constructs (Figure 15).  
Preparation of Nuclear Extract 
   Nuclear extracts (NE) from TPA treated HT29 cells were prepared as described 
(Bernstein and Walker, 1999).  Briefly, HT29 cells were plated at 6 x 106 cells per 150 
mm dish in DMEM containing 10% serum and grown for 4 days.  Cells were treated 
with TPA (10ng/ml) for 90 minutes prior to NE preparation.  Cells were washed 3X with 
PBS and scraped using a rubber spatula into 5ml of PBS (per dish) containing the 
protease inhibitors (PI), leupeptin, aprotinin and PMSF.  Pooled cell suspension was 
washed 3X with PBS containing PI.  The packed cell volume (PCV) was estimated.   
The pellet was resuspended in 5X the PCV in Buffer A (10 mM Hepes, pH 7.5, 10 mM 
KCl, 1.5 mM MgCl2, 4 mM BME, 0.1 mM Phenyl Methyl Sulfonyl Fluoride (PMSF), 
10 µg/ml Leupeptin, 10 µg/ml Aprotenin) and washed 2X.  The pellet was resuspended 
again in 5V of Buffer A and allowed to swell on ice for 10 minutes and then spun down. 
The pellet was further resuspended in 3V of Buffer A and the cells were lysed with 
about 25 strokes of a Teflon pestle driven by a hand-held power drill.  The nuclear pellet 
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was spun out and resuspended in 5V of Buffer B (20 mM Hepes, pH 7.5, 0.2 mM EDTA, 
20% glycerol, 4 mM BME, 0.5 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml Aprotenin).  
4 M ammonium sulfate was added to yield a final concentration of 0.3 M, and the 
suspension was allowed to incubate at 4 °C with twirling for 30 min and then centrifuged 
at 60,000 rpm for 20 minutes.  The supernatant (NE) was quickly recovered prior to re-
swelling of the nuclear pellet and frozen in small aliquots at -80◦C. 
 NE from TPA-treated HeLa cells was prepared by the same method after plating 
3 x 106 HeLa cells per 150 mm dish and growing cells in MEM containing 10% fetal 
bovine serum for four days.  Protein concentrations of extracts were estimated using the 
Bradford colorimetric method (Biorad, Hercules, CA). 
Preparation of DNA Affinity Beads and NAPSTER AP-1 DNA Binding Assays 
   Streptavidin coated beads were obtained from Roche (Cat. #1529188) or from 
Pierce (Cat. #20349) and were conjugated to biotinylated double-stranded 
oligonucleotides (Macromolecular Resources, Boulder, CO) containing wild type AP-1 
core sequence (sequence as used in reporter construct above) from the GALV-LTR as 
described (Kumar and Bernstein, 2001a) according to manufacturer’s instructions 
(Roche Molecular Biochemicals, Indianapolis, IN). 
 Batchwise microscale AP-1 DNA affinity chromatographic NAPSTER assays 
were performed as described (Kumar and Bernstein, 2001a).  NE was dialyzed into 
Buffer Z (25 mM HEPES pH 7.8, 0.1 M KCl, 12.5 mM MgCl2, 1 mM dithiothreitol, 
20% v/v glycerol, 0.1% v/v Nonidet P-40, 0.1 µM ZnCl2, 5 mM NaF, 1 mM sodium 
orthovanadate) containing PI for 50 min at 4°C.   Dialyzed NE was then incubated with  
  
90
 
 
    
 
 
Figure 16   Schematic illustration of the NAPSTER assay.  Nuclear extract proteins 
from human adenocarcinomal HT29 cells were preincubated with excess wild type or 
mutant AP-1 oligos in solution and then subjected to DNA affinity chromatography with 
AP-1 DNA coupled to an immobilized streptavidin matrix. Purified proteins were 
visualized by SDS-PAGE followed by coomassie staining or by western blot with 
specific antibodies. 
Cells
Incubate nuclear proteins with/without 
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6 µg/ml poly (dI/dC) for 10 min on ice.  NE was then split into three equal samples and 
subjected to NAPSTER analyses with wild type GALV-AP-1 DNA beads (Figure 16).  
Sample I consisted of direct batchwise AP-1 DNA affinity chromatography of the NE 
proteins. Samples II and III were pre-incubated with excess wild type or with excess 
mutant GALV AP-1 DNA in solution for 15 min on ice.  The AP-1 DNA affinity 
chromatography was performed as per Lee et al. (Lee et al., 1987) with several 
modifications (Kumar and Bernstein, 2001a and 2001b) for 75 min at 4°C on a rotating 
clip wheel.  Beads were quickly spun down at 4°C, the supernatant was removed and 
then washed again 3X with Buffer Z.  Bound proteins were eluted by boiling the beads in 
SDS sample buffer, and loaded in SDS-PAGE.   
Purification of p47 and p49 Proteins 
 HT29 NE containing 60 mg of protein was dialyzed against buffer Z as described 
(Kumar and Bernstein, 2001a) and then subjected to DNA affinity chromatography on a 
column containing 2.5 mg of mutant AP-1 DNA beads at 4◦C.  The flow-through from 
the column was incubated with 120 µg of poly dI/dC for 10 minutes on ice and then split 
into three portions: sample I, the starting material for NAPSTER purification, and 
samples II, and III, as NAPSTER competitors for detection of specific p47 and p49 
protein bands.  Sample I contained 54 mg of protein and samples II and III contained 3 
mg each of NE protein.  375 mg of wild type or mutant competitor oligo in solution was 
then added to samples II and III respectively and incubated for 15 minutes at 4◦C.  
Streptavidin beads containing 2.7 mg of bound wt AP-1 DNA was added to sample I and 
beads containing 150 micrograms of AP-1 DNA were added to samples II and III and 
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incubated as described (Kumar and Bernstein, 2001a).  The supernatant was withdrawn, 
and the beads were washed 5 times in buffer Z.  
 The proteins bound to beads were eluted twice with buffer Z containing 1M KCL 
after twirling for 30 minutes at 4◦C on a rotating clip wheel.  Eluted proteins were 
precipitated in a final concentration of 10% trichloroacetic acid (v/v; TCA) on ice for 30 
minutes, and then spun at 9,500 x g at 4◦C in a microfuge for 15 minutes.  Pelleted 
samples were then dissolved in 100 µl of distilled water, reprecipitated in 1 ml of 
absolute acetone (EM Science, Darmstadt, Germany) at room temperature for 30 
minutes, and spun at 9,500 x g at 4◦C for 15 minutes.  The supernatant was removed and 
the pellet was air dried for 30 minutes at room temperature, dissolved in SDS sample 
buffer, boiled, and loaded onto a 10% gel in a large format gel apparatus (BioRad 
PROTEAN® II xi, BioRad Hercules, CA).  Samples were then run at 30 mA overnight 
such that the 30 kDa molecular weight marker was run to the bottom of the gel (Kumar 
and Bernstein, 2001a).  The gel was then stained with Coomassie brilliant blue and the 
bands corresponding to p49 and p47 were excised.  One fourth of each of the p47 and 
p49 samples isolated from sample I were run on a second SDS-PAGE gel and subjected 
to immunoblotting analyses with PAN AP-1 Jun/Fos antibodies, and the remaining 
material analyzed by nanospray MS/MS sequencing.   
Mass Spectrometric Mass Spectrometry Fragmentation Sequencing Analysis of p47 and 
p49 
   The excised gel bands corresponding to p47 and p49 prepared as described 
above were submitted for mass spectrometric mass spectrometry fragmentation 
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sequencing analyses (MS/MS sequencing) at the W.M. Keck Foundation Biotechnology 
Resource Laboratory (http://info.med.yale.edu/wmkeck/prochem) at Yale University.  
Proteins for each sample were trypsinized in-gel for 18 hours, eluted, and then subjected 
to nanospray MS/MS analysis. The resulting spectra were searched manually and by 
using the Mascot peptide mass fingerprint algorithm for protein identification 
(http://www.matrix-science.com/search_form_select.html). 
Immunoblotting Analyses  
 Western transfer and immunoblotting analyses were performed as described 
(Walker and Bernstein, 1999).  Western blot targets were visualized using enzyme 
chemiluminescence (ECL, Amersham).  Antibodies were used at the following 
concentrations: αJunD: 0.5 µg/ml; αYB-1 (0.5µg/ml); αFlag (0.49µg/ml); αGAPDH 
(0.4ng/ml).   
Fractionation of Cytosol and Nucleoplasm 
 HeLa cells were plated at 3 x 106 cells per 150 mm culture dish in MEM 
containing 10% serum and allowed to grow for two days. Cells were transiently 
transfected with 15 µg/dish of pcDNA 3.1 (vector control) or with either pcDNAFlag-
YB1 or pNtagHA-NCL or both, using Lipofectamine 2000 (1 µl/µg of DNA; Invitrogen, 
Carlsbad, CA).  The transfection medium was replaced 5 hours following transfection, 
with fresh MEM containing 10% serum and TPA (100ng/ml).  Twenty-four hours post-
transfection, cells were washed 3X in PBS and processed essentially as described for 
nuclear extract preparation in an earlier section with the following modification.  
Following cell lysis and separation of nuclear pellet by centrifugation, the supernatant 
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which constitutes the cytosolic fraction was recovered and frozen in small aliquots at -
80◦C.  The nuclear pellet was processed further as described and the nuclear extract was 
recovered and also frozen in small aliquots at -80◦C. 
Densitometric Analyses    
 Protein densitometric analysis of immunoblotted proteins were performed on a 
Macintosh computer using the public-domain NIH Image 1.62 image analysis program 
(http://rsb.info.nih.gov/nih-image/). 
Luciferase Reporter Gene Assay  
 HeLa cells were plated at 3 x 105 cells per well in 6 well Nunc dishes (Nunc Inc., 
Napersville, IL).  Twenty-four hours after plating, the cells were transiently 
cotransfected with 2 µg of either GALV-AP1-Luc or GALV-mutAP1-Luc reporter 
plasmids along with 1 µg of pcDNAFlagYB1 or 1 µg pNtag4 HA-NCL and 200 ng of 
pSVBgal, using Lipofectamine 2000 (1 µl/µg of DNA; Invitrogen, Carlsbad, CA).  Cells 
that received no transfected pcDNAFlagYB1 were transfected with 1 µg pcDNA3.1 (+) 
vector control plasmid (Invitrogen, Carlsbad, CA).  10 ng of c-Fos or 50 ng of JunD AP-
1 expression constructs were also co-transfected with the other constructs for some 
experiments.  Twenty-four hours post-transfection, cells were washed 3X in PBS and 
cell lysates were prepared by adding 200 µl of lysis buffer/well (Roche Luciferase 
Reporter Gene Assay Kit).  Cells were then scraped with a rubber policeman and 
incubated at room temperature for 15 minutes.  Cellular debris was removed by spinning 
the lysates at 9,500 x g for 10 seconds at room temperature.  Luciferase assays were 
performed using a Luciferase Reporter Gene Assay Kit (Roche, Indianapolis, IN) 
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according to the manufacturer’s instructions, using a Packard Lumicount Luminometer 
(Packard Instruments Co. Downers Grove, IL).  β- galactosidase activity assays for 
normalization of transfection efficiency were performed with 25 µl of lysate using a β-
Galactosidase Enzyme Assay Kit from Promega (Madison, WI), according to 
manufacturer’s instructions.  
Confocal Microscopy   
 HeLa cells were plated at 1 x 105 cells per ml in a LabTek II chamber slide 
(NalgeNunc International Corporation, Naperville, IL).  Twelve hours post-culture, cells 
were treated with TPA (100ng/ml) for 30 minutes, then fixed in 3.7% formaldehyde 
(Mallinckrodt-Baker Inc., Paris, Kentucky) and  permeabilized with 0.1% Nonidet P40 
(NP-40; Roche, Indianapolis, IN). The permeabilized cells were then incubated with 
antibodies against YB-1 or nucleolin (1:1000 dilution for both antibodies) in dPBS at 
room temperature for 60 minutes, followed by incubation with fluorescein- or Texas 
Red-coupled anti-rabbit or anti-mouse immunoglobulin conjugates (Molecular Probes, 
Eugene, OR) for 60 minutes, according to the method of Lefebvre et al (Lefebvre et al, 
2002).  Stained cells were fixed with mounting medium (Prolong Antifade kit, 
Molecular Probes), and visualized using a Biorad Radiance 2000 MP confocal 
microscope.  Images were generated according to procedures described at 
http://www.cvm.tamu.edu/ial/.   
Results 
The NAPSTER Assay for Identification of New DNA Binding Proteins   
 In order to identify new proteins that bind specifically to the AP-1 DNA 
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sequence, we used the affinity chromatography based assay termed the Nucleotide 
Affinity Preincubation Specificity TEst of Recognition Assay ("NAPSTER” Assay; 
Kumar and Bernstein, 2001a and b) designed previously in our laboratory.  NAPSTER 
assay consists of three sample sets processed in parallel as follows.  In sample “I”, NE 
proteins are directly subjected to AP-1 DNA affinity chromatography.  In samples “II” 
and “III”, NE proteins are preincubated with excess wild type or mutant AP-1 oligo (in 
solution) prior to AP-1 DNA affinity chromatography.  DNA affinity chromatography is 
then performed, by means adapted from Lee et al., with numerous modifications (Lee et 
al., 1987; Kumar and Bernstein, 2001a & b).  Following NAPSTER isolation, proteins 
are subjected to SDS-PAGE and Western blotting with antibodies against the proteins of 
interest.   
Validating the ‘Proof of Principle’ of NAPSTER Assay   
 As a control for the efficacy of the NAPSTER assay, we tested the specificity of 
binding of AP-1 subunits to the GALV AP-1 DNA using NAPSTER assay. We 
performed the NAPSTER assay with NE derived from HT29 human colon carcinoma 
cells and GALV AP-1 DNA coupled to streptavidin beads for samples I, II and III.  In 
samples II and III of the assay, the NE proteins were preincubated with 2.5 fold excess 
of wild type or mutant GALV AP-1 oligos in solution respectively, prior to DNA 
affinity chromatography with wild type GALV AP-1 oligo on beads.  Samples from 
NAPSTER isolation were subjected to SDS-PAGE followed by western blotting with 
antibodies against the seven AP-1 subunits.  As shown in Figure 17, we reproducibly 
observed specific binding of multiple AP-1 subunits to the AP-1 DNA sequence.  These  
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Figure 17 Specific binding of Jun and Fos AP-1 subunits to AP-1 DNA. NAPSTER 
analysis for all AP-1 subunits with the exception of FRA-1 were performed with 300 µg 
of HT29 NE protein per sample, and 20 µg of AP-1 DNA on beads. NAPSTERs for Fra-
1 were performed with 600 µg of NE protein and 40 µg of beads.  Samples I, II and III 
were divided into six parts and loaded onto SDS-PAGE gels and subjected to 
immunoblotting with antibodies against the various AP-1 subunits listed next to each 
blot. 
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Figure 18  p47 and p49 proteins bind specifically to AP-1 DNA in NAPSTER assay. 
NAPSTER samples I, II and III were generated from 15 mg of NE proteins as described 
in Materials and Methods.  Coomassie stained bands containing p47 and p49 are 
indicated by arrows.  Mr, Molecular weight marker. Figure reproduced with permission 
from Dr. Twizere. 
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data demonstrate that NAPSTER assay efficiently detects specific AP-1 DNA binding 
proteins. 
Nucleolin Binds to AP-1 DNA Specifically 
 Dr. Twizere isolated a 97 KDa band that bound specifically to AP-1 DNA in 
NAPSTER assay and identified that p97 was nucleolin using MS/MS sequencing (data 
not shown).  The identity was verified by western analyses of NAPSTER samples with 
an antibody specific for nucleolin.  A single band at 97 KDa was observed in samples I 
and III, but not II following immunoblotting with α-NCL antibody (data not shown).   
p47 and p49 Are Novel AP-1 DNA Binding Proteins  
 NAPSTER assay was performed as described in Materials and Methods with NE 
derived from HT29 colon carcinoma cells and GALV AP-1 DNA.  Coomassie staining 
of the gel following the NAPSTER assay revealed two protein bands, at 47 and 49 kDa 
that were present in lanes corresponding to samples I and III (Figure 18) and not in 
sample II. These data demonstrate that p47 and p49 are specific AP-1 DNA binding 
proteins. 
 Based on the molecular weights and specificity of binding of p47 and p49 
proteins to the GALV AP-1 DNA, we initially hypothesized that p47 and p49 proteins 
were AP-1 family members.  To test this hypothesis the p47 and p49 bands were excised 
from the Coomassie stained gel and run on a second SDS-PAGE gel followed by 
western blotting with a mixture of antibodies against all seven AP-1 subunits (Figure 
19).  Although the AP-1 antibodies recognized multiple AP-1 proteins in the NE neither 
p47 nor p49 proteins were recognized by any of the AP-1 antibodies included in the  
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Figure 19   p47 and p49 are not AP-1 proteins.  p47 and p49 proteins were purified from 
sample I of NAPSTER assay starting with 15 mg of NE protein as described in Materials 
and Methods.  Purified proteins were loaded in four lanes in a 10% SDS-PAGE gel to 
resolve the two protein bands.  The bands corresponding to p47 and p49 from one lane 
were excised from the gel and loaded onto a second gel alongside 30 µg of HT29 NE 
extract protein (NE, lane 1).  The samples were immunoblotted with a mixture of all 
seven AP-1 antibodies.  Mr, Molecular weight markers.  
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    10         20         30         40         50         60  
         |          |          |          |          |          |  
MSSEAETQQP PAAPAAALSA ADTKPGSTGS GAGSGGPGGL TSAAPAGGDK KVIATKVLGT  
 
        70         80         90        100        110        120  
         |          |          |          |          |          |  
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       310        320  
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TKAADPPAEN SSAPEAEQGG AE   
 
 
Figure 20   Location of the peptides identified for p47 and p49 bands by MS/MS 
sequencing in the human YB-1 protein sequence.  Peptide sequences from MS/MS data 
were compared to the human YB-1 protein sequence.  p47 peptides sequences that match 
the YB-1 protein sequence are shown in red and green colors and those for p49 are 
shown in blue and green colors respectively. The peptide sequence shown in green color 
was common to both p47 and p49 protein bands.  Location of the C1 peptide used for 
YB-1 antibody production is also shown (underlined). 
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antibody mix despite having loaded coomassie stained quantities of the proteins (Figure 
19, compare lanes 2 and 3 to lane 1).  Preincubation of the AP-1 antibodies with specific 
and nonspecific peptide competitions prior to immunoblotting revealed that the 
antibodies specifically recognized their corresponding protein bands of the predicted 
molecular weights (data not shown).  These data demonstrate that p47 and p49 are not 
AP-1 proteins. 
Purification and MS/MS Identification of p49 and p47 Proteins as Y-box Binding 
Protein 1   
 Purified p47 and p49 protein bands were subjected to MS/MS sequencing. The 
resulting ion fragmentation spectra were then searched against the nr protein database 
manually and using the MASCOT peptide mass fingerprint algorithm for protein 
identification.  Positive identifications are made on the basis of two or more MS/MS 
spectra matches to the same protein entry in the database.  As shown in Figure 20, two 
peptide sequences derived from p49 protein matched the human Y-box binding protein 1 
(YB-1).  Two peptides from p47 protein band also matched YB-1 protein (Figure 20).  
These data suggest that p47 and p49 are YB-1. 
Validation of MS/MS Peptide Identification of YB-1 by Western Blot Analysis   
 In order to validate the MS/MS identification of YB-1, we performed western 
blot analysis on samples I, II and III following the NAPSTER assay with αYB-1 
antibody.  As shown in Figure 21A, YB-1 antibody recognized a specific band at 49 kDa 
in NE samples and in samples I and III, but not in sample II.  The identification of YB-1 
in samples I and III, but not in II, provides evidence for the specific binding of YB-1 
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protein to AP-1 DNA sequence.  Preincubation of the YB-1 antibody with specific and 
nonspecific peptide competitions prior to immunoblotting revealed that the antibody 
recognized the protein band of the right molecular weights specifically (Figure 21B). 
 As indicated earlier, MS/MS fragmentation sequencing analyses of two peptides 
derived from p47 also matched YB-1.  We believe that the p47 band observed in the 
coomassie stained gel is a proteolytic digestion product of YB-1 resulting from 
extensive processing of the protein samples prior to MS/MS sequencing.  While YB-1 
routinely visualized by NAPSTER protocol is isolated by a single-step involving wild 
type DNA affinity chromatography, p47 and p49 purified for coomassie staining and 
MS/MS sequencing were isolated by a multi-step procedure involving four additional 
steps including mutant DNA affinity chromatography, KCl elution, TCA precipitation, 
and acetone precipitation, which may have predisposed the protein to proteolysis.  In 
some routine NAPSTER experiments (3 out of 40), we have visualized a doublet 
(corresponding to p47 and p49) by immunostaining with αYB-1.  This further 
corroborated our hypothesis that p47 purified for MS/MS analyses is a proteolytic 
product of p49.  
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Figure 21  p49 is YB-1.  A. 300 µg of HT 29 NE protein for each of samples I, II and III 
was subjected to NAPSTER analysis, SDS PAGE and then immunoblotted with YB-1. 
 B. Recognition of YB-1 protein by YB-1 antibody is specific.  2700 µg of HT29 NE 
was subjected NAPSTER AP-1 DNA affinity chromatography (Sample I, II and III) and 
divided into three equal portions that were loaded in SDS PAGE and immunoblotted 
with YB-1 antibody either directly (“No comp”) or following preincubation with YB-1 
peptide antigen  (“Sp. pep comp”) or with non specific JunD peptide (“non-Sp. pep 
comp”) as described (Kumar and Bernstein, 2001).    
A 
B 
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 YB-1 has been reported to bind to single-stranded DNA (Mertens et al., 1997). 
The double stranded AP-1 DNA beads are generally prepared by annealing equimolar 
ratios of the complementary strands prior to coupling to the affinity beads. To rule out 
the possibility of contaminating quantities of beads with single-stranded AP-1 DNA, the 
beads used in this experiment (Figure 22) were coupled to double-stranded AP-1 DNA 
made by annealing the biotinylated strand with at least five-fold molar excess of the 
complementary strand.  This data demonstrates that YB-1 binds specifically to double 
stranded AP-1 DNA.  In all the experiments henceforth, AP-1 beads were coupled to 
double stranded AP-1 DNA made by annealing the biotinylated strand with at least 1.5-
fold excess of the complementary strand. 
YB-1 from HeLa Cells also Bind Specifically to AP-1 DNA  
 To test whether AP-1 DNA binding of YB-1 could be observed in a different cell 
line and to test our hypothesis that YB-1 from HeLa NE would bind specifically to AP-1 
DNA in NAPSTER, we performed NAPSTER with NE from HeLa cells as described in 
Materials and Methods.  We observed specific binding of HeLa YB-1 to AP-1 DNA 
(Figure 22).  As a control, specific binding of JunD from HeLa cells was also visualized. 
We chose HeLa cells because they are more amenable to further studies involving 
transfections compared to HT29 cells, which have very low transfection efficiency.  
Specific binding of nucleolin from HeLa cells to AP-1 DNA was also observed (data not 
shown).  These data demonstrate that HeLa cells can be used for further characterization 
of AP-1 DNA binding of these proteins.   
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Figure 22  YB-1 from HeLa cells also binds specifically to AP-1 DNA in the NAPSTER 
assay. 300 µg of NE protein from both HT29 and HeLa cells were subjected to 
NAPSTER analyses for each of samples I, II, and III, followed by SDS-PAGE alongside 
30 µg of NE protein and immunoblotting analyses with αYB-1 antibody (upper panels) 
and with αjunD antibody (lower panels). NE, nuclear extract. 
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YB-1 and Nucleolin Colocalize in the Nucleus  
 We observed specific binding of both YB-1 and nucleolin to AP-1 DNA.  In 
order for this observation to be physiologically relevant, both YB-1 and nucleolin would 
need to localize to the nucleus in vivo.   We hypothesized that endogenous YB-1 and 
nucleolin are present in the nucleus and our prediction was that both YB-1 and NCL 
would be detected in the nucleus. To test this hypothesis, cultured HeLa cells were 
subjected to immunocytochemical staining using an αYB-1 and αNCL antibodies. As 
shown in Figure 23, YB-1 immunostaining was detected in both the cytoplasm and the 
nucleus.  Nucleolin immunostaining was detected mainly in the nucleus with more 
intense staining in the nucleoli.  There was hardly any nucleolin detectable in the 
cytoplasm.  These data demonstrate that both YB-1 and nucleolin are present in the 
nucleus.         
YB-1 and Nucleolin Do Not Co-Immunoprecipitate     
 Since we observed colocalization of YB-1 and NCL proteins in the nucleus, and 
specific binding of both proteins to AP-1 DNA, we hypothesized that YB-1 and NCL 
may interact with each other through protein-protein interactions.  If YB-1 and NCL 
interact with each other, then our prediction was that YB-1 and NCL could be 
reciprocally coimmunoprecipitated.  Although, it should be noted that failure to detect 
coimmunoprecipitation of either protein would not rule out the possibility that they do 
interact, for the reasons that the conformation of transfected proteins, 
immunoprecipitation conditions, and the antibodies used may not be optimum for  
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Figure 23 YB-1 and nucleolin colocalize in the nucleus. HeLa cells were 
immunostained with αYB-1 primary antibody at 1:1000 dilution followed by 
flourescein-coupled anti rabbit secondary antibody (left panel) or with αNCL primary 
antibody followed by Texas red coupled anti mouse secondary antibody (middle panel). 
Top row, probed with αYB-1 antibody; Middle row, Probed with αNCl antibody; 
Bottom row, Merged images. Left column: 20X magnification; Right column: 60X 
magnification. N, nucleus; C, cytoplasm.  
YB-1 
NCL 
Merged 
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detection of such an interaction.  To test whether NCL could be coimmunoprecipitated 
with YB-1, HeLa cells were transiently transfected with both HA-NCL and Flag-YB-1 
overexpression constructs (Figure 24, lanes 1 and 2).  Cell lysate was 
immunoprecipitated with α-Flag antibody followed by western with α-HA antibody.  
Control immunoprecipitation was performed with α-His-antibody.  No 
coimmunoprecipitation of nucleolin was detected.  As control for efficacy of α-Flag 
antibody in immunoprecipitation, probing with αFlag antibody in western revealed that 
α-Flag antibody pulled-down Flag tagged YB-1 protein.  Furthermore, cell lysates tested 
positive for overexpression of the tagged nucleolin protein (Figure 24, lower right 
panel).   
 As mentioned earlier, it is conceivable that the overexpressed Flag-YB-1 protein 
may not have achieved the optimum conformation necessary for interaction with NCL 
protein.   We therefore pursued an alternate approach to detect the interaction of NCl 
with endogenous YB-1 protein by immunoprecipating NCL with α-YB-1 antibody.  
HeLa cells were transiently transfected with HA-nucleolin expression construct.  Cell 
lysate was immunoprecipitated with α-YB-1 antibody followed by western with anti-HA 
antibody. No coimmunoprecipitation of nucleolin was detected (data not shown).  
Control immunoprecipitation was performed with α-GFP antibody.  As control for 
efficacy of α-YB-1 antibody in immunoprecipitation, probing with α-YB-1 antibody in 
western revealed that YB-1 antibody pulled-down YB-1 protein.  Cell lysates tested 
positive for overexpression of the tagged nucleolin protein (data not shown).  
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Figure 24   YB-1 and nucleolin do not co-immunoprecipitate.  Hela cells were 
transfected with Flag-YB-1 and HA-NCL constructs as indicated with “+” signs above 
the panels. In the top left panel, cell lysates were immunoprecipitated with α-His or α-
Flag antibodies followed by western with α-Flag or α-HA antibodies. In the lower right 
panel, western blot analyses on whole cell lysate was done with α-HA antibody.   
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Figure 25  YB-1 and NCL repress TPA induced AP-1 transactivation in HeLa cells.  A. 3 x 105 HeLa cells were transiently co-transfected with 
pcDNAFlagYB-1, pNtag-HA-NCL overexpression constructs and wild type or mutant 3XGALV-AP-1-luciferase reporter constructs.  Cells were then 
treated TPA or DMSO solvent control for 24 hours.  Presence or absence of TPA or of specific reporter constructs is indicated by “-” and “+” under the 
bar graphs.  Bars bracketed by “GALV WT AP-1 luc”, 3X Wild type AP-1-luciferase reporter tranfectants; Bars bracketed by “GALV Mut AP-1 luc”, 
3X mutant AP-1-luciferase reporter tranfectants.  Samples are numerically indicated above the bar graphs.  All data were normalized to β-galactosidase 
expression.  Error bars represent standard error of the mean (SEM) of five independent experiments, each performed in duplicate.   B.  Tagged YB-1 
and NCL proteins are overexpressed in the transient transfectants.  Overexpression of YB-1 and NCL in transient transfectants were confirmed by 
immunoblotting of 10µg of lysates from vector control (pcDNA transfectant), YB-1 or NCL transfected cells with αFlag/αHA antibodies.  Equal 
protein loading was verified by immunoblotting with αGAPDH antibody.  C.  NCL is overexpressed in transient transfectants.  Overexpression of NCL 
in transient transfectants was confirmed by immunoblotting of 10 µg of lysates from (1) vector control (pcDNA transfectant), (2) YB-1, (3) NCL, or (4) 
YB-1 and NCL transfected cells with αNCL antibodies.  Arrows indicate HA-tagged and endogenous NCL proteins. 
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YB-1 and Nucleolin Repress TPA Induced AP-1 Transactivation  
The nuclear localization of YB-1 and NCL and their specific binding to AP-1 
DNA raised the possibility that YB-1 and NCL may regulate AP-1-dependent gene 
expression directly or indirectly.  We hypothesized that YB-1 and NCL bind to AP-1 
DNA and regulate AP-1 transactivation.  If YB-1 and NCL regulate AP-1 
transactivation, then activation or repression of an AP-1 containing promoter would be 
detectable in transactivation assays.  Functional studies were therefore performed in 
HeLa cells to determine the effect of YB-1 and NCL on the transactivation of AP-1 
dependent gene expression.  The wild type 3XAP-1-GALV-luc reporter gene construct 
was transiently cotransfected along with the YB-1 (pcDNA-Flag-YB-1) and/or NCL 
(pNtag-HA-NCL) and β-galactosidase (pSVβgal) expression vectors along with the 
empty vector control (pcDNA3.1) into HeLa cells.  
 The data for TPA and c-fos transactivation experiments presented in Figures 25A 
and B, and 26A and B using the GALV AP-1 reporter constructs were generated by Dr. 
Twizere and are reproduced here with his permission.  As shown in Figure 25A, 
stimulation by TPA resulted in close to 3-fold increase in luciferase activity.  YB-1 and 
NCL, both alone and together, significantly repressed TPA-induced AP-1 transactivation 
of the reporter construct containing the wildtype AP-1 sequence.  NCL caused 52% 
repression of TPA-induced transactivation (Figure 25A, compare bar graphs 5 and 6), 
YB-1 caused 92% repression (compare bar graphs 5 and 7), and the combination of 
overexpressed NCL and YB-1 caused 85% repression (compare bar graphs 5 and 8).  In 
contrast, both YB-1 and NCL did not repress TPA-induced transactivation of the 
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reporter construct containing mutant AP-1 sequence demonstrating that the repression 
was AP-1 sequence specific.  Also as a control, YB-1 and NCL did not significantly 
affect transactivation from a constitutive cytomegalovirus luciferase (pCMV-luc) 
construct, lacking a functional AP-1 site (data not shown).  This indicates that the 
suppressive activity by YB-1 and NCL occur specifically through the AP-1 site.  To 
show that YB-1 and NCL were overexpressed in the transiently transfected cells, whole 
cells lysates from vector control, Flag-YB-1 and HA-NCL transfected HeLa cells were 
analyzed by western blot analysis.  As shown in Figure 25B, proteins of the predicted 
size for YB-1 (50 kDa) and NCL (97 KDa) were immunodetected with αFlag and αHA 
antibodies respectively.  Increase in total protein levels (endogenous and transfected) 
was analyzed by immunoblotting with αYB-1 and αNCL antibodies.  While no increase 
in total intracellular protein level was detectable for YB-1, NCL protein level increased 
1.7-fold (Figure 25C).  The lack of detection of increase in total YB-1 levels is most 
likely due to a failure of the αYB-1 antibody to recognize the flag-tagged YB-1 protein. 
 One possible explanation is that the flag tag in the overexpressed YB-1 protein alters 
the protein conformation such that the αYB-1 antibody epitope on the protein is no 
longer exposed and/or accessible.  To determine whether the YB-1 and NCL mediated 
transactivational repression was due to decreased cell viability resulting from NCL and 
YB-1 overexpression constructs, cell viability was assessed following transfections by 
several independent methods.  Trypan blue dye exclusion assays demonstrated that 
between 97% and 100% of the cells were viable after transfection of NCL and/or YB-1. 
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Figure 26   YB-1 and nucleolin repress c-fos induced transactivation in HeLa cells.  A. HeLa cells were co-transfected with 10 ng of pcDNAc-fos and 
1 µg of pcDNAFlag-YB-1 or pNtag-HA-NCL constructs along with wild type or mutant GALV-AP-1 reporter constructs as described in Materials and 
Methods.  Presence or absence of transfected constructs indicated by “+” and “-” signs.  Bars bracketed by “GALV WT AP-1 luc”, 3X Wild type AP-1-
luciferase reporter tranfectants; Bars bracketed by “GALV Mut AP-1 luc”, 3X mutant AP-1-luciferase reporter tranfectants.   B. Tagged YB-1 and NCL 
are overexpressed in the transient transfectants.  Overexpression of tagged YB-1 and NCL in transient transfectants was confirmed by immunoblotting 
of 10 µg of lysates from vector control (pcDNA transfectant) and YB-1 and/or NCL transfected cells with αFlag/αNCL antibodies.  Equal protein 
loading was verified by immunoblotting with αGAPDH antibody.  C. Transfection with c-Fos increases total c-Fos protein levels. 10 µg lysates from 
vector control (pcDNA transfectant) and c-Fos transfected cells were immunoblotted with α c-Fos antibody. 
HA-NCL 
Flag-YB-1 
c-Fos 
GALV WT AP-1 Luc GALV Mut AP-1 Luc 
HA-NCL 
Flag-YB-1 
GAPDH 
A B 
C 
  
115
YB-1 and Nucleolin Repress Transactivation by c-Fos in HeLa Cells  
 The effect of YB-1 and NCL on transactivation by co-transfected c-fos was also 
examined by Dr. Twizere.  Wild type or mutant AP-1 luciferase reporter constructs were 
transiently cotransfected along with the expression constructs, (1) c-fos (pcDNAc-fos); 
(2) YB-1 (pcDNA-Flag-YB-1) and/or NCL (pNtag-HA-NCL) or empty vector 
(pcDNA3.1) and, (3) β-galactosidase construct (pSVβgal) into HeLa cells.  YB-1 and 
NCL significantly repressed c-Fos induced AP-1 transactivation of luciferase expression 
at the wild type AP-1 site but not the mutant AP-1 site (Figure 26A). NCL caused 72% 
repression of c-fos mediated transactivation of the wild type AP-1 reporter construct, 
YB-1 caused 73% repression, and the two proteins together caused 89% repression.  
Overexpressed c-fos, NCL, and YB-1 had no effect on levels of expression of the mutant 
AP-1 reporter. Overexpression of tagged YB-1 and NCL was confirmed by 
immunoblotting cell lysates from control and transfected cells with αFlag and αNCL 
antibodies respectively (Figure 26B). Overexpression of transfected c-Fos was also 
verified by immunoblotting cell lysates from vector control and c-fos transfected cells 
with αc-Fos antibody (Figure 26C).             
YB-1 but Not Nucleolin Binds Specifically to GCN AP-1 DNA in NAPSTER Assay 
 We reproducibly observed specific binding of YB-1 and NCL proteins to the 
GALV AP-1 DNA sequence in NAPSTER assays.  To test whether the specific binding 
of YB-1 and NCL to AP-1 site was limited to the GALV AP-1 DNA sequence, we 
performed NAPSTER with an AP-1 sequence from yeast GCN promoter (5’-
TCGACTATGATGAGTCATGGGGC-3’) as competitor oligos (minimal AP-1 
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sequence is shown underlined).  NAPSTER was performed with GALV AP1 DNA 
sequence on beads, but with wild type or mutant GCN AP-1 oligos as competitors in 
samples II and III. We also performed NAPSTER assay with wild type or mutant GALV 
AP-1 oligos as competitors, in parallel.  As shown in Figure 27, YB-1 was specifically 
competed by both the wild type GALV AP-1 and GCN AP-1 oligos but not by the 
corresponding mutant oligos.  NCL was specifically competed by wild type GALV AP-1 
but not by GCN AP-1 oligo.  The binding of NCL to GCN AP-1 oligo appears to be non-
specific in this experiment.  These data indicate that the precise binding sites for YB-1 
and NCL on the AP-1 sequences may be different.  The GALV AP-1 and GCN AP-1 
oligos differ in the sequences of their flanking regions.  It is possible that the NCL 
binding site on the GALV AP-1 sequence spans the minimal AP-1 site as well as a 
portion of the flanking sequence and that specific binding of NCL to the AP-1 site is 
partially dependent on the sequence of the flaking region.  c-Jun binding and 
transactivation from AP-1 site also depends on the flanking regions of the consensus 
sequence (Ryseck et al., 1991; Herdegen and Leah, 1998).  An interesting observation in 
this and a few other NAPSTER experiments concerns a slow migrating form of NCL 
with an apparent molecular weight of about 200 KDa which also binds specifically to the 
GALV AP-1 DNA in some experiments.  The size of this NCL protein form in SDS-
PAGE and recognition by αNCL antibody indicate that it is possibly a dimeric form of 
NCL however, the reasons for the sporadic detection of this form in NAPSTER are not 
yet clear. 
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Figure 27  YB-1 but not nucleolin binds specifically to GCN AP-1 DNA in NAPSTER 
assay.  NAPSTER analyses were performed with 300 µg of HT29 NE protein and 20 µg 
of GALV AP-1 DNA on beads per sample in two sets.  In the first set, samples II and III 
were preincubated with 50 µg of wild type or mutant GALV AP-1 oligos (left panels). In 
the second set, samples II and III were preincubated with 50 µg of wild type or mutant 
GCN AP-1 oligos (right panels).  Samples I, II and III from both sets were loaded onto 
SDS-PAGE gels alongside 30 µg of NE protein and subjected to immunoblotting with 
antibodies against those listed next to each blot. 
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Figure 28  YB-1 but not nucleolin represses c-fos induced transactivation at GCN AP-1 site.  A. 
Schematic of the 4X GCN AP-1 luciferase repoter construct used.  B. HeLa cells were transfected with 
4XGCN-AP-1 reporter constructs along with none or 100 ng of pcDNAc-fos and various amounts of 
pcDNAFlag-YB-1 and/or pNtag-HA-NCL constructs as shown below corresponding bar graphs in the 
Figure. Samples are numerically indicated above the bar graphs. All data were normalized to β-
galactosidase expression.  C. HeLa cells were transfected with 4XGCN-AP-1 reporter constructs along 
with 100 or 200 ng of pcDNAc-fos and increasing amounts of pcDNAFlag-YB-1 and/or pNtag-HA-NCL 
constructs as shown below corresponding bar graphs in the Figure. Samples are numerically indicated 
above the bar graphs. Data represent two independent experiments. 
 1       2         3        4        5       6        7        8        9       10     11 
 1       2         3        4        5       6        7        8        9       10     11 
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B 
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YB-1 but Not Nucleolin Represses Transactivation from GCN AP-1 Reporter 
 YB-1 and NCL mediated AP-1 transrepression with a GALV AP-1 DNA reporter 
construct.   To test whether YB-1 and NCL mediated AP-1 transrepression would occur 
at an AP-1 site from an alternate promoter, transactivation assays were performed with a 
4X GCN AP-1 luciferase reporter construct (4X GCN AP-1 luc).  Since the binding of 
YB-1 to GCN AP-1 sequence was specific, but that of NCL to GCN AP-1 sequence was 
non-specific (Figure 28), we hypothesized that YB-1 but not NCL would transrepress 
the GCN AP-1 reporter expression.  The 4X GCN AP-1 luc consisted of four tandem 
GCN AP-1 sequences upstream of a luciferase reporter gene.  4X GCN AP-1 luc 
construct was transiently cotransfected along with the expression constructs for (1) c-Fos 
(pcDNAc-fos); (2) YB-1 (pcDNA-Flag-YB-1) and/or NCL (pNtag-HA-NCL); (3) β-
galactosidase (pSVβ gal) or the empty vector (pcDNA3.1) into HeLa cells.  Consistent 
with our hypothesis, YB-1 significantly repressed c-fos induced AP-1 transactivation of 
luciferase expression at all concentrations tested (Figure 28B and C).  Furthermore, YB-
1 mediated repression of AP-1 transactivation was YB-1 dose-dependent with an 
increase in repression observed as a function of increased dosage of YB-1 (Figure 28C, 
compare bars 6, 7 and 8 with 2; compare bars 13, 14 and 15 with 9).  YB-1 caused up to 
95% repression of c-fos mediated transactivation of the reporter at the highest dose (400 
ng of transfected DNA) tested.  The results for NCL were inconclusive.  NCL repressed 
AP-1 transactivation in one out of three experiments (Figure 28B, compare bars 7 and 8 
with 6) while NCL did not show significant repression or any dose dependent correlation 
of AP-1 transrepression with the GCN AP-1 reporter, in two out of three experiments 
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(Figure 28C, compare bars 3, 4 and 5 with 2; compare bars 10, 11 and 12 with 9).  The 
repression data for NCL in the two experiments correlate with the non-specific binding 
of NCL to competitor GCN AP-1 sequences observed in NAPSTER assays (Figure 27).  
YB-1 and/or Nucleolin Overexpression Does Not Affect AP-1 Protein Level  
 YB-1 and NCL mediated repression of AP-1 transactivation could potentially 
occur in several different ways.  One possible mechanism could be via YB-1 or NCL 
mediated decrease in the levels of AP-1 proteins.  To examine whether the coexpression 
of YB-1 or NCL affected the intracellular level of any of the AP-1 subunits, whole cell 
lysates were generated from pcDNA control and Flag-YB-1 or HA-NCL transfected 
HeLa cells treated with or without TPA.  The expression levels of all seven AP-1 
proteins were measured following overexpression of YB-1 and NCL proteins.  As shown 
in Figure 29A and B, the levels of the Jun and Fos family members were not 
significantly affected by overexpression of YB-1 or NCL.  Additionally, the TPA 
inducibility and gel-migration pattern of all the seven AP-1 subunits was consistent with 
previously published data (Kovary and Bravo, 1991; Bernstein et al., 1992).  
Overexpression of YB-1 and NCL were confirmed by immunoblotting with αFlag and 
αHA antibodies respectively (Figure 29C).  These data demonstrate that YB-1 and NCL 
mediated repression of AP-1 transactivation does not occur via decrease in AP-1 protein 
levels.  
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Figure 29   Overexpression of YB-1 and nucleolin do not affect the intracellular levels of AP-1 subunits.  
A. and B. 4.5 x 105 HeLa cells plated in 150 mm tissue culture dishes were transiently transfected with 20 
µg of pcDNA3.1 vector control or with pcDNAFlag-YB-1 or pNtag-HA-NCL constructs.  Whole cell 
lysates were prepared after treating the cells with 100ng/ml of TPA for 24 hours.  10 µg of total proteins 
per sample were separated on SDS-PAGE and immunoblotted with antibodies against all the seven AP-1 
subunits.  C. Transient transfectants overexpress tagged YB-1 and nucleolin proteins. 10 µg of protein per 
sample were subjected to SDS PAGE followed by western blot analysis with αFlag or αΗΑ antibody. 
Brackets indicate the constructs used in the transfections. “-”, no TPA; “+”, with TPA. 
A
C 
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Figure 30  Overexpression of YB-1 and nucleolin do not affect the subcellular localization of AP-1 
subunits.  A. and B.   Hela cells were transfected with vector control or flag YB-1 or HA-NCL and treated 
with TPA for 24 hours.  The cells then underwent extraction to isolate the cytosolic and nuclear fractions. 
Extracts from each fraction corresponding to 4 x 105 cells per sample was subjected to SDS-PAGE 
followed by immunoblotting with antibodies against all the seven AP-1 subunits and with αOct-1 
antibody.  NE, nuclear extract; C, cytosol.  C. Transfected cells overexpress tagged YB-1 and nucleolin 
protein in nucleus and cytosol. 10 µg of total protein per sample of nuclear extract and cytosol from Flag 
YB-1 and HA-NCL transfected cells were subjected to SDS PAGE followed by western blot analysis with 
αFlag or αΗΑ antibody. 
A
C 
B 
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YB-1 and Nucleolin Overexpression Does Not Inhibit Nuclear Localization of AP-1 
Proteins   
 A second possible mechanism of repression could be via YB-1 or NCL mediated 
decrease in nuclear localization of the AP-1 proteins.  In order for AP-1 proteins to bind 
to the AP-1 site and transactivate gene expression, they need to translocate from the 
cytoplasm into the nucleus.  To determine whether overexpression of YB-1 or NCL 
decreased the nuclear localization of the AP-1 proteins, YB-1 or NCL transfected HeLa 
cells were fractionated into nuclear and cytosolic fractions.  Levels of all seven AP-1 
components were then analyzed in the two cellular fractions by immunoblotting.  
Nuclear and cytoplasmic levels of all seven AP-1 components were not altered by 
overexpression of YB-1 or NCL (Figure 30A and B).  Most AP-1 subunits localized to 
the nucleus.  Fra-1 and JunB were also detectable in the cytosolic compartment of both 
vector and YB-1 or NCL transfected cells, although the role for these transcription 
factors in the cytosol is unclear.  Additionally, two bands were detected for Fra-1 protein 
both in the cytosol and nuclear compartments with the faster migrating form detected at 
higher levels in the nuclear fraction.  Three isoforms of c-Jun with different 
electrophoretic mobilities were detected and possibly represent differentially 
phosphorylated forms of the protein.  Immunoblotting with ;Flag and ;HA antibodies 
confirmed that tagged YB-1 and nucleolin were overexpressed, with transfected proteins 
detectable in both cellular compartments (Figure 30C).  Immunobloting with an antibody 
against Oct-1 (a nuclear transcription factor) demonstrated exclusive localization of Oct-
1 to the nucleus, confirming that nuclear and cytosolic fractions were free from cross-
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contamination.  These data demonstrate that YB-1 and NCL mediated repression of AP-
1 transactivation does not occur via changes in AP-1 protein localization in the cytosolic 
and nuclear compartments.  
Establishing Equilibrium Binding Conditions for YB-1, Nucleolin and AP-1 Jun Subunits 
 Having ruled out YB-1 and NCL mediated decrease in AP-1 protein levels and 
localization in the subcellular compartments as possible mechanisms of repression, we 
hypothesized that YB-1 and NCL mediate repression of AP-1 transactivation via 
decreasing AP-1 binding to AP-1 site.  One method to test this notion would be to 
analyze the binding of each of the AP-1 subunits to AP-1 DNA, by the NAPSTER assay, 
in cells overexpressing YB-1 or NCL proteins. The prediction then would be that 
overexpression of YB-1 and NCL would cause decrease in AP-1 DNA binding.  
However, this seemingly simple experiment posed several challenges.  The first issue 
was the sheer size of the experiment of precisely analyzing the binding of each of the 
seven AP-1 subunits in a quantitative manner. However, because Fos subunits can only 
bind to the AP-1 DNA following heterodimerization with one of the Jun family 
members, analysis of the binding of just the three Jun members would be equally 
informative.  
 The second issue pertained to possible differences in DNA binding kinetics of 
each of the proteins. The incubation time of the DNA-protein interactions should be 
sufficient to reach binding equilibrium for each of the proteins. Additionally, the 
concentration of DNA and protein had to be optimized.  In order to observe any change 
in binding of the jun proteins to AP-1 DNA following YB-1 and NCL overexpression, 
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concentrations of DNA should be limiting for each of the Jun proteins. This involved 
titrations of various DNA-protein ratios. These two critical parameters needed to be 
optimized.  
 Since both YB-1 and NCL are fairly abundant proteins in cells, we reasoned that 
in order to detect a decrease in the binding of AP-1 subunits to the AP-1 DNA, the DNA 
binding conditions would have to be in equilibrium for all the proteins concerned 
including YB-1, NCL and the AP-1 proteins.  To begin, we sought to determine such an 
equilibrium binding condition. AP-1 DNA affinity chromatography (NAPSTER sample 
I) was performed using increasing durations of DNA-protein interaction times. An initial 
titration of concentrations of DNA and NE proteins revealed that DNA was limiting for 
all proteins including YB-1, NCL, JunB, c-Jun and JunD at a 1:40 ratio (data not 
shown).  We restricted our analyses to the Jun AP-1 subunits because the Fos subunits 
bind to AP-1 DNA only as heterodimers with Jun subunits.  Therefore for the following 
experiment, DNA and NE proteins were used at 1:40 ratio and the incubations were 
performed for 15, 75, 120, 180, 240 and 360 minutes. Western blot analysis of the 
affinity purified samples was carried out with αYB-1, αNCL and αJun antibodies.  
Qualitative and densitometric analysis of protein bands at various time points revealed 
that by 180 minutes, all of the proteins tested had reached binding equilibrium (Figure 
31A and B).   
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Figure 31  Equilibrium binding curves for YB-1, NCL and AP-1 jun subunits.  A. AP-1 DNA affinity 
chromatography (NAPSTER sample I) was performed using 120 µg of AP-1 DNA on beads and 4800 µg 
of HeLa NE protein.  Protein samples were removed at 15, 75, 120, 180, 240 and 360 minutes of DNA-
protein incubation followed by washes, SDS PAGE and then immunoblotted with αYB-1, αΝCL, αc-jun, 
αJunB and αJunD antibodies.  B. Graph displaying the DNA-binding kinetics of YB-1, NCL, c-jun, junD 
and junB as a function of incubation time.  Densitometric quantitation of protein bands was performed 
using the NIH Image 1.62 program as described in Materials and Methods. 
A
B
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Establishing AP-1 DNA Binding Curve for YB-1, Nucleolin and AP-1 Jun Subunits   
 Initial titrations of concentrations of DNA:NE proteins had established that DNA 
was limiting for all proteins including YB-1, NCL, JunB, c-Jun and JunD at a 1:40 ratio 
(data not shown). The incubation time for this DNA-protein binding reaction used was 
75 minutes. To determine if 1:40 ratio was still limiting for all the proteins after 180 
minutes equilibrium incubation time, AP-1 DNA affinity chromatography (NAPSTER 
sample I) was performed using increasing amounts of AP-1 DNA probe and 800 
microgram of NE protein. DNA: protein ratios tested included 1:7.5, 1:15, 1:30, 1:40, 
1:50 and 1:60 and the incubations were performed for 180 minutes. Western blot 
analysis of the affinity purified samples was carried out with αYB-1, αNCL and αJun 
antibodies. Qualitative and densitometric analysis of protein bands at various ratios 
revealed that at 1:40 ratio, DNA was limiting for all of the proteins tested (Figure 32A 
and B). 
Establishing Competition Curve for YB-1 in NAPSTER Assay 
  To determine the optimum concentration of competition oligos for NAPSTER 
assays under the newly standardized conditions of 1:40 ratio (DNA:protein) and 180 
minutes (equilibrium incubation time), we performed NAPSTER assays involving 
preincubation of NE proteins increasing amounts of wild type or mutant AP-1 oligos 
prior to AP-1 DNA affinity chromatography. Western blot analysis of the affinity 
purified samples was carried out with αYB-1 antibody.  At 5-fold molar excess 
(compared to AP-1 DNA on beads), both wild type and mutant competition oligos 
compete almost equally for YB-1 binding (Figure 33).   
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Figure 32 AP-1 DNA binding curve for YB-1, NCL and AP-1 jun subunits.  A.  NAPSTER analyzes was 
performed using AP-1 DNA on beads and HeLa NE protein at the ratio of 1:7.5, 1:15, 1:30, 1:40, 1:50 
and 1:60.  The proteins were incubated with the DNA for 180 minutes followed by washes, SDS PAGE 
and then immunoblotted with αYB-1, αΝCL, αc-jun, αJunB and αJunD antibodies.  B. Graph displaying 
binding of YB-1, NCL, c-jun, junD and junB at various ratios of DNA: protein.  Densitometric 
quantitation of protein bands was performed using the NIH Image 1.62 program as described in Materials 
and Methods. 
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Figure 33  Establishing competition curve for YB-1 in NAPSTER assay. NAPSTER analysis was 
performed using 20 µg of AP-1 DNA on beads and 800 µg of NE protein following preincubation with 
increasing fold excess of wild type and mutant AP-1 competition oligos.  The proteins were incubated 
with the DNA on beads for 180 minutes followed by washes, SDS PAGE and then immunoblotted with 
αYB-1 antibody.  
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The 2.5-fold molar excess competitions yield optimum specificity of binding, with 
effective competition clearly detectable with the wild type oligo but not the mutant 
oligo. Similar results were obtained previously for NCL (data not shown). 
Binding of AP-1 Subunits to AP-1 Site in Cells Overexpressing YB-1 and/or Nucleolin 
 Having determined the equilibrium binding conditions and the limiting DNA 
concentrations through the experiments described in the previous sections, we tested the 
hypothesis that YB-1 and NCL mediate repression of AP-1 transactivation via decreases 
in AP-1 binding to AP-1 site.  HeLa cells were transiently transfected with pcDNA3.1 
vector or with pcDNAFlag-YB-1 and/or pNtagHA-NCL constructs.  Nuclear extracts 
were prepared following incubation of the cells with 100ng/ml of TPA for 24 hours.  NE 
protein for each of samples I, II and III from vector control and YB-1 and/or NCL 
transfectants were subjected to NAPSTER analyses. The NE proteins were incubated 
with the AP-1 DNA on beads at 1:40 ratio for 180 minutes followed by washes, SDS 
PAGE and then immunoblotted with αYB-1, αNCL, αc-jun, αJunB or αJunD 
antibodies (Figure 34).  The results from this set of experiments were inconclusive due 
to the non specific binding of NCL to AP-1 DNA (see panel probed with αNCL 
antibody) and due to high variability in DNA binding within and between independent 
experiments (compare all panel corresponding to Experiment #1 with #2).  Furthermore, 
we could not detect any increase in the binding of YB-1/Flag-YB-1 or of NCL/HA-NCL 
protein to the AP-1 DNA in transfectants when compared to control.  However blotting 
with αFlag and αHA antibodies clearly demonstrated that flag-tagged YB-1 and HA-
tagged NCL proteins are overexpressed and that Flag YB-1 bound specifically to AP-1  
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Figure 34  Binding of AP-1 subunits to AP-1 site in cells overexpressing YB-1 and/or 
nucleolin.  4.5 x 105 HeLa cells plated in 150 mm tissue culture dishes were transiently 
transfected with 15 µg of pcDNA3.1 vector control or with pcDNAFlag-YB-1 and or 
pNtag HA-NCL constructs.  Nuclear extracts were prepared after treating the cells with 
100ng/ml of TPA for 24 hours.  800 µg of NE protein for each of samples I, II and III 
from vector control and YB-1/NCL transfectants were subjected to NAPSTER analyses 
using 20 µg of DNA on beads.  The proteins were incubated with the DNA for 180 
minutes followed by washes, SDS PAGE and then immunoblotted with αYB-1, αNCL, 
αc-jun, αJunB, αJunD or αΗΑ antibodies.  The JunB membrane from above experiment 
was reprobed with αFlag antibody and shows residual junB chemiluminiscence in the 
membrane, indicated with an arrow. 
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DNA in NAPSTER assay (Figure 34, see panel probed with αFlag antibody).  It is 
possible that the increase in the levels of total nuclear YB-1 and NCL proteins in the 
transfectants was not sufficient for detection.  The results for these experiments are 
inconclusive and our hypothesis that YB-1 and NCL mediate repression of AP-1 
transactivation via decreases in AP-1 binding to AP-1 site remains to be tested possibly 
by an alternate experimental approach presented in the discussion section.   
Discussion 
 In this study, YB-1 and NCL were identified as novel AP-1 DNA binding 
transrepressors.  We used a microscale analytical AP-1 DNA affinity chromatography 
method devised previously in our lab (Kumar and Bernstein, 2001) for identification and 
purification of these proteins.  The YB-1 study had a fortuitous beginning.  During the 
course of isolation of the p97 band (later identified as nucleolin) using the NAPSTER 
assay by Twizere, I noticed two coomassie stainable bands at 47 and 49 KDa in addition 
to the 97 KDa protein band that Dr. Twizere was attempting to isolate, that bound 
specifically to the AP-1 DNA.  Using MS/MS sequencing, I identified the 49 KDa 
protein as YB-1 and our data suggest that 47 KDa protein is most likely a degradation 
product of YB-1 protein.  Dr. Twizere identified the 97 KDa protein as nucleolin. 
 The present study is the first report demonstrating that YB-1 and NCL bind 
specifically to the AP-1 DNA sequence.  This conclusion was supported both by MS/MS 
sequencing of specific coomassie stainable NAPSTER bands and by immunoblotting 
detection of specific bands with YB-1 and NCL antibodies.  Since YB-1 and NCL are 
abundant mammalian proteins, their binding specificity for the AP-1 site is intriguing.  
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The binding of these abundant proteins to the AP-1 site seems to have been missed since 
AP-1 was first discovered. 
 YB-1 proteins were originally found by screening cDNA expression libraries for 
proteins that could bind to DNA sequences containing an inverted CCAAT element 
(Didier et al., 1988).  Studies have shown that YB-1 protein can also bind to other 
sequences including the W-box, B-box, and apurinic DNA and a triplex forming H-DNA 
(Hasegawa et al., 1991; Cohen et al., 1991; Lenz et al., 1990; Horwitz et al., 1994) 
which accounts for its diverse roles in transcriptional activation, repression, DNA repair 
and translational control.  Nucleolin has also been implicated in a variety of cellular 
processes including, regulation of rRNA transcription and processing, mRNA stability, 
chromatin decondensation, transcription, immunoglobulin switching, cell cycle 
regulation and signal transduction (see Ginisty et al., 1999 and Kohno et al., 2003 for 
review).  NCL also binds to a variety of RNA and DNA sequencing including the 3’ 
UTR of APP (Amyloid Precursor Protein), human preprorenin mRNA, the B motif of 
the alpha-1 acid glycoprotein promoter, matrix attachment region (MAR), telomeric 
DNA sequence, human papilloma virus-18 (HPV-18) enhancer, mRNA in Xenopus 
oocytes, 3’ non-coding region of poliovirus, and the core binding site of the B cell 
specific LR1 complex (reviewed in Ginisty, et al., 1999).   
 The observation that YB-1 and NCL bind specifically to AP-1 DNA, led us 
hypothesize that sufficient levels of nucleolin and YB-1 would be detectable in the 
nucleoplasm in HeLa cells.  We investigated the localization of these proteins in the cell 
by confocal microscopy, and both YB-1 and NCL were detectable in the nucleus.  Based 
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on this observation we further hypothesized that YB-1 and NCL may interact with each 
other through protein-protein interactions.  Our attempts to coimmunoprecipitate NCL 
with YB-1 using both αYB-1 and α-Flag antibodies were unsuccessful.  Reciprocal 
immunoprecipitation of YB-1 with NCL using αNCL has not yet been tested due non-
availability of effective immunoprecipitating NCL antibodies.  Detection of YB-1 and 
NCL interaction is further complicated because of possible requirement of DNA for YB-
1-NCL association.  Chen et al. demonstrated that nucleolin and YB-1 could be 
coprecipitated with each other from crude cytoplasmic extracts of stimulated Jurkat cells, 
but the interaction was abolished by RNase treatment (Chen et al., 2000), indicating the 
critical role of RNA.  
  Another novel finding made in this study is that YB-1 and NCL repress 
transactivation of AP-1 dependent gene expression.  Using a trimer of the wild type or 
mutant AP-1 target sequence linked to a luciferase reporter, Dr. Twizere demonstrated 
that both NCL and YB-1 site specifically represses transactivation of AP-1 dependent 
gene expression from the wild type but not the mutant AP-1 target sequence.  
Additionally we demonstrated that YB-1 represses c-fos induced AP-1 transactivation at 
a GCN AP-1 site.   
 There is increasing evidence that YB-1 and NCL bind DNA and serve as specific 
transcriptional regulators.  YB-1 binds to the promoter of several genes including genes 
for matrix metalloproteinase 2 (Mertens et al., 1997), MDR 1 (Oda et al., 1998; Bargou 
et al., 1997), chick collagen α2 (Bayarsaihan et al., 1996), GRP78 (Li et al., 1997).  
Recent studies have shown that YB-1 functions as a transcriptional repressor.  YB-1 
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binds to a Y-box sequence in the human MHC II (-90 bp to -40 bp) promoter and 
functions as a repressor (Ting et al., 1994). Furthermore, YB-1 represses the expression 
of Fas (Lasham et al, 2000) and collagen (Norman et al., 2001).  NCL represses 
transcription by RNA polymerase I by inhibiting the transcriptional machinery and/or 
via interactions with promoter sequences in rDNA (Roger et al., 2002).  NCL binds the 
B motif of the alpha-1 acid glycoprotein promoter represses mRNA transcription (Yang 
et al., 1994).  For many transcriptional factors, additional proteins have been found to 
contribute to their DNA binding and/or trans-activation functions (Auwerx and Sassone-
Corsi, 1992). These include: MyoD that is regulated by Id (Benezra et al., 1990), the 
glucocorticoid receptor by hsp90 (Picard et al., 1988) and Cfl-a by Drosophila I-POU 
(Treacy et al., 1991).  
 Given that YB-1 and NCL bind to AP-1 sequence, our initial hypothesis is that 
they transrepress by a mechanism involving DNA binding, but other mechanisms may 
also be operative.  The mechanism of YB-1 and NCL mediated repression of AP-1 
transactivation may theoretically involve either/or a combination of the following 
mechanisms; 
(i) Decrease in the levels of AP-1 proteins in the nucleus.  It is conceivable 
that decreases in the AP-1 protein levels in the nucleus could result in decreased AP-1 
mediated transactivation at the AP-1 DNA binding site, because of the non-availability 
of sufficient amounts of AP-1 proteins.  The expression level of AP-1 proteins in the 
nucleus may be governed by one or more of the following processes; 
(a) Decreased transcription of genes encoding AP-1 subunits 
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(b) Changes in AP-1 mRNA processing resulting in decreased 
 translocation of AP-1 transcripts into the cytoplasm for translation  
(c) Decreased stability of AP-1 transcripts/increased degradation 
(d) Decreased translation of AP-1 transcripts 
(e) Decreased stability of AP-1 proteins 
(f) Decreased transport of AP-1 proteins from cytoplasm into the 
 nucleus 
 Our data rule out all of the above mechanisms through experiments that 
demonstrate that (a) YB-1 and NCL overexpression does not downregulate of the levels 
of any of the AP-1 proteins and, (b) YB-1 and NCL do not affect the subcellular 
localization of any of the AP-1 proteins. 
(ii) Phosphorylation status of AP-1 proteins.  Regulation of protein 
phosphorylation is a critical mechanism in the control of protein activity.  c-Jun 
transcriptional activity has been reported to be stimulated by phosphorylation of its Ser-
63 and Ser-73 residues in its activation domain (Smeal et al., 1991 and Arias et al., 
1994).  
(iii) Dimerization of AP-1 subunits.  The DNA binding, stability and 
transactivation potential of AP-1 proteins can be substantially altered by changes in 
composition of AP-1 dimers.  While homodimers of c-Jun have strong affinity for AP-1 
DNA, heterodimers of c-Fos:c-Jun are more stable and bind AP-1 DNA with higher 
affinity (Herdegen and Leah, 1998).   De Cesare demonstrated that while c-Jun: ATF2 
dimers bind to a TRE-like element of the human urokinase enhancer and stimulate 
  
137
transcription, c-Jun:c-Fos dimers appear to repress transcription of the enhancer at the 
same site (De Cesare et al., 1995). 
 Experiments to test the effects of YB-1 and/or NCL on the phosphorylation and 
dimerization status of all AP-1 subunits would be labor intensive and have not yet been 
tested.  While a role for phosphorylation and/or dimerization of AP-1 proteins in 
repression has not been ruled out, based on the observation that YB-1 and NCL bind 
specifically to the AP-1 DNA, we hypothesize that YB-1 and NCL mediate repression 
of AP-1 by competing against the AP-1 proteins for binding to the AP-1 site.  
 (iv)     Decreased DNA binding of AP-1 proteins.  Decreased DNA binding of 
AP-1 proteins to the AP-1 site would directly decrease AP-1 transactivation.  The 
binding of AP-1 proteins to AP-1 DNA may be altered through several processes 
including those mentioned in above sections, i.e., phosphorylation and dimerization.  
Alternatively, YB-1 and NCL may bind to the AP-1 site and competitively or sterically 
inhibit direct interaction between AP-1 proteins and AP-1 site. Competition for DNA 
binding has been shown to be an important mechanism of transcriptional regulation.  
The human factor NF-E binds to the CCAAT box in the promoter of fetal γ-globin gene 
and inhibits the binding of the transcriptional activator, CP-1, thus preventing the 
expression of this gene in adults (Superti-Furga et al., 1988).  Similarly, cAMP response 
element binding factor (CREB) downregulates AP-1 transactivation by competing with 
AP-1 proteins for AP-1 consensus sequence (Masquilier and Sassone-Corsi et al., 
1992). 
 Our strategy to test the notion that YB-1 and NCL decrease AP-1 binding to AP-
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1 site was to analyze the binding of each of the AP-1 subunits to AP-1 DNA by the 
NAPSTER assay, in cells overexpressing YB-1 and/or NCL proteins.  Effect of YB-1 
and NCL overexpression on AP-1 binding to AP-1 site in NAPSTER assay was 
compared in two independent experiments. The results from these experiments were 
inconclusive due to the high variability in DNA binding within and between 
experiments.  Furthermore, we were unable to detect significant increase in total levels 
of YB-1 and/or NCL protein binding to the AP-1 site.  Immunoblotting with αFlag and 
αHA antibodies clearly demonstrated that flag-YB-1 and HA-NCL were overexpressed 
and bound to AP-1 site in the transfected cells.      
(v) Decreased AP-1 transactivation by other mechanisms.  This may include 
direct quenching or masking of the AP-1 transactivation domains by YB-1 and NCL 
following binding to the AP-1 site, recruitment a corepressor molecule(s) that could then 
inhibit AP-1 transactivation, interaction with proteins of the general transcriptional 
machinery and prevention of AP-1 dependent initiation of transcription, and YB-1 
and/or NCL mediated modification of the local chromatin architecture to render 
transcription site inaccessible to the transcriptional machinery.  The contribution of one 
or more of these mechanisms in YB-1 and NCL mediated AP-1 transactivational 
repression has not been ruled out and remains to be tested.  
 Further studies are required to unravel the precise mechanism of YB-1 and NCL 
mediated AP-1 repression.  Firstly, overexpression of YB-1 protein in the flag YB-1 
transfectants needs to be verified using an alternate αYB-1 antibody.  Secondly, an 
alternate method of quantitation of DNA-protein interaction needs to be adopted. While 
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the NAPSTER assay is a rapid and sensitive method for accurate identification of 
specific DNA binding proteins, its application to quantitative comparisons of DNA 
binding between samples seems to be limited.  Electrophoretic mobility shift assay (also 
called gel shift assays) qualifies as an equally rapid and more sensitive method of 
identification of specific DNA binding proteins and represents a more accurate assay for 
quantitative comparison of DNA binding.  Gel shift assays are generally performed 
under conditions of low protein:DNA concentrations and therefore may favor detection 
of high affinity DNA:protein interaction and consequently suffer from reduced 
sensitivity to detection of low affinity DNA:protein interactions.  Additionally, the 
applicability of supershift assays, hinges upon availability of strong supershifting 
antibodies.   Nevertheless, we attempted both gel shift and supershift assays as an 
alternative to NAPSTER for analyses of YB-1 and NCL binding to the AP-1 site. 
 Our efforts to detect YB-1 and NCL supershifting activity were unsuccessful 
under numerous gel shift conditions including variations of temperature, ionic 
conditions, protein concentrations, electrophoretic conditions and two different YB-1 
and NCL antibodies (data not shown).  We speculate that this may in part be due to low 
affinity of the DNA:protein interaction.  Super shift assays, in conjunction with UV 
crosslinking represents a powerful approach to resolving this problem.  UV crosslinking 
may serve to stabilize the DNA-protein interaction. Specificity of binding to the AP-1 
site may be tested by using wild type and mutant competition oligos and specific protein 
interactions could then identified by using specific antibodies.  Minimal handling of 
samples during the assay may reduce variability within and between experiments and 
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yield more quantifiable data. 
 It is possible that the negative regulation exerted by YB-1 and NCL proteins 
require the interactions with additional factors binding to nearby sites on the DNA that 
differ between the regulatory regions of different genes, or that variations in the flanking 
sequences surrounding a given AP-1 site favor the binding of particular YB-1 and/or 
NCL complexes with different transcriptional potential.  Location and site-specific 
factors may influence the activity of YB-1 and NCL protein within the context of a 
particular promoter region.  We attempted to characterize the precise binding site for 
YB-1 and NCL within the GALV AP-1 sequence using DNAse I footprinting, but these 
attempts were unsuccessful.  We were unable to demonstrate specific protection of any 
residues when double stranded template was used, presumably due to the low affinity of 
YB-1 and NCL binding.  Similar results have been previously reported for YB-1 at the 
R2 element (Mertens et al., 1999) and the RE-1 element (Mertens et al., 1997). 
 The precise mechanism of YB-1 and nucleolin mediated repression is currently 
under investigation in our laboratory. Further studies will unravel the biological 
significance of transrepression by YB-1 and NCL at the AP-1 site.  YB-1 and NCL may 
control the expression of specific target genes at the AP-1 site to regulate cell 
proliferation, anchorage independent growth and other processes integral to 
carcinogenesis. 
Limitations of Present Study 
 This study used the NAPSTER assay as the means to identifying YB-1 and NCL 
as novel AP-1 DNA binding proteins.  While several attributes of the NAPSTER assay 
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make it more suitable than conventional gel shift assays for identifying low affinity 
DNA-protein interactions, a major limitation of the NAPSTER assay however, is that it 
is not suited to quantitative comparisons between sample sets.  Our efforts at using the 
NAPSTER assay to compare the binding of AP-1 proteins to the AP-1 DNA in control 
and YB-1 and/or NCL transfectants were inconclusive, primarily because we were 
unable to make quantitative comparisons between the two sets of NAPSTER samples 
due to the large variations within and between experiments.   A key limitation of this 
study was inapplicability of gel shift and super shift assays in further analyses of the 
YB-1 and NCL binding to AP-1 site.  This is perhaps because the low affinity YB-
1/NCL-AP-1 DNA interaction was unstable under the gel shift conditions tested in the 
study.  
Suggestions for Future Work 
 In the present study, a combination of DNA affinity chromatography and MS/MS 
sequencing identified YB-1 and NCL as specific AP-1 DNA binding proteins.  Reporter 
gene assays showed that YB-1 and NCL play a critical role in mediating repression at 
the AP-1 site.  Data generated in this study rule out changes in AP-1 levels and 
localization as mediators of YB-1 and NCL mediated repression of AP-1 dependent gene 
expression.  However, further studies are needed to understand the precise mechanism 
by which YB-1 and NCL mediate AP-1 transactivational repression.  
 Apart from the mechanisms of repression addressed in this study and alluded to 
in the discussion section, quite a few other mechanisms of repression are possible.  One 
such mechanism is by binding of YB-1 and NCL to the AP-1 site and recruitment of 
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corepressor molecule/s that reduce AP-1 transactivation (squelching).  Also, YB-1 and 
NCL may bind to AP-1 proteins and prevent binding of AP-1 proteins to the AP-1 DNA 
(sequestering).  Conceptually, physical interactions between YB-1/NCL and AP-1 may 
also result in occlusion of the AP-1 transactivation domain.  Additional experiments to 
determine whether YB-1/NCL interacts with AP-1 transcription factors may include 
coimmunoprecipitation of YB-1/NCL and AP-1 proteins.  Roles for YB-1 and NCL as 
competitive inhibitors may be studied by titrating recombinant YB-1/NCL and/or AP-1. 
 If interaction between YB-1/NCL and AP-1 is detected, precise mapping of the 
interacting regions between YB-1/NCL and AP-1 will be necessary to determine 
whether the interacting domain occludes AP-1 transactivation domain.  Understanding 
the physiological significance of such interactions and the mechanism by which they 
modulate AP-1 activity will be challenging. 
 Further analyses also need to be performed in order to localize the region of YB-
1/NCL proteins that are necessary and sufficient for mediating DNA binding and 
repression of AP-1 transactivation.  A systematic deletion analysis of the protein 
sequence would probably be the best approach to achieving these aims.  Wild type YB-
1/NCL protein and/or YB-1/NCL derivatives lacking various protein domain/s may be 
used to determine which derivative is necessary for AP-1 DNA binding.  Furthermore, 
wild type YB-1/NCL protein and/or YB-1/NCL derivatives lacking various protein 
domain/s may be cotransfected with AP-1 reporter to assess which derivative is 
necessary and/or sufficient to repress AP-1 activated transcription.   
 More studies are also needed to identify the in-vivo AP-1 DNA sequences and 
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the endogenous target genes that are regulated by YB-1 and NCL binding and to 
elucidate the molecular events that trigger YB-1 and nucleolin mediated 
transactivational repression.  Experiments employing the chromatin 
immunoprecipitation (ChIP) assays followed by PCR analyses are currently underway in 
our laboratory to verify gene sequences to which YB-1 binds in vivo in a native 
chromatin context.  As more information on transactivational repression by YB-1 and 
NCL becomes available, the mechanisms by which genes containing AP-1 site are 
downregulated by these proteins should become clearer, and may provide valuable 
insights into mechanisms of regulation of gene expression in general. 
 Finally and most importantly, possible roles for YB-1 and NCL in cancer need to 
be investigated.  Because AP-1 is implicated in cancer, and since data from this study 
clearly demonstrate transrepression of AP-1 by YB-1 and NCL, it is logical to postulate 
a tumor suppressor role for YB-1 and NCL.  Preliminary soft agar transformation assays 
in our laboratory (Twizere, Kim and Bernstein, unpublished data) demonstrated that 
overexpression of YB-1 inhibits neoplastic transformation of P+ tumor promotion 
sensitive JB6 cells treated with tumor promoter TPA.  The effect of NCL overexpression 
on neoplastic transformation of TPA treated P+ JB6 cells remains to be tested. 
  
144
CHAPTER IV 
CONCLUSION 
 The core subject of this research was gene expression.  In the search for key 
molecules that regulate gene expression and the mechanism by which changes in gene 
expression govern physiological and pathological processes in the cell, we have pursued 
two complementary approaches.  First, we used large scale gene expression profiling to 
identify genes whose altered expression is related or causal to neoplastic transformation. 
By combining gene array technology with the JB6 mouse model of susceptibility and 
resistance to neoplastic transformation, we have identified differential expression of 
several candidate genes that contribute to tumor promotion sensitivity and resistance.  
Several of the genes we identified are implicated for the first time in cancer.  Overall, 
our findings from this study have added substantially to our understanding of the 
pathways that may lead to tumor promoter induced transformation. 
 As a complementary approach, we studied regulation of gene expression.  The 
expression of specific genes in particular cell types or tissues is regulated by protein 
binding to specific DNA motifs present within the promoter or enhancer elements of 
those genes.  We have used a DNA affinity chromatography based protocol to identify 
proteins that bind to AP-1 site.  AP-1 is known to bind and transactivate genes that are 
involved in cell growth, differentiation, signalling and cell death.  Aberrant expression 
of these genes is implicated in several human cancers.  The rationale for our study was 
that once identified, these proteins can be used as targets in preclinical and clinical 
studies to correct dysregulated expression of AP-1 target genes in cancer.  Using the 
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DNA-affinity chromatography based assay termed the Nucleotide Affinity Preincubation 
Specificity Test of Recognition (NAPSTER) assay devised previously in our laboratory, 
we purified two proteins that bound specifically to AP-1 DNA binding site.  Analyses of 
the NAPSTER purified proteins by mass spectrometric sequencing determined the 
identities of two of these proteins as nucleolin and Y-box binding Protein 1 (YB-1).  We 
further tested the hypothesis that these proteins bind to the AP-1 site and regulate 
transactivation at the AP-1 site.  Overexpression of nucleolin and YB-1, both alone and 
in combination, was found to repress AP-1 dependent gene expression.  To further 
understand the mechanism of transrepression, we analysed whether overexpression of 
nucleolin and/or YB-1 affected the levels and/or disrupted the intracellular localization 
of the AP-1 subunit proteins.  Western blot analysis of all the AP-1 species revealed that 
intracellular levels of AP-1 were unaffected.  Furthermore, cell fractionation followed by 
western blot analysis confirmed that the AP-1 levels were not altered in the cytoplasmic 
or nuclear compartments.  Further studies are underway to elucidate the precise 
mechanism of repression mediated by these proteins at the AP-1 site.  
 To summarize, we have identified and characterized nucleolin and YB-1 as novel 
AP-1 DNA binding proteins. Strong evidence is presented that they repress AP-1 
transactivation. These data open a new area of investigation on the mechanisms of 
transcriptional regulation by these proteins. Our studies provide the basis for several 
avenues of future investigations both in the fields of regulation of gene expression at the 
AP-1 site and in TPA induced neoplastic transformation. 
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